News Releases

Webcast ImageWebcast
CryoLife, Inc. at Canaccord Genuity Medical Technologies and Diagnostics Forum (Replay)
11/17/16 at 8:00 a.m. ET
Webcast ImageWebcast
CryoLife, Inc. at Piper Jaffray Healthcare Conference (Replay)
11/29/16 at 4:00 p.m. ET
 
2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle 
11/10/16CryoLife to Present at Two Investor Conferences in November 2016
ATLANTA, Nov. 10, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that Pat Mackin, Chairman, President and Chief Executive Officer, will present at two investor conferences in November 2016. The first conference is the Canaccord Genuity Medical Technologies and Diagnostics Forum in New York. Event: Canaccord Genuity Medical Technologies and Diagnostics Forum Date: Thursday, November 17,... 
Printer Friendly Version
10/26/16CryoLife Reports Third Quarter 2016 Financial Results
Increases 2016 Financial Guidance ATLANTA, Oct. 26, 2016 /PRNewswire/ -- Third Quarter Highlights: Revenue Increased 23 Percent Year-over-Year to $45.3 Million; Non-GAAP Revenues Increased Six Percent Year-over-Year Gross Margins Increased to 66 Percent; Non-GAAP Gross Margins Increased to 67 Percent GAAP Net Income was $3.0 Million, or $0.09 Per Fully Diluted Common Share; Non-GAAP Net Income was $4.4 Million, or $0.13 Per Fully Diluted Common Share CryoLife, Inc. (NYSE: ... 
Printer Friendly Version
10/25/16James W. Bullock Joins CryoLife Board of Directors
ATLANTA, Oct. 25, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced the appointment of James W. Bullock to its Board of Directors effective immediately. Pat Mackin, Chairman, President, and Chief Executive Officer,  commented, "Jim Bullock has nearly 40 years of experience in the medical device sector, including recently leading two well respected cardiac device companies, Atritech and Endocardial S... 
Printer Friendly Version
10/12/16CryoLife Announces Release Date and Teleconference Call Details for 2016 Third Quarter Financial Results
ATLANTA, Oct. 12, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2016 third quarter financial results will be released on Wednesday, October 26, 2016 after the market closes.  On Thursday, October 27, 2016 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by J. Patrick Mackin, Chairman, Presid... 
Printer Friendly Version
09/19/16CryoLife to Present at Ladenburg Thalmann 2016 Healthcare Conference
ATLANTA, Sept. 19, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016 at the Sofitel Hotel in New York. A live webcast of the Company's presentation is scheduled to begin at 1:30 p.m. ET and will feature an overview of the company by Pat Mackin, Chairman, President and Chief Exec... 
Printer Friendly Version
09/17/16CryoLife to Present at Morgan Stanley Global Healthcare Conference
ATLANTA, Sept. 7, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York. A live webcast of the Company's presentation is scheduled to begin at 4:40 p.m. ET and will feature an overview of the company and a fireside chat with Pat Mackin, Chairman, President and Chief Execut... 
Printer Friendly Version
09/17/16CryoLife Appoints James McDermid as Chief Human Resources Officer
ATLANTA, Sept. 6, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today the appointment of James McDermid to the position of Chief Human Resources Officer, effective immediately.  Mr. McDermid joins the company from Medtronic where he was Group Vice President, Human Resources for the Cardiac and Vascular Group. He will report to Pat Mackin, Chairman, President, and Chief Executive Officer. Mr. Mac... 
Printer Friendly Version
09/07/16CryoLife to Present at Morgan Stanley Global Healthcare Conference
ATLANTA, Sept. 7, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York. A live webcast of the Company's presentation is scheduled to begin at 4:40 p.m. ET and will feature an overview of the company and a fireside chat with Pat Mackin, Chairman, President and Chief Execut... 
Printer Friendly Version
09/06/16CryoLife Appoints James McDermid as Chief Human Resources Officer
ATLANTA, Sept. 6, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today the appointment of James McDermid to the position of Chief Human Resources Officer, effective immediately.  Mr. McDermid joins the company from Medtronic where he was Group Vice President, Human Resources for the Cardiac and Vascular Group. He will report to Pat Mackin, Chairman, President, and Chief Executive Officer. Mr. Mac... 
Printer Friendly Version
08/11/16CryoLife to Present at 2016 Wedbush PacGrow Healthcare Conference
ATLANTA, Aug. 11, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 in New York. A live webcast of the Company's presentation is scheduled to begin at 1:55 p.m. ET and will feature an overview of the company by Pat Mackin, Chairman, President and Chief Executive Officer. The live... 
Printer Friendly Version
08/04/16CryoLife to Present at 36th Annual Canaccord Genuity Growth Conference
ATLANTA, Aug. 4, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming 36th Annual Canaccord Genuity Annual Growth Conference on Wednesday, August 10, 2016 in Boston, MA. A live webcast of the Company's presentation is scheduled to begin at 12:30 p.m. ET and will feature an overview of the company and fireside chat with Pat Mackin, Chairman, President and Ch... 
Printer Friendly Version
07/25/16CryoLife Reports Second Quarter 2016 Financial Results
Increases 2016 Revenue and Earnings Guidance ATLANTA, July 25, 2016 /PRNewswire/ -- Second Quarter Highlights: Revenue Increased 33 Percent Year-over-Year to $47.1 Million; Non-GAAP Revenues Increased Nine Percent Year-over-Year Gross Margins Increased to 64 Percent; Non-GAAP Gross Margins Increased to 66 Percent GAAP Net Income was $2.3 Million, or $0.07 Per Fully Diluted Common Share; Non-GAAP Net Income was $4.3 Million, or $0.13 Per Fully Diluted Common share CryoLife,... 
Printer Friendly Version
07/12/16CryoLife Announces Release Date and Teleconference Call Details for 2016 Second Quarter Financial Results
ATLANTA, July 12, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2016 second quarter financial results will be released on Monday, July 25, 2016 after the market closes.  On Tuesday, July 26, 2016 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by J. Patrick Mackin, Chairman, President and C... 
Printer Friendly Version
04/27/16CryoLife Reports First Quarter 2016 Financial Results
ATLANTA, April 27, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today its results for the first quarter of 2016.  Recent Highlights: First Quarter Revenue Increased 27 Percent Year-over-Year to $43.0 Million; Pro Forma Revenues Increased Nine Percent Year-over-Year Strengthened Focus on Cardiac Surgery Technologies and Enhanced Growth Potential Through Strategic Initiatives, including: ... 
Printer Friendly Version
04/14/16CryoLife Exercises Right to Acquire PhotoFix™ Bovine Pericardium Patch from Genesee BioMedical
ATLANTA, April 14, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it has exercised its right to acquire the PhotoFix™ bovine pericardium patch ("PhotoFix") from Genesee BioMedical, Inc. for $2.3 million in cash. CryoLife acquired the distribution rights and purchase option for PhotoFix in August 2014. J. Patrick Mackin, Chairman, President, and Chief Executive Officer of CryoLife, said,... 
Printer Friendly Version
04/13/16CryoLife Announces Release Date and Teleconference Call Details for 2016 First Quarter Financial Results
ATLANTA, April 13, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2016 first quarter financial results will be released on Wednesday, April 27, 2016 after the market closes.  On Thursday, April 28, 2016 the Company will hold a teleconference call and live webcast at 8:00 a.m. ET to discuss the results, followed by a question and answer session hosted by J. Patrick Mackin, Chairman, President... 
Printer Friendly Version
03/18/16CryoLife Announces Sale of ProCol® Distribution Rights and Purchase Option to LeMaitre Vascular, Inc.
ATLANTA, March 18, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that LeMaitre Vascular, Inc. (Nasdaq: LMAT) has acquired CryoLife's ProCol Vascular Bioprosthesis ("ProCol") distribution rights and purchase option and has exercised that option to acquire ProCol from Hancock Jaffe Laboratories Inc. ("Hancock Jaffe"). J. Patrick Mackin, Chairman, President, and Chief Executive Officer of Cryo... 
Printer Friendly Version
02/17/16CryoLife to Present at RBC Capital Markets Global Healthcare Conference
ATLANTA, Feb. 17, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming RBC Capital Markets Global Healthcare Conference on Tuesday, February 23, 2016 at the New York Palace Hotel in New York. A live webcast of the Company's presentation is scheduled to begin at 1:35 p.m. ET and will feature an overview of the company by Pat Mackin, President and Chief Execu... 
Printer Friendly Version
02/15/16CryoLife Reports Fourth Quarter and Full Year 2015 Financial Results
Recent Highlights: - Completed Acquisition of On-X® Life Technologies (On-X) and Sale of HeRO® Product Line, Strengthening Focus on Cardiac Surgery and Enhancing Growth Potential - Fourth Quarter Revenues Increased 7 Percent Year-over-Year to a Record $39.8 Million - Fourth Quarter Gross Margin Improved to 67 Percent ATLANTA, Feb. 15, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today i... 
Printer Friendly Version
02/04/16CryoLife Announces Sale of HeRO Graft to Merit Medical Systems
ATLANTA, Feb. 4, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that it sold its HeRO Graft product line to Merit Medical Systems, Inc. (NASDAQ: MMSI) for $18.5 million in cash. J. Patrick Mackin, Chairman, President, and Chief Executive Officer of CryoLife, said, "The recent acquisition of On-X Life Technologies strengthened our strategic focus on aortic and mitral valve repair and replacem... 
Printer Friendly Version
02/03/16CryoLife Announces Release Date and Teleconference Call Details for 2015 Fourth Quarter and Year End Financial Results
ATLANTA, Feb. 3, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today that 2015 fourth quarter and year end financial results will be released on Tuesday, February 16, 2016.  On that day, the Company will hold a teleconference call and live webcast at 8:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Pat Mackin, president and chief executive officer of C... 
Printer Friendly Version
01/20/16CryoLife Completes Acquisition of On-X Life Technologies Holdings, Inc.
ATLANTA, Jan. 20, 2016 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of On-X Life Technologies Holdings, Inc. ("On-X"), an Austin, Texas-based, privately held mechanical heart valve company.  About CryoLife Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distrib... 
Printer Friendly Version
12/22/15CryoLife Announces Definitive Agreement to Acquire On-X Life Technologies Holdings, Inc.
Provides Entry into $220 Million Mechanical Heart Valve Market with First-and-Only Pure Pyrolytic Carbon Valve More Than Doubles U.S. Direct Cardiac Surgery Sales Force, Providing Expanded Coverage Accelerates Revenue Growth and Gross Margin Expansion Opportunities Expected to Drive Double Digit Compounded Growth in Non-GAAP earnings from 2016-2020 Conference Call and Webcast Tomorrow, December 23, 2015, at 8:00 a.m. EST ATLANTA, Dec. 22, 2015 /PRNewswire/ -- CryoLife, In... 
Printer Friendly Version
11/23/15CryoLife to Present at 27th Annual Piper Jaffray Healthcare Conference
ATLANTA, Nov. 23, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 27th Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2015 at The New York Palace Hotel in New York City. A live webcast of the Company's presentation is scheduled to begin at 2:30 p.m. ET and will feature an overview of the company and fireside chat with... 
Printer Friendly Version
11/17/15CryoLife Announces Resolution of PerClot Litigation with Medafor Inc.
ATLANTA, Nov. 17, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has entered into a resolution with Medafor Inc., a subsidiary of C.R. Bard, Inc. ("Medafor"), to end the patent dispute in the U.S. District Court for the District of Delaware (the "Court") between the companies regarding PerClot. Under terms of the resolution, which is subject to approval by the Court, all... 
Printer Friendly Version
11/10/15CryoLife to Present at Canaccord Genuity 2015 Medical Technology and Diagnostics Forum
ATLANTA, Nov. 10, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming Canaccord Genuity 2015 Medical Technology and Diagnostics Forum on Thursday, November 19, 2015 at the Westin Grand Central Hotel  in New York. A live webcast of the Company's presentation is scheduled to begin at 4:00 p.m. ET and will feature an overview of the company by Pa... 
Printer Friendly Version
10/27/15CryoLife Reports Third Quarter Financial Results
Recent Highlights: - Received Expanded Indication for BioGlue in Japan - Commenced Direct Sales in France - Strengthened Management Team ATLANTA, Oct. 27, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the third quarter and first nine months of 2015.  J. Patrick Mackin, Chairman, President, and Chief Executive Officer, said, "During the third quart... 
Printer Friendly Version
10/22/15CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2015
ATLANTA, Oct. 22, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the fourth quarter 2015 of $0.03 per share of common stock outstanding.  The quarterly cash dividend of $0.03 per share will be paid on December 18, 2015 to all common stockholders of record as of December 11, 2015.  The ex-dividend date for the quar... 
Printer Friendly Version
10/15/15CryoLife Announces Release Date and Teleconference Call Details for 2015 Third Quarter Financial Results
ATLANTA, Oct. 15, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2015 third quarter financial results will be released on Tuesday, October 27, 2015.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Of... 
Printer Friendly Version
09/21/15CryoLife to Present at Ladenburg Thalmann 2015 Healthcare Conference
ATLANTA, Sept. 21, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29, 2015 at the Sofitel Hotel in New York. A live webcast of the Company's presentation is scheduled to begin at 1:00 p.m. ET and will feature an overview of the company by Pat Mackin, President and Chief E... 
Printer Friendly Version
09/08/15CryoLife Appoints John Davis as Senior Vice President, Global Sales and Marketing
ATLANTA, Sept. 8, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the appointment of John Davis to the position of Senior Vice President, Global Sales and Marketing, effective September 8, 2015. Mr. Davis will have responsibility for CryoLife's sales and marketing teams and will report directly to Pat Mackin, Chairman, President, and Chief Executive Officer. Mr. Mackin commented,... 
Printer Friendly Version
08/05/15CryoLife to Present at Canaccord Genuity 35th Annual Growth Conference
ATLANTA, Aug. 5, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming Canaccord Genuity 35th Annual Growth Conference on Wednesday, August 12, 2015 at the InterContinental Hotel in Boston. A live webcast of the Company's presentation is scheduled to begin at 1:30 p.m. ET and will feature an overview of the company by Pat Mackin, President and C... 
Printer Friendly Version
07/28/15CryoLife Reports Second Quarter Financial Results
Recent Highlights: - Received Expanded Indication for BioGlue® in Japan - Announced Plans to Transition to Direct Sales Model in France ATLANTA, July 28, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the second quarter and first six months of 2015.  Pat Mackin, Chairman, President and Chief Executive Officer, said, "During the quarter we continued to... 
Printer Friendly Version
07/22/15CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2015
ATLANTA, July 22, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the third quarter 2015 of $0.03 per share of common stock outstanding.  The quarterly cash dividend of $0.03 per share will be paid on September 18, 2015 to all common stockholders of record as of September 11, 2015.  The ex-dividend date for the qua... 
Printer Friendly Version
07/15/15CryoLife Announces Release Date and Teleconference Call Details for 2015 Second Quarter Financial Results
ATLANTA, July 15, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2015 second quarter financial results will be released on Tuesday, July 28, 2015.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Offi... 
Printer Friendly Version
07/09/15CryoLife Receives Expanded Indication for BioGlue® in Japan
ATLANTA, July 9, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that the Japanese Pharmaceuticals and Medical Device Agency (PMDA) has approved an expanded indication for BioGlue.  BioGlue is now indicated for adhesion and support of hemostasis for aortotomy closure sites, suture/anastomosis sites (including aortic dissection and anastomosis sites with a use of a prosthetic graft), a... 
Printer Friendly Version
06/22/15CryoLife to Transition to Direct Sales Model in France
ATLANTA, June 22, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will transition to a direct sales model in France, effective October 1, 2015. This announcement confirms CryoLife's previous indications of its intent to transition to a direct sales model in a major European territory. CryoLife has concluded an agreement with its French distribution partner to facilitate this t... 
Printer Friendly Version
05/21/15CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015
ATLANTA, May 21, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the second quarter 2015 of $0.03 per share of common stock outstanding.  The quarterly cash dividend of $0.03 per share will be paid on June 19, 2015 to all common stockholders of record as of June 12, 2015.  The ex-dividend date for the quarterly div... 
Printer Friendly Version
04/28/15CryoLife Reports First Quarter Results
ATLANTA, April 28, 2015 /PRNewswire/ -- Recent Highlights: Cleared FDA Warning Letter Enrolled first patient in PerClot® IDE CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the first quarter of 2015.  Pat Mackin, Chairman, President and Chief Executive Officer, said, "We recently achieved significant milestones regarding two of our top organizational objectives.  Firs... 
Printer Friendly Version
04/28/15CryoLife Announces Enrollment of First Patient in PerClot® IDE Clinical Trial
ATLANTA, April 28, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the enrollment of the first patient in its PerClot Investigational Device Exemption (IDE) clinical trial, the Company's pivotal clinical trial to gain approval to commercialize PerClot in the U.S. "The first patient enrolled in the PerClot IDE clinical trial is a positive milestone for the Company and our strategy... 
Printer Friendly Version
04/27/15CryoLife Appoints William Matthews as Senior Vice President, Operations, Quality, and Regulatory
ATLANTA, April 27, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the appointment of William Matthews to the newly created position of Senior Vice President, Operations, Quality, and Regulatory, effective May 1, 2015.  Mr. Matthews will report directly to Pat Mackin, Chairman, President, and Chief Executive Officer. Mr. Mackin commented, "Bill is a seasoned industry executive w... 
Printer Friendly Version
04/27/15CryoLife Announces Resolution of FDA Warning Letter
ATLANTA, April 27, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received a close-out letter from the United States Food and Drug Administration ("FDA") verifying that the Company has successfully implemented corrective actions put in place following the warning letter it received from the FDA in January 2013. The close-out letter follows a re-inspection in March 20... 
Printer Friendly Version
04/21/15CryoLife Announces Release Date and Teleconference Call Details for 2015 First Quarter Financial Results
ATLANTA, April 21, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2015 first quarter financial results will be released on Tuesday, April 28, 2015.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Off... 
Printer Friendly Version
04/10/15CryoLife Announces Retirement of Founder and Executive Chairman Steven G. Anderson
ATLANTA, April 10, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced that Steven G. Anderson, 76, Executive Chairman of the Board of Directors, has decided to retire effective immediately.  As a result of his retirement, he will step down from all positions with the company and its subsidiaries, including as a member of the Board of Directors and Executive Officer of the company.  Pat Mackin,... 
Printer Friendly Version
04/01/15CryoLife Appoints Jean Holloway as General Counsel
ATLANTA, April 1, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the appointment of Jean F. Holloway to the position of Vice President, General Counsel and Corporate Secretary effective April 1, 2015.  Ms. Holloway will report directly to Pat Mackin, President and Chief Executive Officer. Mr. Mackin commented, "Jean is tremendously talented and has extensive legal experience in... 
Printer Friendly Version
03/12/15CryoLife Provides Update on PerClot Litigation
ATLANTA, March 12, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, today provided an update on its ongoing litigation with C.R. Bard, Inc. and certain of its subsidiaries regarding PerClot. The U.S. District Court for the District of Delaware (the "Court") has allowed CryoLife's declaratory judgment lawsuit against C.R. Bard's Medafor, Inc. subsidiary ("Medafor") to proceed. The Court also granted Me... 
Printer Friendly Version
02/17/15CryoLife Fourth Quarter Revenues Increase 5 Percent to $37.2 Million; Full Year Revenues Increase 3 Percent to $144.6 Million
ATLANTA, Feb. 17, 2015 /PRNewswire/ -- Financial and Recent Highlights: Product revenues grew 12 percent for the quarter and 7 percent for the full year BioGlue® revenues grew 11 percent for the quarter and 7 percent for the full year HeRO® revenues grew 10 percent for the quarter and 24 percent for the full year PerClot® revenues grew 52 percent for the quarter and 23 percent for the full year Tissue processing revenues decreased 4 percent for the quarter and 3 percent for the ... 
Printer Friendly Version
02/13/15CryoLife Announces Quarterly Cash Dividend for the First Quarter 2015
ATLANTA, Feb. 13, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the first quarter 2015 of $0.03 per share of common stock outstanding.  The quarterly cash dividend of $0.03 per share will be paid on March 20, 2015 to all common stockholders of record as of March 13, 2015.  The ex-dividend date for the quarterly d... 
Printer Friendly Version
02/05/15CryoLife Announces Release Date and Teleconference Call Details for 2014 Fourth Quarter and Year End Financial Results
ATLANTA, Feb. 5, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2014 fourth quarter and year end financial results will be released on Tuesday, February 17, 2015.  On that day, the Company will hold a teleconference call and live webcast at 8:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Pat Mackin, president and chief executive... 
Printer Friendly Version
01/21/15CryoLife Founder and Executive Chairman Steven Anderson to Receive 2015 Georgia Bio Industry Growth Award
ATLANTA, Jan. 21, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Founder and Executive Chairman, Steven G. Anderson, will receive a 2015 Georgia Bio Industry Growth Award.  Mr. Anderson is being honored for his dedication to the implantable medical device industry in the state of Georgia. The Industry Growth Awards are the highest honors bestowed each year by Georgia Bi... 
Printer Friendly Version
11/24/14CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference
ATLANTA, Nov. 24, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at The New York Palace Hotel in New York City. A live webcast of the Company's presentation is scheduled to begin at 1:30 p.m. ET and will feature an overview of the company by Pat Mackin, Preside... 
Printer Friendly Version
11/13/14CryoLife to Present at the Canaccord Genuity 2014 Medical Technology and Diagnostics Forum
ATLANTA, Nov. 13, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming Canaccord Genuity 2014 Medical Technology and Diagnostics Forum on Thursday, November 20, 2014 at the Westin Grand Central Hotel in New York. A live webcast of the Company's presentation is scheduled to begin at 3:30 p.m. ET and will feature an overview of the company by Pat... 
Printer Friendly Version
10/28/14CryoLife Third Quarter 2014 Revenues Increase 2 Percent to $37.1 Million
ATLANTA, Oct. 28, 2014 /PRNewswire/ --  Third Quarter Highlights: Appointed Pat Mackin as President and Chief Executive Officer effective September 2, 2014 Product revenues grew 8 percent year-over-year to $20.4 million BioGlue® revenues grew 6 percent year-over-year to $15.1 million HeRO® Graft revenues grew 45 percent year-over-year to $2.0 million PerClot® revenues grew 13 percent year-over-year to $1.0 million Tissue processing revenues decreased 4 percent year-over-year to... 
Printer Friendly Version
10/23/14CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2014
ATLANTA, Oct. 23, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the fourth quarter 2014 of $0.03 per share of common stock outstanding.  The quarterly cash dividend of $0.03 per share will be paid on December 19, 2014 to all common stockholders of record as of December 12, 2014.  The ex-dividend date for the quar... 
Printer Friendly Version
10/22/14Pat Mackin Joins CryoLife Board of Directors
ATLANTA, Oct. 22, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that James Patrick (Pat) Mackin, President and Chief Executive Officer, has been elected to the Company's Board of Directors, effective October 21, 2014. Steven G. Anderson, Executive Chairman of CryoLife, stated, "Since joining the Company in September, Pat has proven to be an excellent leader who is well position... 
Printer Friendly Version
10/14/14CryoLife Announces Release Date and Teleconference Call Details for 2014 Third Quarter Financial Results
ATLANTA, Oct. 14, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2014 third quarter financial results will be released on Tuesday, October 28, 2014.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Pat Mackin, president and chief executive officer of C... 
Printer Friendly Version
08/07/14CryoLife Acquires Distribution Rights and Purchase Option for Genesee BioMedical's PhotoFix™ Bovine Pericardial Patch
Anticipates U.S. Commercial Launch in October 2014 ATLANTA, Aug. 7, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has acquired the distribution rights to PhotoFix, a bovine pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde from Genesee BioMedical, Inc., a Denver, Colorado-based manufacturer of cardiac surgery instru... 
Printer Friendly Version
08/05/14CryoLife to Present at 34th Annual Canaccord Genuity Growth Conference
ATLANTA, Aug. 5, 2014 /PRNewswire/ --CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 34th Annual Canaccord Genuity Growth Conference on Wednesday, August 13, 2014 at the InterContinental Boston Hotel. A live webcast of the Company's presentation is scheduled to begin at 8:00 a.m. ET and will feature an overview of the company by D. Ashley Lee, executive vice p... 
Printer Friendly Version
07/30/14CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014
ATLANTA, July 30, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the third quarter 2014 of $0.03 per share of common stock outstanding.  The quarterly cash dividend of $0.03 per share will be paid on September 19, 2014 to all common stockholders of record as of September 12, 2014.  The ex-dividend date for the qua... 
Printer Friendly Version
07/24/14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million
ATLANTA, July 24, 2014 /PRNewswire/ -- Second Quarter and Recent Highlights: Appointed Pat Mackin as President and Chief Executive Officer effective September 2, 2014 Product revenues grew 12 percent year-over-year to $20.4 million BioGlue® revenues grew 14 percent year-over-year to $15.3 million PerClot® revenues grew 22 percent year-over-year to $1.1 million HeRO® Graft revenues grew 20 percent year-over-year to $1.7 million Tissue processing revenues decreased 6 percent year... 
Printer Friendly Version
07/15/14CryoLife Announces Release Date and Teleconference Call Details for 2014 Second Quarter Financial Results
ATLANTA, July 15, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2014 second quarter financial results will be released on Thursday, July 24, 2014.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive offic... 
Printer Friendly Version
07/10/14CryoLife Appoints Pat Mackin as President and Chief Executive Officer
ATLANTA, July 10, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has appointed James Patrick (Pat) Mackin, age 47, as President and Chief Executive Officer, effective September 2, 2014. Mr. Mackin is expected to be appointed to the Company's Board of Directors after his employment begins. Steven G. Anderson will continue to serve CryoLife as its Presi... 
Printer Friendly Version
05/22/14CryoLife Increases Quarterly Cash Dividend Nine Percent for the Second Quarter 2014
ATLANTA, May 22, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a nine percent increase in the quarterly cash dividend for the second quarter 2014 from $0.0275 to $0.03 per share of common stock outstanding.  At the new rate, the indicated dividend on an annual basis is $0.12 per share compared to the previous rate of $0.11 per share.  The qua... 
Printer Friendly Version
04/29/14CryoLife Posts Record First Quarter Revenues of $35.7 Million
ATLANTA, April 29, 2014 /PRNewswire/ --  First Quarter Highlights: Grew HeRO® Graft revenues 26 percent year-over-year to $1.6 million Received FDA approval to begin PerClot® clinical trial Received FDA 510(k) clearance for PerClot Topical Secured distribution rights and purchase option for ProCol® Vascular Bioprosthesis Established new regional headquarters in Singapore to expand presence in rapidly growing Asia-Pacific medical device market CryoLife, Inc. (NYSE: CRY), a le... 
Printer Friendly Version
04/29/14CryoLife Receives FDA 510(k) Clearance for PerClot® Topical Hemostatic Powder in the U.S.
Requests Court Confirmation that PerClot Does Not Infringe Bard Patent ATLANTA, April 29, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received 510(k) clearance for PerClot Topical hemostatic powder from the U.S. Food and Drug Administration (FDA).  This clearance allows CryoLife to begin commercialization of PerClot Topical hemostatic powder in the U.S.  The Compa... 
Printer Friendly Version
04/15/14CryoLife Announces Release Date and Teleconference Call Details for 2014 First Quarter Financial Results
ATLANTA, April 15, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2014 first quarter financial results will be released on Tuesday, April 29, 2014.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive offic... 
Printer Friendly Version
04/02/14CryoLife Receives FDA Approval to Begin Clinical Trials for PerClot® in the U.S.
ATLANTA, April 2, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration (FDA).  This approval allows CryoLife to begin its pivotal clinical trial to gain approval to commercialize PerClot in the U.S. The Company plans to begin enrollment in the trial in... 
Printer Friendly Version
03/27/14CryoLife Acquires Distribution Rights and Purchase Option for ProCol® Vascular Bioprosthesis for Hemodialysis Access
Provides access for dialysis patients; complementary to HeRO® Graft ATLANTA, March 27, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has acquired the exclusive worldwide distribution rights for the ProCol Vascular Bioprosthesis ("ProCol") from Hancock Jaffe Laboratories, Inc.  In addition, beginning 24 months after execution of the agreement, CryoLife has the right to a... 
Printer Friendly Version
03/19/14CryoLife Continues To Support Customer Education With Third Central Venous Pathology Summit
ATLANTA, March 19, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will host its third Central Venous Pathology (CVP) Summit on March 25-27, 2014 at CryoLife's training facility at its corporate headquarters in suburban Atlanta.  The Company expects that over 80 physicians and dialysis therapy professionals will attend the CVP Summit. The CVP Summit will be led by William ... 
Printer Friendly Version
02/20/14CryoLife Fourth Quarter 2013 Revenues Increased 8 Percent to a Record $35.5 Million
Issues 2014 Financial Guidance Fourth Quarter Highlights: - Earnings per share increased to $0.31 per share - Product revenues grew 11 percent year-over-year to $19.4 million - HeRO revenues grew 51 percent year-over-year to $1.7 million - BioGlue revenues grew 10 percent year-over-year to $14.7 million - Received $15.4 million for shares of Medafor common stock due to C.R. Bard's acquisition of Medafor; potential for additional payments of up to $8.4 million ATLANTA, Feb.... 
Printer Friendly Version
02/19/14CryoLife Announces Quarterly Cash Dividend for the First Quarter 2014
ATLANTA, Feb. 19, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the first quarter 2014 of $0.0275 per share of common stock outstanding.  The quarterly cash dividend of $0.0275 per share will be paid on March 21, 2014 to all common stockholders of record as of March 14, 2014.  The ex-dividend date for the quarter... 
Printer Friendly Version
02/18/14CryoLife to Present at 2014 RBC Capital Markets' Global Healthcare Conference
ATLANTA, Feb. 18, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 2014 RBC Capital Markets' Global Healthcare Conference on Wednesday, February 26, 2014 at The New York Palace Hotel in New York City. A live webcast of the Company's presentation is scheduled to begin at 10:00 a.m. ET and will feature an overview of the company by Steven G. An... 
Printer Friendly Version
02/18/14CryoLife Announces Expansion in Asia Pacific Markets
ATLANTA, Feb. 18, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the establishment of CryoLife Asia Pacific Pte. Ltd., a wholly-owned subsidiary of CryoLife, Inc., to expand the Company's presence in the rapidly growing Asia Pacific medical device market.  To support the new subsidiary, CryoLife will relocate Mr. Rich Gridley, vice president sales, Canada, Asia-Pacific, and The Ameri... 
Printer Friendly Version
02/05/14CryoLife Announces Release Date and Teleconference Call Details for 2013 Fourth Quarter and Year End Financial Results
ATLANTA, Feb. 5, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2013 fourth quarter and year end financial results will be released on Thursday, February 20, 2014.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief... 
Printer Friendly Version
11/25/13CryoLife to Present at 25th Annual Piper Jaffray Healthcare Conference
ATLANTA, Nov. 25, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at The New York Palace Hotel in New York City. A live webcast of the Company's presentation is scheduled to begin at 3:00 p.m. ET and will feature a brief overview of the company by D. Ashley Lee, e... 
Printer Friendly Version
11/21/13CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2013
ATLANTA, Nov. 21, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the fourth quarter 2013 of $0.0275 per share of common stock outstanding.  The quarterly cash dividend of $0.0275 per share will be paid on December 20, 2013 to all common stockholders of record as of December 13, 2013.  The ex-dividend date for the ... 
Printer Friendly Version
11/05/13CryoLife To Host Second Central Venous Pathology Summit in 2013
ATLANTA, Nov. 5, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will host its second Central Venous Pathology (CVP) Summit of the year on November 7-8, 2013 at CryoLife's training facility at its corporate headquarters in suburban Atlanta and at the St. Joseph Translational Research Institute in Atlanta, Georgia.  The Company expects approximately 80 physicians and dialysis t... 
Printer Friendly Version
10/29/13CryoLife Third Quarter 2013 Revenues Increase 8 Percent to a Record $36.3 Million
Increases 2013 Financial Guidance ATLANTA, Oct. 29, 2013 /PRNewswire/ -- Third Quarter and Recent Financial Highlights: Net income increases 106 percent to $3.2 million, or $0.11 per share Product revenues grew 11 percent year-over-year to $18.8 million Tissue processing revenues grew 6 percent year-over-year to $17.4 million BioGlue revenues grew 12 percent year-over-year to $14.2 million Revascularization technologies revenues grew 14 percent year-over-year In October, r... 
Printer Friendly Version
10/24/13CryoLife Receives $15.4 Million Payment for its Shares of Medafor, Inc.
Third Quarter 2013 Results and Update Conference Call Scheduled for Tuesday, October 29, 2013 at 10:00 am ET ATLANTA, Oct. 24, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced that it received in the fourth quarter of 2013 a payment of $15.4 million for its 2,379,554 shares of Medafor, Inc. common stock associated with the closing of the acquisition of Medafor, Inc. Third Quarter 20... 
Printer Friendly Version
10/14/13CryoLife Announces Release Date and Teleconference Call Details for 2013 Third Quarter Financial Results
ATLANTA, Oct. 14, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2013 third quarter financial results will be released on Tuesday, October 29, 2013.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive offi... 
Printer Friendly Version
10/07/13CryoLife to Receive Approximately $15.1 Million from Acquisition of Medafor, Inc. by C. R. Bard, Inc.
ATLANTA, Oct. 7, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that it expects to receive an initial payment of approximately $15.1 million for its 2,379,554 shares of Medafor common stock due to C.R. Bard, Inc.'s acquisition of Medafor, Inc.  CryoLife could receive additional payments of up to $8.4 million upon the release of funds held in escrow and the satisfaction of certain con... 
Printer Friendly Version
09/16/13CryoLife To Host Aortic Valve and Root Training Session
Educational Program on Advanced Surgical Techniques for Cardiac Surgery Residents ATLANTA, Sept. 16, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that it will host an Aortic Valve and Root "Boot Camp" training session on September 18-20, 2013 at CryoLife's training facility at its corporate headquarters in suburban Atlanta. The course directors for the training session will be... 
Printer Friendly Version
08/21/13CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2013
ATLANTA, Aug. 21, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the third quarter 2013 of $0.0275 per share of common stock outstanding.  The quarterly cash dividend of $0.0275 per share will be paid on September 20, 2013 to all common stockholders of record as of September 13, 2013.  The ex-dividend date for the... 
Printer Friendly Version
07/31/13CryoLife Announces First European Implant Of HeRO Graft
University of Leuven in Belgium first to use new solution for end-stage renal disease hemodialysis patients ATLANTA, July 31, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that the first European clinical implant of the Company's HeRO (Hemodialysis Reliable Outflow) Graft was performed at the University of Leuven Hospital in Belgium.  The procedure was performed by Professor In... 
Printer Friendly Version
07/25/13CryoLife Reports Record Second Quarter Revenues
ATLANTA, July 25, 2013 /PRNewswire/ -- Second Quarter Financial Highlights: Product revenues grew 9 percent year-over-year to $18.2 million PerClot® revenue grew 36 percent year-over-year Revascularization technologies revenue grew 19 percent year-over-year HeRO® Graft revenue increased to $1.4 million Increased quarterly cash dividend 10 percent to $0.0275 per share   Second Quarter Regulatory Highlights: Received conditional approval to begin PerClot clinical trial... 
Printer Friendly Version
07/11/13CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
ATLANTA, July 11, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2013 second quarter financial results will be released on Thursday, July 25, 2013.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive offic... 
Printer Friendly Version
07/10/13CryoLife Receives FDA Premarket Approval (PMA) for New Sologrip Minimally Invasive TMR Laser Fiber-Optic Delivery System
ATLANTA, July 10, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received U.S. Food and Drug Administration (FDA) premarket approval for its new Sologrip® minimally invasive laser fiber-optic delivery system.  The Sologrip delivery system is a single-use, disposable handset designed for use with the Company's Cardiogenesis transmyocardial revascularization (TMR) system.  ... 
Printer Friendly Version
07/09/13CryoLife Enhances International Presence with Appointment of Andres Sarmiento as Latin America Sales Manager
ATLANTA, July 9, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today it has appointed Andres Sarmiento as Latin American Sales Manager for CryoLife, Inc.  In this newly created position, Mr. Sarmiento will have responsibility for expanding sales of CryoLife's full product line in the Latin American region.  CryoLife's products are currently sold in Argentina, Chile, Uruguay, Paraguay, Bra... 
Printer Friendly Version
06/19/13CryoLife Receives Conditional IDE Approval to Begin Clinical Trials for PerClot® in the U.S.
ATLANTA, June 19, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that it has received conditional approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration (FDA). PerClot is a unique hemostat composed of absorbable polysaccharide granules and is intended for use in surgical procedures as an adjunctive hemostatic device w... 
Printer Friendly Version
06/10/13CryoLife Receives CE Mark For HeRo® Graft
First European Cases Anticipated in July, Followed by Controlled Market Introduction in the Second Half of 2013 ATLANTA, June 10, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today achievement of a CE (Conformite Europeenne) Mark for the HeRO (Hemodialysis Reliable Outflow) Graft system produced at the Company's new manufacturing facility in Atlanta. The HeRO Graft is a proprietary ... 
Printer Friendly Version
05/28/13CryoLife Increases Quarterly Cash Dividend 10 Percent for the Second Quarter 2013
ATLANTA, May 28, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a 10 percent increase in the quarterly cash dividend for the second quarter 2013 from $0.025 to $0.0275 per share of common stock outstanding.  At the new rate, the indicated dividend on an annual basis is $0.11 per share compared to the previous rate of $0.10 per share.  The quar... 
Printer Friendly Version
04/30/13CryoLife 2013 First Quarter Revenues Grew 10 Percent to a Record $35.5 Million
ATLANTA, April 30, 2013 /PRNewswire/ -- First Quarter and Recent Highlights: Total revenues grew 10 percent year-over-year to a record $35.5 million Product revenues grew 20 percent year-over-year to $19.8 million Received 510(k) clearance for next generation HeRO® device Central Venous Pathology Summit attended by over 50 healthcare professionals Earnings per share doubles to $0.08 Reiterates 2013 financial guidance CryoLife, Inc. (NYSE: CRY), a leading tissue processing ... 
Printer Friendly Version
04/09/13CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
ATLANTA, April 9, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2013 first quarter financial results will be released on Tuesday, April 30, 2013.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive office... 
Printer Friendly Version
04/08/13CryoLife To Host Central Venous Pathology Summit
Educational Summit to Highlight HeRO® Graft and Other Emerging Technologies to 75+ Healthcare Professionals Focused on End-Stage Renal Disease ATLANTA, April 8, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will host a Central Venous Pathology (CVP) Summit on April 18-19, 2013 at CryoLife's training facility at its corporate headquarters in suburban Atlanta and at the S... 
Printer Friendly Version
04/04/13CryoLife Receives FDA Clearance For Next Generation HeRO Device
New Adaptor Allows Use with Early Access Arterial Grafts ATLANTA, April 4, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a next generation HeRO (Hemodialysis Reliable Outflow) device.  The HeRO device is the only subcutaneous AV access solution clinically proven to maintain long-term access for en... 
Printer Friendly Version
02/14/13CryoLife Expands Stock Repurchase Program
ATLANTA, Feb. 14, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that its Board of Directors authorized the Company's purchase of $15 million of its common stock through October 31, 2014.  Under this program, the purchase of shares can be made from time to time in the open market or through privately negotiated transactions on such terms as management deems appropr... 
Printer Friendly Version
02/14/13CryoLife 2012 Annual Revenues Grew to a Record $131.7 Million
Provides 2013 Financial Guidance ATLANTA, Feb. 14, 2013 /PRNewswire/ -- Full Year Highlights: Total revenues grew 10% year-over-year to a record $131.7 million Product revenues grew 14% year-over-year to $67.5 million Tissue processing revenues grew 6% year-over-year to $63.6 million Generated $19.0 million in cash flow from operations Fourth Quarter Highlights: Total revenues grew 8% year-over-year to a record $32.8 million Product revenues grew 13% year-over-year... 
Printer Friendly Version
02/13/13CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
ATLANTA, Feb. 13, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the first quarter 2013 of $0.025 per share of common stock outstanding.  The quarterly cash dividend of $0.025 per share will be paid on March 21, 2013 to all common stockholders of record as of March 14, 2013.  The ex-dividend date for the quart... 
Printer Friendly Version
01/31/13CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
ATLANTA, Jan. 31, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2012 fourth quarter and year end financial results will be released on Thursday, February 14, 2013.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and ... 
Printer Friendly Version
12/05/12CryoLife Receives Expanded Indication for BioFoam in Europe
ATLANTA, Dec. 5, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received regulatory approval in Europe to market its BioFoam® Surgical Matrix as an adjunct to hemostasis in cardiovascular surgery when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  BioFoam has previously been approved in Europe as an adjunct to hemostasi... 
Printer Friendly Version
11/20/12CryoLife to Present at 24th Annual Piper Jaffray Health Care Conference
ATLANTA, Nov. 20, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 24th Annual Piper Jaffray Health Care Conference on Tuesday, November 27, 2012 at The New York Palace Hotel in New York City. The live webcast is scheduled to begin at 3:30 p.m. ET and will feature a brief overview of the company by D. Ashley Lee, executive vice president,... 
Printer Friendly Version
11/19/12CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2012
ATLANTA, Nov. 19, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the fourth quarter 2012 of $0.025 per share of common stock outstanding. The quarterly cash dividend of $0.025 per share will be paid on December 21, 2012 to all common stockholders of record as of December 14, 2012. The ex-dividend date for the ... 
Printer Friendly Version
11/06/12CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
ATLANTA, Nov. 6, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that Steven G. Anderson, president and chief executive officer of CryoLife, Inc., is scheduled to present in the upcoming Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 3:00 pm ET in New York City.  CryoLife's live presentation may be accessed through its Web site, www.cr... 
Printer Friendly Version
10/30/12CryoLife Reports 13% Revenue Growth for Third Quarter 2012
Increases Full Year 2012 Revenue and EPS Guidance Updated dial-in information for the 10 a.m. teleconference is contained in the press release below Third Quarter Highlights: - Total revenues grew 13% year-over-year to $33.4 million - Product revenues grew 13% year-over-year to $16.9 million - Tissue processing revenues grew 12% year-over-year to $16.4 million - EPS of $0.06, or $0.08 on a non-GAAP basis - Generated $6.1 million in cash flow from operations - Initiated $0... 
Printer Friendly Version
10/11/12CryoLife Announces Release Date and Teleconference Call Details for 2012 Third Quarter Financial Results
ATLANTA, Oct. 11, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2012 third quarter financial results will be released on Tuesday, October 30, 2012.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive ... 
Printer Friendly Version
08/21/12CryoLife Announces Initiation of Quarterly Cash Dividend
ATLANTA, Aug. 21, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved the initiation of a quarterly cash dividend of $0.025 per share of common stock outstanding.  The initial quarterly cash dividend of $0.025 per share will be paid on September 21, 2012 to all common stockholders of record as of September 14, 2012.  The ex-dividend date for th... 
Printer Friendly Version
07/31/12CryoLife Reports 13% Revenue Growth for Second Quarter 2012
Increases Full Year 2012 Revenue and EPS Guidance Second Quarter Highlights: - Total revenue grew 13% year-over-year to $33.2 million - Product revenues grew 15% year-over-year to $16.7 million - Tissue processing revenues grew 11% year-over-year to $16.3 million - Net income grew 83% year-over-year to $3.3 million, or $0.12 per share - Enhanced product portfolio with acquisition of Hemosphere - Settled all significant outstanding litigation ATLANTA, July 31, 2012 /PR... 
Printer Friendly Version
07/11/12CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
ATLANTA, July 11, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that 2012 second quarter financial results will be released on Tuesday, July, 31, 2012.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive o... 
Printer Friendly Version
06/14/12CryoLife Announces Settlement of Patent Litigation with CardioFocus
ATLANTA, June 14, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery, announced today that it has entered into a settlement agreement with CardioFocus, Inc. ending the outstanding patent dispute between CryoLife's wholly owned subsidiary, Cardiogenesis Corporation (acquired by CryoLife in May 2011), and CardioFocus that was pending in the United States District Court of Massachusetts. Under the terms of the settlement,... 
Printer Friendly Version
06/14/12CryoLife Announces Settlement of Medafor Lawsuit
CryoLife to Receive $3.5 Million Settlement Payment ATLANTA, June 14, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery, announced today that it has reached full settlement of the outstanding CryoLife, Inc. v. Medafor, Inc. lawsuit that was pending in the Northern District Court of Georgia. Under terms of the settlement, Medafor has agreed to pay CryoLife $3.5 million in cash. Fifty percent of the p... 
Printer Friendly Version
05/23/12CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
ATLANTA, May 23, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 3rd Annual Benchmark Company, LLC One-on-One Investor Conference on Thursday, May 31, 2012 in Milwaukee. D. Ashley Lee, executive vice president, chief operating officer, and chief financial officer of CryoLife, Inc., will participate on behalf of the Company.  This conference will allow institu... 
Printer Friendly Version
05/21/12Jon Salveson Joins CryoLife Board of Directors
ATLANTA, May 21, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery, announced today that Jon Salveson, Vice Chairman of Investment Banking at Piper-Jaffray & Co (NYSE: PJC), has been elected to the Company's Board of Directors, effective May 16, 2012. Steven G. Anderson, Chairman, President and Chief Executive Officer of CryoLife, said, "Jon is an expert in the medical devices industry having spent the last 19 ye... 
Printer Friendly Version
05/16/12CryoLife Completes Acquisition of Hemosphere
ATLANTA, May 16, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of Hemosphere, Inc.  Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction. CryoLife wi... 
Printer Friendly Version
05/15/12CryoLife to Acquire Hemosphere
HeRO® Graft is Standard of Care to Establish Permanent Access for Catheter Dependent Hemodialysis Patients Leverages CryoLife's Cardiovascular Sales Force to Accelerate HeRO Graft Growth in $250+ Million Worldwide Market Opportunity Conference Call Scheduled for 11:00 am ET ATLANTA, May 15, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has signed a definitive agre... 
Printer Friendly Version
04/26/12CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Product Segment Revenues Grew 14 Percent Year-over-year to $16.5 million, including 14 Percent BioGlue® Revenue Growth Reiterates Full Year 2012 Revenue and EPS Guidance ATLANTA, April 26, 2012 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today its results for the first quarter of 2012. Revenues for the first quarter of 2012 increased 7 percent to a record $32.3 million compa... 
Printer Friendly Version
04/12/12CryoLife Announces Release Date and Teleconference Call Details for 2012 First Quarter Financial Results
ATLANTA, April 12, 2012 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that 2012 first quarter financial results will be released on Thursday, April 26, 2012. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief exec... 
Printer Friendly Version
02/16/12CryoLife Reports Record Quarterly Revenues in Fourth Quarter of 2011
Provides 2012 Financial Guidance, Including 5 percent to 8 percent Total Revenue Growth and 10 percent to 15 percent Growth in Product Segment 2011 Earnings of $0.26 Per Share vs. 2010 Earnings of $0.14 Per Share Operating Cash Flow Totals $16.8 Million for 2011 ATLANTA, Feb. 16, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today its results for the fourth quarter and full ye... 
Printer Friendly Version
02/02/12CryoLife Announces Release Date and Teleconference Call Details for 2011 Fourth Quarter and Year End Financial Results
ATLANTA, Feb. 2, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that 2011 fourth quarter and year end financial results will be released on Thursday, February 16, 2012.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and c... 
Printer Friendly Version
01/04/12CryoLife Enhances Management Team with Promotions
New Vice Presidents Provide Added Focus to Key Growth Drivers ATLANTA, Jan. 4, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has promoted David C. Gale, Ph.D., to the position of Vice President, Research and Development; and David P. Lang to the newly created position of Vice President, Market Development Surgical Adhesives and Starch Medical Rel... 
Printer Friendly Version
11/29/11CryoLife to Present at 6th Annual Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference
ATLANTA, Nov. 29, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 6th Annual Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference on Tuesday, December 6, 2011 at the St. Regis Hotel in San Francisco. D. Ashley Lee, executive vice president, chief operating office, and chief financial officer of CryoLife, Inc., ... 
Printer Friendly Version
11/21/11CryoLife to Present at 23rd Annual Piper Jaffray Health Care Conference
ATLANTA, Nov. 21, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 23rd Annual Piper Jaffray Health Care Conference on Wednesday, November 30, 2011 at The New York Palace Hotel in New York City. Steven G. Anderson, president and chief executive officer of CryoLife, Inc., is scheduled to present at 4:00 p.m. Eastern Time.   CryoLife's live... 
Printer Friendly Version
11/03/11CryoLife to Present at Upcoming Investor Conferences in New York
ATLANTA, Nov. 3, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that Steven G. Anderson, president and chief executive officer of CryoLife, Inc., is scheduled to present in the upcoming Lazard Capital Markets Eighth Annual Healthcare Conference on Tuesday, November 15, 2011 at 3:00 pm ET in New York City. CryoLife is also scheduled to present at the Stephens, Inc Fall In... 
Printer Friendly Version
11/01/11CryoLife Expands Stock Repurchase Program
ATLANTA, Nov. 1, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that its Board of Directors authorized the Company's purchase of $15 million of its common stock through December 31, 2012. The $15 million in new purchases includes approximately $7.7 million remaining from a $15 million stock repurchase program that the Board of Directors authorized in May 2010 and that was ... 
Printer Friendly Version
10/31/11CryoLife Closes $20 Million Credit Facility with GE Capital, Healthcare Financial Services
ATLANTA, Oct. 31, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced it has entered into a credit facility with GE Capital, Healthcare Financial Services for up to $20 million in revolving credit for working capital, acquisitions and other corporate purposes.  The credit agreement expands upon the Company's borrowing capacity from its previous facility of $15 million and expires in Octobe... 
Printer Friendly Version
10/27/11CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
Third Quarter BioGlue Revenues Increase 10 Percent Compared to Third Quarter 2010 Third Quarter Net Income of $0.07 Per Share; Non-GAAP Adjusted Net Income of $0.08 Per Share Operating Cash Flow of $13.7 Million for the Nine Months Ended September 30, 2011 ATLANTA, Oct. 27, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today its results for the third quarter and first nin... 
Printer Friendly Version
10/24/11CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
ATLANTA, Oct. 24, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc., (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver pare... 
Printer Friendly Version
10/17/11CryoLife Announces Release Date and Teleconference Call Details for 2011 Third Quarter Financial Results
ATLANTA, Oct. 17, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that 2011 third quarter financial results will be released on Thursday, October 27, 2011. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief exe... 
Printer Friendly Version
10/13/11CryoLife Provides Update on ValveXchange®, Inc. Investment
ValveXchange successfully completed first human implants with Vitality two-part heart valve system ATLANTA, Oct. 13, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that ValveXchange, Inc., a company in which CryoLife owns a minority interest, has completed the first three human implants with its novel Vitality(TM) two-part heart valve system. The surgeries were perfor... 
Printer Friendly Version
07/28/11CryoLife Reports Record Revenues for the Second Quarter and First Six Months of 2011
Advances Growth Strategy with Acquisition of Cardiogenesis and Investment in ValveXchange® Inc. Second Quarter Net Income of $0.07 Per Share; Non-GAAP Adjusted Net Income of $0.12 Per Share ATLANTA, July 28, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today its results for the second quarter and first six months of 2011. Revenues for the second quarter were a record $29.4... 
Printer Friendly Version
07/20/11CryoLife Announces Release Date and Teleconference Call Details for 2011 Second Quarter Financial Results
ATLANTA, July 20, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced todaythat 2011 second quarter financial results will be released on Thursday, July 28, 2011. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief execut... 
Printer Friendly Version
07/07/11CryoLife Makes Equity Investment in ValveXchange® Inc.
New Heart Valve Technology being Developed to Offer a Lifetime Tissue Valve Platform for Patients of All Ages ATLANTA, July 7, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today a $3.5 million equity investment in ValveXchange® Inc. ValveXchange is a private medical device company that was spun-off out of Cleveland Clinic to develop a lifetime heart valve replacement technol... 
Printer Friendly Version
05/17/11CryoLife Announces Completion of Acquisition of Cardiogenesis
ATLANTA, and IRVINE, Calif., May 17, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced that it has successfully completed its acquisition of Cardiogenesis Corporation ("Cardiogenesis"). The acquisition of Cardiogenesis adds to the company's portfolio a leading surgical product used in the treatment of diffuse coronary artery disease and severe angina. Cardiogenesis had sales of appr... 
Printer Friendly Version
05/06/11CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
Cardiogenesis Calls Special Meeting of Shareholders for May 16, 2011 to Approve Merger ATLANTA and IRVINE, Calif., May 6, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced the final results of its tender offer, including proration results, through its wholly owned subsidiary CL Falcon, Inc., for 49.9 percent of the outstanding shares of Cardiogenesis Corporation ("Cardiogenesis") (O... 
Printer Friendly Version
05/03/11CryoLife Completes Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
ATLANTA and IRVINE, Calif., May 3, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced the completion of its tender offer, through its wholly owned subsidiary CL Falcon, Inc., for 49.9 percent of the outstanding shares of Cardiogenesis Corporation ("Cardiogenesis") (OTCQB: CGCP). The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on Monday, May 2, 2011. ... 
Printer Friendly Version
04/28/11CryoLife Posts Record Quarterly Revenues of $30.2 Million
First quarter Net Income of $0.06 Per Share; Non-GAAP Adjusted Net Income of $0.09 Per Share Excluding Items ATLANTA, April 28, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the first quarter of 2011. Revenues for the first quarter increased 2 percent to a quarter record of $30.2 million compared to $29.7 million for the first quarter of 2010. "We continue t... 
Printer Friendly Version
04/25/11CryoLife Launches BioGlue(R) Surgical Adhesive in Japan
ATLANTA, April 25, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced that its BioGlue Surgical Adhesive has launched in Japan and is expected to be available in hospitals by late May 2011. BioGlue received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for use in the repair of aortic dissections in September 2010. Prior to distribution, MHLW complet... 
Printer Friendly Version
04/18/11CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results
ATLANTA, April 18, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that 2011 first quarter financial results will be released on Thursday, April 28, 2011. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive offi... 
Printer Friendly Version
04/18/11CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation
ATLANTA and IRVINE, Calif., April 18, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced the expiration of the 20-day "go-shop" period that is part of its definitive agreement with Cardiogenesis Corporation ("Cardiogenesis"), whereby CryoLife is conducting a cash tender offer for 49.9 percent of the outstanding shares of Cardiogenesis. During the "go-shop" period, Cardiogenesis was... 
Printer Friendly Version
04/15/11CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
Reduces shares sought to 49.9 percent of outstanding shares Committed to acquiring remaining Cardiogenesis shares in subsequent merger ATLANTA and IRVINE, Calif., April 15, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced it has amended its tender offer related to its proposed acquisition of Cardiogenesis Corporation ("Cardiogenesis") to acquire only 49.9 percent of the outstandin... 
Printer Friendly Version
04/05/11CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
ATLANTA and IRVINE, Calif., April 5, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE:CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it, through its wholly-owned subsidiary CL Falcon, Inc., has commenced a cash tender offer for all outstanding shares of Cardiogenesis Corporation (OTCQB: CGCP) common stock. The tender offer is being made pursuant to the previously announced definitive Agreement and Plan of Merger dated Mar... 
Printer Friendly Version
04/04/11CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot(R) in the U.S.
ATLANTA, April 4, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today thatit has filed an IDE with the United States Food and Drug Administration (FDA) to begin clinical trials for the purpose of obtaining Pre-Market Approval (PMA) to distribute PerClot in the U.S. to control bleeding during surgical procedures or following traumatic injuries. PerClot is a unique, absorbable powder ... 
Printer Friendly Version
03/29/11CryoLife Signs Definitive Agreement to Acquire Cardiogenesis
Acquisition represents significant addition to CryoLife's cardiovascular surgery portfolio All-cash transaction values Cardiogenesis at approximately $22 million and is expected to be break-even to slightly accretive to CryoLife diluted net earnings per share in 2011, excluding acquisition-related charges and integration costs CryoLife will host a conference call at 10:00 AM Eastern Time ATLANTA, and IRVINE, Calif., March 29, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an imp... 
Printer Friendly Version
02/17/11CryoLife Posts Record Annual Revenues of $116.6 Million
2010 Operating Cash Flow Increases to $20.8 Million Fourth Quarter Net Income of $0.08 Per Share ATLANTA, Feb. 17, 2011 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the fourth quarter and the full year of 2010. Revenues for the fourth quarter increased 2 percent to a fourth quarter record of $29.2 million compared to $28.6 million for the fourth quarter of 2009. ... 
Printer Friendly Version
02/01/11CryoLife Announces Release Date and Teleconference Call Details for 2010 Fourth Quarter and Year End Financial Results
ATLANTA, Feb. 1, 2011 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that 2010 fourth quarter and year end financial results will be released on Thursday, February 17, 2011. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief... 
Printer Friendly Version
11/09/10CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
ATLANTA, Nov. 9, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it will participate in the Lazard Capital Markets 7th Annual Healthcare Conference at The St. Regis Hotel in New York City. Steven G. Anderson, president and CEO of CryoLife, Inc., will present a corporate overview on Tuesday, November 16, 2010 at 4:10 p.m., Eastern Time. CryoLife's live presentation may be ac... 
Printer Friendly Version
11/04/10CryoLife Posts Record Third Quarter Revenues of $28.4 Million
Operating Cash Flow for the First Nine Months of 2010 Reaches $13.8 million ATLANTA, Nov. 4, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the third quarter of 2010. Revenues for the third quarter increased 1 percent to a third quarter record of $28.4 million compared to $28.2 million for the third quarter of 2009. "During the third quarter we achieved signific... 
Printer Friendly Version
10/25/10CryoLife Begins Distribution of Blood-Clotting Agent PerClot(R) in Europe
European Distribution Comes on Heels of Worldwide Distribution and Manufacturing Agreement with Starch Medical, Inc. ATLANTA, Oct 25, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today thatit has begun European distribution of PerClot(R), a novel polysaccharide hemostatic agent used to control bleeding during surgical procedures or following traumatic injuries. "PerClot is an exci... 
Printer Friendly Version
10/14/10CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
ATLANTA, Oct 14, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that 2010 third quarter financial results will be released on Thursday, November 4, 2010. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive off... 
Printer Friendly Version
10/12/10The Ross Summit 2010 to Focus on New Survival Data, Technique Refinement and Availability of the Procedure
CryoLife's Third Annual Surgical Congress for the Ross Procedure to Draw More Than 100 Cardiovascular Surgeons From Around the World ATLANTA, Oct 12, 2010 /PRNewswire via COMTEX/ -- More than 100 cardiovascular surgeons and cardiologists from 25 countries are scheduled to attend the third annual global Ross Summit, a two-day surgical congress focused on the Ross Procedure. Filled with a number of point-counterpoint discussions, the forum will feature the presentation of much new data about t... 
Printer Friendly Version
10/07/10CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
ATLANTA, Oct 07, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced that its BioGlue Surgical Adhesive has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for use in the repair of aortic dissections. CryoLife's partner Century Medical, Inc. (CMI) will distribute BioGlue in Japan for use in this subset of cardiac surgery. Prior to distribution, ... 
Printer Friendly Version
10/04/10David P. Lang Appointed Vice President of CryoLife International, Inc.
ATLANTA, Oct 04, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has appointed David P. Lang as vice president of market development for CryoLife International Inc. In this newly created position, Mr. Lang will have responsibility for coordinating and developing the international marketing and distribution strategies for PerClot, a novel hemostatic agent that the Company rec... 
Printer Friendly Version
09/28/10CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
ATLANTA, Sept 28, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has entered into a worldwide distribution agreement and a manufacturing agreement with Starch Medical Inc. (SMI) of San Jose, California for PerClot(R), a novel polysaccharide hemostatic agent used in surgery. PerClot is a unique, absorbable powder hemostat that has CE Mark designation allowing commercial ... 
Printer Friendly Version
09/15/10CryoLife to Present at UBS Global Life Sciences Conference
ATLANTA, Ga., Sept 15, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it will participate in the UBS Global Life Sciences Conference at The Grand Hyatt Hotel in New York City. D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present a corporate overview on Tuesday, September 21, 2010 at 3:30 p.m., Eastern Ti... 
Printer Friendly Version
08/09/10CryoLife Receives FDA 510(k) Clearance for CryoPatch(R) SG Pulmonary Human Cardiac Patch Shelf-life Extension
ATLANTA, Aug 09, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch(R) SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft(R) technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular r... 
Printer Friendly Version
07/29/10CryoLife Posts Record Second Quarter Revenues and Operating Income
Reports fully diluted earnings per share of $0.10 for second quarter of 2010 Grows six month revenues by 8 percent to a six month record $59.0 million ATLANTA, July 29, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the second quarter of 2010. Revenues for the second quarter increased 4 percent to a second quarter record of $29.3 million compared to $28.2 milli... 
Printer Friendly Version
07/08/10CryoLife Announces Release Date and Teleconference Call Details for 2010 Second Quarter Financial Results
ATLANTA, July 8, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that 2010 second quarter financial results will be released on Thursday, July 29, 2010. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive office... 
Printer Friendly Version
06/30/10CryoLife Announces Medafor Resuming Shipments of HemoStase(R)
ATLANTA, June 30, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that Medafor, Inc. is in the process of shipping approximately $2.1 million in HemoStase in accordance with the terms of the parties exclusive distribution agreement ("EDA"). On June 28, 2010 Medafor and CryoLife participated in a hearing with the District Court for the Northern District of Georgia, Atlanta Divisi... 
Printer Friendly Version
06/16/10CryoLife to Present at Sidoti's 2010 Semi Annual New York Micro-Cap Conference
ATLANTA, June 16, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it will participate in the Sidoti & Company, LLC 2010 Semi Annual New York Micro-Cap Conference at The Grand Hyatt Hotel. Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will present a corporate overview on Friday, June 25, 2010 at 10:00 a.m., Eastern Time. A copy of CryoLif... 
Printer Friendly Version
06/08/10CryoLife Receives FDA 510(k) Clearance for CryoValve(R) SG Pulmonary Heart Valve Shelf-life Extension
ATLANTA, June 8, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc., (NYSE: CRY) a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoValve(R) SG pulmonary human heart valve processed with the Company's proprietary SynerGraft(R) technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from the valve wit... 
Printer Friendly Version
06/07/10CryoLife Strengthens BioGlue(R) Surgical Adhesive Portfolio with Patent Purchase
ATLANTA, June 7, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company whose products include BioGlue Surgical Adhesive, announced today that it has completed the purchase of U.S. patent # 6,329,337. The patent involves the formulation and use of recombinant human serum albumin and gluteraldehyde, and now becomes part of CryoLife's protein hydrogel patent portfolio, which includes BioGlue. "CryoLife wi... 
Printer Friendly Version
06/01/10CryoLife Board of Directors Authorizes Purchase of its Common Stock
ATLANTA, June 1, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that its Board of Directors has authorized the purchase of up to $15 million of its common stock over the course of the next two years, beginning no earlier than June 2, 2010. The purchase of shares will be made from time to time in the open market or through privately negotiated transactions on such terms as manageme... 
Printer Friendly Version
05/27/10CryoLife to Present at Jefferies 2010 Global Life Sciences Conference
ATLANTA, May 27, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it will participate in the Jefferies 2010 Global Life Sciences Conference at The Grand Hyatt Hotel in New York City. Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will present a corporate overview on Tuesday, June 8, 2010 at 9:30 a.m., Eastern Time. CryoLife's live presentation ... 
Printer Friendly Version
05/25/10CryoLife Sends Letter to Medafor, Inc. Shareholders
ATLANTA, May 25, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has sent a letter to Medafor shareholders, which is included below. May 25, 2010 Medafor Shareholders: WITHHOLD Your Vote on Directors Pasquale, Gray, Halverson, Shope and Van Eeckhout Important Proxy Voting Materials ... 
Printer Friendly Version
04/28/10CryoLife Grows First Quarter Revenues by 11 Percent to a Record $29.7 Million
Posts fully diluted earnings per share of $0.07 for first quarter of 2010 ATLANTA, April 28, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today its results for the first quarter of 2010. Revenues for the first quarter increased 11 percent to a quarterly record of $29.7 million compared to $26.7 million for the first quarter of 2009. Net income for the first quarter of 2010 was $1.... 
Printer Friendly Version
04/15/10CryoLife Announces Release Date and Teleconference Call Details for 2010 First Quarter Financial Results
ATLANTA, April 15, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that 2010 first quarter financial results will be released on Wednesday, April 28, 2010. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive of... 
Printer Friendly Version
04/13/10Medafor Abandons Efforts to Deny Shareholder Status to CryoLife CEO
ATLANTA, April 13, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that the lawsuit filed by Medafor, Inc. against Steven G. Anderson, CryoLife's chairman, president and chief executive officer, in November 2009 was settled. The matter was mediated on April 6, 2010, with Myron S. Greenberg serving as mediator. The settlement does not require that Mr. Anderson make any payments to Med... 
Printer Friendly Version
03/30/10CryoLife Files for Preliminary Injunction Against Medafor
CryoLife Believes Attempt to Terminate Distribution Agreement Is Improper ATLANTA, March 30, 2010 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it filed an emergency motion for a preliminary injunction against Medafor, Inc. in the United States District Court for the Northern District of Georgia, Atlanta division. CryoLife contends that Medafor is improperly attempting to termina... 
Printer Friendly Version
03/24/10CryoLife Withdraws Its Proposal to Acquire Medafor
ATLANTA, March 24, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has withdrawn its $2.00 per share proposal to acquire Medafor, Inc. CryoLife previously notified the Medafor board of its intention to withdraw its offer in five business days. Based on the limited information that Medafor has made available to its shareholders, CryoLife continues to believe that the Medafo... 
Printer Friendly Version
03/19/10CryoLife Comments on Status of Medafor Distribution Agreement
ATLANTA, March 19, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today responded to Medafor's allegation that it has repudiated the Exclusive Distribution Agreement ("Agreement") between the two companies. On March 18, 2010, Medafor informed CryoLife that it is treating the Agreement as terminated. Medafor alleges that it had reasonable grounds, pursuant to Georgia law, to demand that CryoLife p... 
Printer Friendly Version
03/18/10CryoLife Sends Letter to Medafor, Inc. Board of Directors
ATLANTA, March 18, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has sent the following letter to Medafor's Board of Directors: March 18, 2010 VIA FEDEX Michael F. Pasquale, Chairman of the Board Medafor, Inc. Dear Michael, As Medafor's largest shareholder, CryoLife is deeply concerned about the rationale for and transparency surrounding Medafor's recent agreem... 
Printer Friendly Version
03/11/10CryoLife Sends Letter to Medafor, Inc. Shareholders
ATLANTA, March 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE:CRY - News), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has sent a letter to Medafor shareholders, which is included below.   CryoLife is being advised by Leerink Swann, LLC as financial advisors. Important Information for Medafor Shareholders March 10, 2010 Dear Fellow Medafor Shareholder: In their communications to Medafor shareholders, Medafor'... 
Printer Friendly Version
02/23/10CryoLife Sends Letter to Medafor, Inc. Shareholders
Important Information for Medafor Shareholders February 23, 2010 Dear Fellow Medafor Shareholder: On February 18, 2010, CryoLife, Inc. announced its earnings for the fourth quarter of 2009. Enclosed is a copy of the press release for your information. In light of our proposal to acquire Medafor for a combination of cash and CryoLife stock, we want to ensure that Medafor shareholders have access to the latest information about CryoLife, its financial performance, and its outlook for growth. ... 
Printer Friendly Version
02/18/10CryoLife Grows Fourth Quarter Revenues by 12 Percent to a Record $28.6 Million
Posts fully diluted earnings per share of $0.08 for fourth quarter of 2009; $0.09 excluding items Generates over $16.5 million in operating cash flow for 2009 ATLANTA, Feb 18, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that revenues for the fourth quarter of 2009 increased 12 percent to a quarterly record of $28.6 million compared to $25.5 million for the fourth quar... 
Printer Friendly Version
02/17/10CryoLife Sends Letter to Medafor, Inc. Board of Directors
ATLANTA, Feb 17, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has sent the following letter to Medafor's Board of Directors: February 16, 2010 VIA FEDEX Michael F. Pasquale, Chairman of the Board Medafor, Inc. Dear Michael, As Medafor's largest shareholder, CryoLife is deeply disappointed to learn that Medafor's board of directors has rejected our $2.00 pe... 
Printer Friendly Version
02/09/10CryoLife Sends Letter to Medafor, Inc. Shareholders
ATLANTA, Feb 09, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has sent the following letter to Medafor shareholders. Important Information for Medafor Shareholders February 9, 2010 Dear Fellow Medafor Shareholder: As you have read in our press release dated February 2, 2010, CryoLife now owns approximately 11 percent of Medafor ("the Company"). As a result, CryoLif... 
Printer Friendly Version
02/08/10CryoLife Sends Letter to Medafor, Inc. Board of Directors
ATLANTA, Feb 08, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has sent the following letter to Medafor's Board of Directors: February 5, 2010 VIA FEDEX Michael F. Pasquale, Chairman of the Board Medafor, Inc. Dear Michael, Thank you for your response, which we received on January 22, 2010. We are encouraged by your statement that yo... 
Printer Friendly Version
02/02/10CryoLife Increases Stake in Medafor, Inc. to Approximately 11 Percent
ATLANTA, Feb 02, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has purchased approximately 740,000 additional shares of Medafor's common stock from Medafor shareholders for $2.00 per share. Based on the most recent information available to CryoLife, the company now owns approximately 11 percent of Medafor and continues to be Medafor's largest shareholder. CryoLife has prop... 
Printer Friendly Version
02/01/10CryoLife Announces Release Date and Teleconference Call Details for 2009 Fourth Quarter and Year End Financial Results
ATLANTA, Feb 01, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that 2009 fourth quarter and year end financial results will be released on Thursday, February 18, 2010. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of ... 
Printer Friendly Version
01/21/10CryoLife Sends Letter to Medafor, Inc. Shareholders
ATLANTA, Jan 21, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has sent the following letter to Medafor shareholders discussing its strategic proposal to purchase the outstanding shares of Medafor: Important Information for Medafor Shareholders January 21, 2010 Dear Fellow Medafor Shareholder: You have probably seen the headlines regarding CryoLife's increased sta... 
Printer Friendly Version
01/13/10CryoLife Becomes Largest Shareowner of Medafor, Inc. and Proposes Combination Between the Two Companies
ATLANTA, Jan 13, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has purchased approximately 1.6 million shares of Medafor's common stock from Medafor's founders and certain principal shareholders for approximately $2.00 per share. Based on the most recent information available to CryoLife, these shares represent approximately 8 percent ownership of Medafor. CryoLife current... 
Printer Friendly Version
12/01/09CryoLife Provides Initial 2010 Financial Guidance
Company expects record revenues and operating profits in 2010 ATLANTA, Dec. 1 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced its initial financial guidance for 2010. The Company expects total revenues for the full year of 2010 to be between $118.0 million and $123.0 million, which includes between $1.5 million and $2.5 million related to funding received from the Department of De... 
Printer Friendly Version
11/23/09CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
ATLANTA, Nov. 23 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it is scheduled to participate in the upcoming Piper Jaffray 21st Annual Health Care Conference at The New York Palace Hotel on December 1, 2009. Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will provide a corporate overview regarding CryoLife and recent developments and ho... 
Printer Friendly Version
11/11/09CryoLife to Present at Upcoming Investor Conferences in New York
ATLANTA, Nov. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that Steven G. Anderson, president and chief executive officer of CryoLife, Inc., is scheduled to present in the upcoming Lazard Capital Markets Sixth Annual Healthcare Conference on Wednesday, November 18, 2009 at 1:15 pm ET in New York City. CryoLife's live presentation may be accessed through its Web site, www.cryolife.c... 
Printer Friendly Version
10/29/09CryoLife Reports Record Quarterly Revenues of $28.2 Million
Company posts fully diluted earnings per share of $0.07 for third quarter of 2009; Revenues increased 5 percent for third quarter of 2009 compared to third quarter of 2008 ATLANTA, Oct. 29 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that revenues for the third quarter of 2009 increased 5 percent to a quarterly record of $28.2 million compared to $26.8 million for the third quarter... 
Printer Friendly Version
10/27/09CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
ATLANTA, Oct. 27 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. BioFoam will be used to help seal liver parenchymal tissue when cessation of bleeding by liga... 
Printer Friendly Version
10/13/09CryoLife Announces Release Date and Teleconference Call Details for 2009 Third Quarter Financial Results
ATLANTA, Oct. 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that 2009 third quarter financial results will be released on Thursday, October 29, 2009. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive office... 
Printer Friendly Version
10/06/09CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves
ATLANTA, Oct. 6 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received a Humanitarian Use Device (HUD) designation from the Food and Drug Administration (FDA) for its CryoValve® SG aortic human heart valve. The HUD designation is the first step in obtaining a Humanitarian Device Exemption (HDE) for the CryoValve SG aortic human heart valve, which is processed with the C... 
Printer Friendly Version
09/21/09Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit
Growing Outcomes Evidence Spurs Renewed Interest in Unique Heart Valve Procedure ATLANTA, Sept. 21 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY) -- Elite cardiovascular surgeons from around the world will travel to suburban Atlanta this week for the two-day Ross Summit to review and discuss current peer-reviewed data relating to the survival advantage of the Ross Procedure and to practice the technical nuances required to perform this heart surgery successfully. To view the multimedia... 
Printer Friendly Version
09/14/09CryoLife to Present at UBS Global Life Sciences Conference
ATLANTA, Sept. 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it is scheduled to participate in the upcoming UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City. Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will present Monday, September 21 at 2:00 p.m., Eastern Time. CryoLife's live presentation may be accessed... 
Printer Friendly Version
09/10/09CryoLife Announces First Clinical Use of BioFoam(R)
Newly CE Marked Product Used to Stop Bleeding During Liver Resection ATLANTA and LONDON, Sept. 10 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced the first clinical implant of its BioFoam(R) Surgical Matrix, which received CE mark approval in August 2009. BioFoam was used in a liver resection procedure following tumor removal as a supplemental measure to promote hemostasis (a comple... 
Printer Friendly Version
09/03/09CryoLife's Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
The Ross Summit 2009 to focus on new patient data supporting the Ross heart reconstruction procedure and the use of SynerGraft(R) processed human heart valves in the Ross Procedure ATLANTA, Sept. 3 /PRNewswire-FirstCall/ -- More than 130 cardiovascular surgeons from approximately 30 countries are scheduled to attend the second annual global Ross Summit, a two-day surgical congress focused on the highly complex Ross Procedure, which is performed on up to 1,500 individuals globally each year ... 
Printer Friendly Version
08/18/09CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
ATLANTA, Aug. 18 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced the first three implantations of the CryoPatch SG pulmonary human cardiac patch since FDA clearance. The surgeries were performed on pediatric patients at the University of Michigan C.S. Mott Children's Hospital in Ann Arbor, MI by Richard G. Ohye, M.D., associate professor of surgery, division head, pediatric c... 
Printer Friendly Version
08/12/09CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
ATLANTA, Aug. 12 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CryoPatch SG pulmonary human cardiac patch. CryoPatch SG is processed with the Company's proprietary SynerGraft technology designed to remove allogeneic donor cells and cellular remnants from tissue without compromising ... 
Printer Friendly Version
08/04/09CryoLife Receives CE Mark Approval for BioFoam(R) Hemostatic Technology
ATLANTA, Aug. 4 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced it has received CE mark approval for its BioFoam Surgical Matrix (BioFoam). The CE mark allows immediate, unrestricted commercial distribution of BioFoam in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other ... 
Printer Friendly Version
07/30/09CryoLife Reports Record Quarterly Revenues of $28.2 Million
Company posts fully diluted earnings per share of $0.09 for second quarter of 2009; Revenues increased 6 percent sequentially for second quarter of 2009 compared to first quarter of 2009 ATLANTA, July 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that revenues for the second quarter of 2009 increased 4 percent to a quarterly record of $28.... 
Printer Friendly Version
07/13/09CryoLife Announces Release Date and Teleconference Call Details for 2009 Second Quarter Financial Results
ATLANTA, July 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY),an implantable biological medical device and cardiovascular tissue processing company,announced today that 2009 second quarter financial results will be released on Thursday, July 30, 2009. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive of... 
Printer Friendly Version
06/29/09BioGlue(R) Surgical Adhesive Hits 500,000 Procedure Milestone Worldwide, Company Data Indicates
ATLANTA, June 29, 2009 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that, according to company data, CryoLife's BioGlue(R) Surgical Adhesive has been used in more than 500,000 surgical procedures throughout the world since its introduction into the international market in 1998 and in the United States in 2001. BioGlue is a leading surgical adhesive used in cardiovascular su... 
Printer Friendly Version
04/30/09CryoLife Reports Record First Quarter Revenues of $26.7 Million
Operating income increases 26 percent in first quarter of 2009 compared to 2008 ATLANTA, April 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that revenues for the first quarter of 2009 increased 4 percent to a first quarter record of $26.7 million compared to $25.6 million for the first quarter of 2008. Operating income for the first quarter of 2009 increased 26 pe... 
Printer Friendly Version
04/15/09CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
ATLANTA, April 15 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and tissue processing company, announced today that 2009 first quarter financial results will be released on Thursday, April 30, 2009. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of Cry... 
Printer Friendly Version
04/06/09Department of Defense Awards CryoLife $1.7 million to Develop BioFoam Hemostatic Technology
ATLANTA, April 6 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and tissue processing company, today announced it has been awarded approximately $1.7 million under the Department of Defense (DoD) Appropriations Bill to continue further development of CryoLife's protein hydrogel technology. Preclinical studies of CryoLife's BioFoam(R) Surgical Matrix, a protein hydrogel product under development for organ sealing, are nearing completion. ... 
Printer Friendly Version
03/19/09CryoLife to Present at Sidoti's 13th Annual New York Emerging Growth Institutional Forum
ATLANTA, March 19, 2009 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and tissue processing company, announced today that it will participate in the Sidoti & Company, LLC 13th Annual New York Emerging Growth Institutional Forum at The Grand Hyatt Hotel on Wednesday, March 25, 2009. D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present a corporate overview at 2:05 ... 
Printer Friendly Version
02/19/09CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
Operating Income Increases 65% to $13.7 Million for FY 2008 ATLANTA, Feb. 19 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and tissue processing company, announced today that revenues for the year ended December 31, 2008 increased 11 percent to $105.1 million compared to $94.8 million for the year ended December 31, 2007. Excluding orthopaedic tissue processing revenues of $725,000 and $4.2 million in the years ended December 3... 
Printer Friendly Version
02/17/09FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve
ATLANTA, Feb 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that the U.S. Food and Drug Administration (FDA) has cleared a new claim for the CryoValve(R) SG pulmonary human heart valve. The new labeling claim relates to reducing a component of the immune response in recipients of the CryoValve SG. CryoValve SG pulmonary human heart valve is processed with the Company's proprietary S... 
Printer Friendly Version
02/05/09CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
ATLANTA, Feb. 5 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that 2008 fourth quarter and year end financial results will be released on Thursday, February 19, 2009. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, February 19, 2009, to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and CEO of CryoLife, I... 
Printer Friendly Version
01/21/09CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
ATLANTA, Jan. 21 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that it achieved an industry milestone when it received tissue from its 100,000th individual donor. The tissue, received January 14, 2009 came from a Kansas-based organ and tissue procurement organization. Since 1984, through the generosity of donor families and with the support of the organ and tissue procurement organizations, CryoLife has been able to provide more than 160,000 cryopreserved t... 
Printer Friendly Version
11/24/08CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
ATLANTA, Nov. 24 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the 20th Annual Piper Jaffray Health Care Conference at The New York Palace Hotel on December 2, 2008. Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will provide a corporate overview and host a question and answer session at 2:30 p.m. Eastern Time. CryoLife's li... 
Printer Friendly Version
10/30/08CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
Revenues increased 21 percent in third quarter of 2008 versus third quarter of 2007 ATLANTA, Oct. 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that revenues for the third quarter of 2008 increased 21 percent to $26.8 million compared to $22.2 million in the third quarter of 2007. Excluding orthopaedic tissue processing revenues of $38,000 and $566,000 in the t... 
Printer Friendly Version
10/16/08CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results
ATLANTA, Oct. 16 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that third quarter 2008 financial results will be released on Thursday, October 30, 2008. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, October 30, 2008, to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and CEO of CryoLife, Inc. To lis... 
Printer Friendly Version
10/07/08CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
Surgical Congress to focus on new patient data supporting the Ross heart reconstruction procedure and the use of SynerGraft processed human heart valves in the Ross procedure ATLANTA, Oct. 7 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that cardiovascular surgeons from around the globe will participate in the Ross Summit 2008, a two-day surgical congress to be held at the Company's corporate headquar... 
Printer Friendly Version
09/22/08CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc.
Unique hemostatic powder is available in ready-to-use applicator ATLANTA, Sept. 22 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has begun distribution in Canada, through Sorin Group Canada, Inc., of Hemostase MPH to control bleeding in general, cardiac and vascular surgery. CryoLife began distributing Hemostase MPH in the U. S., the United Kingdom and Germany in the second quarter ... 
Printer Friendly Version
09/17/08CryoLife to Present at UBS Global Life Sciences Conference
ATLANTA, Sept. 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the upcoming UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City. D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present Wednesday, September 24 at 2:30 p.m., Eastern Time. CryoLife's live pres... 
Printer Friendly Version
09/11/08CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
Unique hemostatic powder is available in ready-to-use applicator ATLANTA, Sept. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has begun distribution in France, through Laboratoire Gamida, of Hemostase MPH for use in general, cardiac and vascular surgery. CryoLife began distributing Hemostase MPH in the U.S., the United Kingdom and Germany in the second quarter of 2008. Distrib... 
Printer Friendly Version
08/04/08CryoLife Announces Management Promotions
ATLANTA, Aug. 4 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that Bruce G. Anderson has been promoted to vice president of U.S. sales and marketing, and that Richard C. Gridley has been promoted to vice president of international sales and marketing. Both men will report to Gerald B. Seery, senior vice president of worldwide sales and marketing. Additionally, the company has announced the promotion... 
Printer Friendly Version
07/31/08CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007
Company posts record quarterly revenues of $27.2 million ATLANTA, July 31 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that revenues for the second quarter of 2008 increased 18 percent to $27.2 million compared to $23.0 million in the second quarter of 2007. Excluding orthopaedic tissue processing revenues of $297,000 and $1.2 million in the second quarters of 2008 and 2007, respectively,... 
Printer Friendly Version
07/15/08CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results
ATLANTA, July 15 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that second quarter 2008 financial results will be released on Thursday, July 31, 2008. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, July 31, 2008, to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and CEO of CryoLife, Inc. To listen t... 
Printer Friendly Version
06/30/08Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
ATLANTA, June 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, has announced that positive mid-term performance data on the CryoValve(R) SG decellularized pulmonary human heart valve were presented on June 28th at the 34th Annual Western Thoracic Surgical Association Meeting in Kona, Hawaii. The data, used earlier this year to support the marketing clearance for the valve, were presented by John W. Brown, M.D., prof... 
Printer Friendly Version
06/10/08CryoLife's BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery
ATLANTA and SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), and BioForm Medical, Inc. (Nasdaq: BFRM) today announced that they have received a CE Mark for the use of CryoLife's BioGlue Surgical Adhesive for periosteal fixation following endoscopic browplasty or brow lift, a reconstructive plastic surgery procedure. The CE Mark approval allows the product to be marketed in the European Community (EU). BioGlue will be distributed by CryoLife's partne... 
Printer Friendly Version
05/27/08CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference
ATLANTA, May 27 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the FBR Capital Markets Annual Spring Investor Conference, Thursday, May 29, 2008 at the Grand Hyatt Hotel in New York City. Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will present at 12:50 p.m. Eastern Time. CryoLife's live presentation may be accessed throug... 
Printer Friendly Version
05/12/08CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
ATLANTA, May 12 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, today announced the first implantation of the combination aortic-mitral allograft heart valve in a patient at the Cleveland Clinic. The surgery was performed by Dr. Jose Navia, a cardiac surgeon with the Heart and Vascular Institute at the Cleveland Clinic. The method used to process the combination aortic-mitral human heart valve was developed by ... 
Printer Friendly Version
05/01/08Harvey Morgan Joins CryoLife Board of Directors
ATLANTA, May 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials, medical device and tissue processing company, announced today that Harvey Morgan has been elected to the Company's Board of Directors, effective immediately. Mr. Morgan is a Managing Director at Bentley Associates L.P., an investment banking firm. Mr. Morgan has more than 35 years of investment banking experience with significant expertise in mergers and acquisitions, strate... 
Printer Friendly Version
04/30/08CryoLife's Earnings Per Share Increases 150 Percent to $0.10 in First Quarter of 2008 from $0.04 in First Quarter of 2007
Company raises revenue guidance ATLANTA, April 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that revenues for the first quarter of 2008 increased 4 percent to $25.6 million compared to $24.5 million in the first quarter of 2007. Excluding orthopaedic tissue processing revenues of $327,000 and $1.8 million in first quarters of 2008 and 2007, respectively, total revenues incr... 
Printer Friendly Version
04/24/08CryoLife Conducts Surgeons Cardiac Allograft Symposium
ATLANTA, April 24 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is conducting the 2008 Cardiac Allograft Symposium at its corporate headquarters training facility in suburban Atlanta, GA, April 25-26. The program will focus on current clinical outcomes, indications and surgical techniques of aortic valve replacement utilizing aortic allografts and the CryoValve(R) SG pulmonary human heart val... 
Printer Friendly Version
04/17/08CryoLife to Distribute FDA-approved Hemostatic Agent Under Private Label
ATLANTA, April 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has signed an exclusive three-year agreement with Minneapolis-based Medafor, Inc. Under terms of the agreement CryoLife will distribute Medafor's microporous polysaccharide hemostatic agent for use in cardiac and vascular surgery in the U.S. and for cardiac, vascular and general surgery, other than orthopaedic and ear, nose and t... 
Printer Friendly Version
04/14/08CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2008 Financial Results
ATLANTA, April 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that first quarter 2008 financial results will be released on Wednesday, April 30, 2008. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, April 30, 2008, to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and CEO of CryoLife, Inc. To liste... 
Printer Friendly Version
04/08/08William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education
ATLANTA, April 8, 2008 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY) a biomaterials, medical device and tissue processing company, announced today that William F. Northrup, III, M.D. has joined CryoLife as vice president of medical relations and education, reporting to Steven G. Anderson, president and CEO. In this newly created position, Dr. Northrup, a board-certified cardiovascular surgeon, will create educational programs focused on CryoLife SynerGraft technologies and ... 
Printer Friendly Version
03/31/08CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services
ATLANTA, March 31 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY) (the "Company"), a biomaterials, medical device and tissue processing company, announced it has entered into a credit facility with GE Healthcare Financial Services, which provides for up to $15 million in revolving credit for working capital, acquisitions and other corporate purposes. The credit agreement expires in March 2011, at which time the outstanding principal balance will be due. Amounts borrowed bear... 
Printer Friendly Version
03/24/08CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
ATLANTA, March 24 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials, medical device and tissue processing company, today announced implantation of the first CryoValve(R) SG pulmonary human heart valve since the product was cleared by the Food and Drug Administration (FDA) in February. The procedure was performed on a patient at St. Louis Children's Hospital in St. Louis, Mo. The CryoValve SG is processed with the Company's proprietary SynerGraft(R) technology, which... 
Printer Friendly Version
02/21/08CryoLife Reports Net Income of $0.26 Per Share in 2007 Compared to a Net Loss of ($0.02) Per Share in 2006
Company reports record annual revenues of $94.8 million, increasing 17 percent in 2007 compared to 2006; Company posts fourth quarter net income of $0.10 per share in 2007 compared to a net loss of ($0.01) per share in 2006 ATLANTA, Feb. 21 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that revenues for the full year of 2007 increased 17 percent to $94.8 ... 
Printer Friendly Version
02/13/08CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
ATLANTA, Feb. 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the Roth Capital Partners 20th Annual OC Growth Stock Conference, February 19, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, Calif. D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present Tuesday, February 19 at 8:30 a.m... 
Printer Friendly Version
02/07/08CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
ATLANTA, Feb. 7 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for its CryoValve(R) SG pulmonary human heart valve processed with the Company's proprietary SynerGraft technology. CryoLife's proprietary SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from the valve without compromi... 
Printer Friendly Version
01/31/08CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2007 Financial Results
ATLANTA, Jan. 31 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that fourth quarter and year end 2007 financial results will be released on Thursday, February 21, 2008. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, February 21, 2008, to discuss the results followed by a question and answer session hosted by Steven G. Anderson, president and chief executive of... 
Printer Friendly Version
01/11/08CryoLife Responds to Inaccurate Assertions from Plaintiff's Attorney
ATLANTA, Jan. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has been notified that a lawsuit will be filed against it in the Superior Court of Cobb County, Georgia relating to a meniscal allograft. The lawsuit concerns an individual who contracted an infection following a transplant of a meniscal allograft in December 2006. Meniscal transplants are commonly used for patients with signi... 
Printer Friendly Version
01/10/08CryoLife Announces Record Preservation Services and Product Revenues for 2007
Preliminary full year and fourth quarter 2007 preservation services and product revenues increased 16% and 17%, respectively, to approximately $93.7 million for the year and $24.6 million for the fourth quarter ATLANTA, Jan. 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that preservation services and product revenues for 2007 were approximately $93.7 million compared to $81.1 million in... 
Printer Friendly Version
01/08/08CryoLife Announces Worldwide License Agreement With Trophic Solutions, LLC for an Organ Transport Solution That Could Extend the Storage Time for Kidneys From 3 to 6 Days
ATLANTA, Jan. 8 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today an exclusive license agreement with Trophic Solutions, LLC to develop and market products related to the cold storage and preservation of internal organs prior to transport. Under terms of the agreement, the Company will license from Trophic Solutions the right to develop, manufacture and market products and processes derived from a patent ... 
Printer Friendly Version
01/02/08CryoLife to Present at OneMedPlace Finance Forum
ATLANTA, Jan. 2 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the OneMedPlace Finance Forum, January 7-8, 2008 at the Sir Francis Drake Hotel in Union Square, San Francisco. D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., will present on Tuesday, January 8th at 5:00 p.m. Pacific Time. Informatio... 
Printer Friendly Version
11/20/07CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
ATLANTA, Nov. 20 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the 19th Annual Piper Jaffray Health Care Conference at the Pierre Hotel in New York City on Tuesday, November 27, 2007. Steven G. Anderson, president and CEO of CryoLife, Inc. will deliver the Company's presentation beginning at approximately 1:30 p.m. EST. CryoLife's live presentation may ... 
Printer Friendly Version
11/01/07CryoLife Reports Third Consecutive Profitable Quarter
Company posts third quarter net income of $1.9 million and $0.07 per share compared to $2.0 million and $0.07 per share in 2006; Non-GAAP EPS for third quarter was $0.09 compared to $0.00 per share in 2006 ATLANTA, Nov. 1 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that revenues for the third quarter of 2007 increased 11 percent to $22.2 million compared to $20.0 million in the third ... 
Printer Friendly Version
10/30/07CryoLife Announces Additions to Management Team
ATLANTA, Oct 30, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that Scott B. Capps has been named vice president, clinical research, effective October 29, 2007. Mr. Capps has served as vice president and general manager of CryoLife Europa, Ltd., based in the U.K., since February 2005. Mr. Capps joined CryoLife in 1995 and has held several positions with the Company including... 
Printer Friendly Version
10/18/07CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
ATLANTA, Oct. 18 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it will conduct its annual Cardiac Surgery Fellows Allograft Symposium on October 19, 2007, at the Company's corporate headquarters training facility in Kennesaw, Ga. The program will include discussions and demonstrations of surgical techniques of aortic valve replacement and thoracoabdominal aortic aneurysm repair, as well as provi... 
Printer Friendly Version
10/11/07CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
Combined cardiac and vascular tissue processing revenues in the third quarter of 2007 increased 25 percent compared to the third quarter of 2006 FDA completes re-inspection ATLANTA, Oct. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that product and preservation services revenues for the third quarter of 2007 were approximately $21.9 million compared to $20.0 milli... 
Printer Friendly Version
09/17/07CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
Hernia repair is one of the most commonly performed surgical procedures worldwide ATLANTA, Ga., Sept. 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has signed a distribution agreement allowing Proxy Biomedical Limited to include CryoLife's BioGlue(R) Surgical Adhesive into a hernia repair kit. In addition to BioGlue, the kit includes a surgical mesh fr... 
Printer Friendly Version
09/05/07CryoLife to Present at Bear Stearns Healthcare and First Albany Capital's Regenerative Technologies Conferences in New York
ATLANTA, Sept. 5 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that D. Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife, Inc., is scheduled to present at the Bear Stearns 20th Annual Healthcare Conference on Monday, September 10, 2007 at 4:30 p.m. EDT. Mr. Lee will also present at the First Albany Capital Regenerative Technologies Conference on Tue... 
Printer Friendly Version
09/04/07CryoLife Names Philip Theodore as Vice President, General Counsel
ATLANTA, Sept. 4 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that Philip A. Theodore has been named vice president, general counsel, effective September 4, 2007. Mr. Theodore will report directly to Steven G. Anderson, chairman, president and chief executive officer of the Company. As general counsel, Mr. Theodore will be responsible for all corporate legal and governance activities, and will b... 
Printer Friendly Version
07/31/07CryoLife Reports Second Quarter and First Half 2007 Financial Results
Company posts second quarter net income of $1.3 million and $0.05 per share compared to $217,000 and $0.00 per share in 2006; First half 2007 revenues increased 18 percent compared to 2006 ATLANTA, July 31 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that revenues for the second quarter of 2007 increased 11 percent to $23.0 million compared to $20.8 million in the second quarte... 
Printer Friendly Version
07/11/07CryoLife Announces Preliminary First Half 2007 Revenues Increase 18% to Approximately $47.2 Million
Preliminary Second Quarter 2007 Revenues Increase 10 Percent to Approximately $22.9 Million; Company Raises Lower End of Range of 2007 Product and Processing Revenue Guidance ATLANTA, July 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that product and preservation services revenues for the second quarter of 2007 were approximately $22.9 million compared to $20.8 million i... 
Printer Friendly Version
07/10/07CryoLife Establishes Direct Sales Force in Germany
ATLANTA, July 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today announced that it has established a direct sales force through its European subsidiary, CryoLife Europa, Ltd., to service the German medical market. Headquartered in the biotechnology cluster of Baden-Wuerttemberg in Freiburg, the German team is CryoLife's second direct sales force outside of the U.S. CryoLife also sells direct in the United Kingdom. "We ar... 
Printer Friendly Version
06/26/07BioForm Medical Enrolls First Patient in Clinical Trial of CryoLife's BioGlue(R) Surgical Adhesive for Use in Cosmetic and Plastic Surgery
ATLANTA, Ga. and SAN MATEO, Calif., June 26 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY) and BioForm Medical, Inc. announced that the first patient has been enrolled in a clinical study evaluating BioGlue(R) Surgical Adhesive as a method of fixation in brow lifts. BioForm recently received permission from Food and Drug Administration (FDA), under an Investigational Device Exemption (IDE), to initiate enrollment in a feasibility study to evaluate the safety and effectiveness of... 
Printer Friendly Version
06/14/07CryoLife Awarded U. S. Patent for BioFoam(R)
Potential Product Applications Include Battlefield Injuries, Internal Organ and Vascular Tissue Sealing, and Tissue Augmentation ATLANTA, June 14, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device, and tissue processing company, today announced that it has been awarded a patent by the U.S. Patent Office for BioFoam(R), a protein hydrogel foam for rapidly filling and sealing open wounds. Scientists at CryoLife invented and dev... 
Printer Friendly Version
06/04/07CryoLife Exercises Right to Convert Preferred Stock into Common Stock
ATLANTA, June 4 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today it is exercising its right to convert its 6% convertible preferred stock (Cusip # 228903209; NYSE: CRYPR) into the company's common stock on June 25, 2007. The preferred stock contains provisions that allow the company to convert its preferred stock into common stock if the common stock closes above $12.06 per share for any 20 trading days... 
Printer Friendly Version
05/01/07CryoLife's First Quarter 2007 Revenues up 26 Percent
Earnings per diluted share of $0.04; $0.08 before items; Gross margins up from 55 percent in Q1 2006 to 61 percent in Q1 2007; 2007 revenue guidance raised ATLANTA, May 1 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that revenues for the first quarter of 2007 increased 26 percent to $24.5 million compared to $19.4 million in the first quarter of 2006. Net ... 
Printer Friendly Version
04/30/07CryoLife's BioDisc(TM) Nucleus Pulposus Replacement to be Featured at Two Medical Conferences in Berlin
ATLANTA, April 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, today announced that its BioDisc(TM) Nucleus Pulposus Replacement will be featured at two separate medical conferences in Berlin, Germany, this week. BioDisc, now undergoing clinical evaluation, is a fast-setting protein hydrogel designed to fill the void created during the removal, or discectomy, of nucleus material after a lumbar spinal disc herniatio... 
Printer Friendly Version
04/10/07CryoLife Announces Preliminary First Quarter 2007 Revenues of Approximately $24.4 Million
First quarter 2007 revenues increase 26 percent compared to the first quarter of 2006 ATLANTA, April 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that product and preservation services revenues for the first quarter of 2007 were approximately $24.4 million compared to $19.4 million in the first quarter of 2006, an increase of 26 percent. BioGlue(R) revenues ... 
Printer Friendly Version
03/13/07CryoLife Declares a Dividend of Approximately $0.75 Per Share on Its Convertible Preferred Stock
ATLANTA, March 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that the Company has declared a dividend of approximately $0.75 per share on its 6% convertible preferred stock, payable on April 2, 2007, to shareholders of record as of the close of business on March 22, 2007. About CryoLife Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living hum... 
Printer Friendly Version
02/20/07CryoLife Returns to Profitability in 2006
Revenues increase 17 percent in 2006 compared to 2005; Recent transactions provide platform for future growth ATLANTA, Feb. 20 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that revenues for the fourth quarter of 2006 increased 17 percent to $21.1 million compared to $18.0 million in the fourth quarter of 2005. Net loss in the fourth quarter of 2006 was ($50,000), and ($0.01) ... 
Printer Friendly Version
02/08/07CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2006 Financial Results
ATLANTA, Feb. 8 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that fourth quarter and year end 2006 financial results will be released on Tuesday, February 20, 2007. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, February 20, 2007, to discuss the results followed by a question and answer session hosted by Steven G. Anderson, President and CEO of CryoLife, Inc... 
Printer Friendly Version
01/17/07CryoLife Signs Agreement With MAST Biosurgery, Inc. to Distribute CardioWrap(TM) in U. S.
Bioresorbable sheet used as pericardium replacement in cardiac patients facing re-operation within six months ATLANTA, Jan. 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has signed a multi-year agreement with MAST Biosurgery, Inc. to distribute CardioWrap(TM), a bioresorbable thin film sheet used to replace the pericardium in cardiac reconstruction and other cardiac ... 
Printer Friendly Version
01/11/07CryoLife Announces Preliminary Fourth Quarter 2006 Revenues of Approximately $21 Million
2006 product and preservation services revenues increase 17% to over $81 million ATLANTA, Jan. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that product and preservation services revenues for 2006 were approximately $81.1 million compared to $69.2 million in 2005, an increase of 17%. Product and preservation services revenues for the fourth quarter of 2006 we... 
Printer Friendly Version
01/10/07CryoLife Announces Agreement with Cleveland Clinic to Develop Innovative Heart Valve for High Risk Patients
ATLANTA, Jan. 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today an agreement with Cleveland Clinic to develop an innovative allograft, or human tissue, heart valve for patients suffering from serious heart infections. Under terms of the agreement, the Company will work with Cleveland Clinic to develop a combination aortic-mitral allograft heart valve for patients with infective endocarditis, a conditio... 
Printer Friendly Version
12/20/06CryoLife Provides Additional Comments on Exchange and Service Agreement with Regeneration Technologies
CryoLife expects transaction to be accretive to 2007 earnings ATLANTA, Dec. 20 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY), a biomaterials and biosurgical device company, is providing additional information regarding the exchange and service agreement with Regeneration Technologies (RTI) (Nasdaq: RTIX) announced yesterday. As a result of this transaction, the Company expects an initial economic benefit of up to $2 million on an annual basis, a portion of which wil... 
Printer Friendly Version
12/19/06Cryolife and Regeneration Technologies Enter Into Exchange and Service Agreement
Cryolife to Sharpen Focus on Core Cardiovascular Business ATLANTA, Dec. 19 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY), a biomaterials and biosurgical device company, and Regeneration Technologies Inc., (RTI) (Nasdaq: RTIX), a Florida-based processor of biologic implants, today announced that they have entered into an exchange and service agreement respecting their orthopedic and cardiovascular activities. According to the agreement, CryoLife will cease acceptin... 
Printer Friendly Version
12/13/06CryoLife Receives European and Canadian Approval to Market New Rigid Applicator Tip for BioGlue(R) Surgical Adhesive
Extended 34 cm length enables precise delivery in minimally invasive surgeries ATLANTA, Dec. 13 /PRNewswire/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials and biosurgical device company, today announced that it has received CE Mark and Health Canada approval for a new rigid applicator tip for its BioGlue Surgical Adhesive. The new tip, designed to reach areas beyond 27 cm, enables precise delivery of BioGlue over an extended length. "With the increase in laparoscopic and video-ass... 
Printer Friendly Version
12/11/06CryoLife to Present at MedTech Insight's In Spine & Orthopedics Conference in Las Vegas
ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that it is scheduled to participate in the MedTech Insight In Spine & Orthopedics Meeting at the Venetian Resort Hotel-Casino in Las Vegas on Tuesday, December 12, 2006. Gerald B. Seery, Senior Vice President, Sales and Marketing, CryoLife, Inc., will deliver the Company's presentation at 2:25 p.m. PST. About CryoLife Founded in 1984, CryoL... 
Printer Friendly Version
12/11/06CryoLife Receives FDA 510(k) Clearance for ProPatch(TM) Soft Tissue Repair Matrix
ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials and biosurgical device company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for its ProPatch(TM) Soft Tissue Repair Matrix. ProPatch, developed from bovine pericardial tissue, is used to reinforce weakened soft tissues and provides a resorbable scaffold that is replaced by the patient's own soft tissue. "ProPatch provides an effective alternat... 
Printer Friendly Version
12/05/06CryoLife Declares a Dividend of Approximately $0.75 Per Share on Its Convertible Preferred Stock
ATLANTA, Dec. 5 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that the Company has declared a dividend of approximately $0.75 per share on its 6% convertible preferred stock, payable on January 2, 2007, to shareholders of record as of the close of business on December 22, 2006. About CryoLife Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues f... 
Printer Friendly Version
11/29/06CryoLife To Present at 18th Annual Piper Jaffray Health Care Conference in New York
ATLANTA, Nov 29, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that it is scheduled to participate in the 18th Annual Piper Jaffray Health Care Conference at the Pierre Hotel in New York City on Friday, December 1, 2006. D. Ashley Lee, Executive Vice President, Chief Operating Officer and Chief Financial Officer of CryoLife, Inc. will deliver the Company's presentation beginning at approxi... 
Printer Friendly Version
11/02/06CryoLife Identifies Key Growth Strategies as Result of Strategic Review
ATLANTA, Nov. 2 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today announced that in addition to continuing to focus on growing its business and leveraging its strengths and expertise in its core marketplaces, it will pursue three key strategies designed to generate revenue and earnings growth. These strategies were identified and evaluated as part of a strategic review begun in January 2006 at the request of the Company's Board ... 
Printer Friendly Version
11/02/06CryoLife Reports Profitable Third Quarter 2006
Company Posts Third Quarter Net Income of $2.0 Million; Forecasts Record Revenues in 2007 ATLANTA, Nov. 2 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that revenues for the third quarter of 2006 increased 22 percent to $20.0 million compared to $16.5 million in the third quarter of 2005. Net income in the third quarter of 2006 was $2.0 million, and $0.07 per basic and fully dilute... 
Printer Friendly Version
10/30/06CryoLife Announces Agreement With BioForm Medical to Develop and Market BioGlue(R) for Use In Cosmetic and Plastic Surgery
ATLANTA, Oct. 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today announced that it has signed a licensing and distribution agreement with BioForm Medical, Inc. ("BioForm"), for the development and commercialization of CryoLife's proprietary BioGlue(R) Surgical Adhesive for use in cosmetic and plastic surgery indications. BioGlue is currently approved in the United States as an adjunct to sutures and staples for use in adult pa... 
Printer Friendly Version
10/19/06CryoLife Conducts Cardiac Allograft Symposium
ATLANTA, Oct. 19 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials and biosurgical device company, announced today that it is conducting a cardiac reconstruction symposium focusing on the use of human heart valves and tissues at its corporate headquarters training facility in Kennesaw, GA, October 19-21. The program includes the following: current indications and clinical outcomes, surgical techniques associated with the implantation of aortic and pulmonary allograf... 
Printer Friendly Version
10/18/06Signed Defense Bill Provides 2007 Funding for Protein Hydrogel Development
ATLANTA, Oct 18, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials and biosurgical device company, today announced that President George W. Bush has signed into law a Department of Defense (DoD) Appropriations Bill that includes $1 million for the continued development of protein hydrogel for the battlefield trauma program in fiscal year 2007. CryoLife's BioFoam(TM), now in preclinical studies, is included in this product category, making Cry... 
Printer Friendly Version
10/12/06CryoLife's Preliminary 2006 Third Quarter Revenues Increased 22% Compared to 2005, Company Provides Conference Call Information
ATLANTA, Oct 12, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that revenues for the third quarter of 2006 were approximately $20.0 million compared to $16.5 million in the third quarter of 2005, an increase of 22 percent. Revenues for the first nine months of 2006 were approximately $60.2 million compared to $51.3 million in the first nine months of 2005, an increase of 17 percent. Tissu... 
Printer Friendly Version
10/02/06CryoLife to Receive $2.25 Million to Settle Dispute
ATLANTA, Oct. 2 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that it has settled an outstanding insurance coverage dispute for $2.25 million. The dispute involved losses stemming from amounts paid in 2005 by the Company. In resolving the dispute, no party admitted any liability. Steven G. Anderson, President and Chief Executive Officer stated, "We believe that the settlement of this dispute was in the best in... 
Printer Friendly Version
09/07/06CryoLife Declares a Dividend of Approximately $0.75 Per Share on Its Convertible Preferred Stock
ATLANTA, Sept. 7 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that the Company declared a dividend of approximately $0.75 per share on its 6% convertible preferred stock, payable on October 2, 2006, to shareholders of record as of the close of business on September 22, 2006. About CryoLife Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for... 
Printer Friendly Version
08/03/06CryoLife Reports Profitable Second Quarter
Company posts second quarter net income of $217,000 Company raises full year 2006 revenue guidance to between $80 - $82 million ATLANTA, Aug. 3 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that revenues for the second quarter of 2006 increased 21 percent to $20.8 million compared to $17.2 million in the second quarter of 2005. Net income in the second quarter of 2006 was $217,000, or $0.00 per basic... 
Printer Friendly Version
07/19/06CryoLife Completes Enrollment Of BioDisc(TM) Study
Company to File for CE Mark for European Distribution in Late 2006; Presently Evaluating Potential Partners for European CommercializationATLANTA, July 19, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today announced that it has completed the enrollment of patients in its BioDisc(TM) Spinal Disc Repair System study. The 10-patient study, being conducted at a hospital in the United Kingdom, targets disc hern... 
Printer Friendly Version
07/11/06CryoLife Announces Preliminary Second Quarter 2006 Revenues of $20.8 Million
Tissue processing revenues increased 38 percent over second quarter of 2005; BioGlue(R) second quarter revenues were a record $10.3 million ATLANTA, July 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that revenues for the second quarter of 2006 were approximately $20.8 million compared to $17.2 million in the second quarter of 2005, an increase of 21 percent. Revenues for the first half of 2006 were app... 
Printer Friendly Version
06/19/06CryoLife Receives Tissue from 85,000th Donor
ATLANTA, June 19 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that it has now received tissue from over 85,000 individual donors of organs or tissues since its founding in 1984. Tissue from the 85,000th donor was received on June 16, 2006 from an organ and tissue procurement organization based in Utah. Through the generosity of donor families and with the support of the organ and tissue procurement organizations, CryoLife has been able to provide more tha... 
Printer Friendly Version
06/07/06CryoLife Declares a Dividend of Approximately $0.75 Per Share on Its Convertible Preferred Stock
ATLANTA, June 7 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that the Company declared a dividend of approximately $0.75 per share on its 6% convertible preferred stock payable on July 3, 2006, to shareholders of record at the close of business on June 23, 2006. About CryoLife Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardi... 
Printer Friendly Version
05/09/06CryoLife's BioDisc(TM) Nucleus Pulposus Replacement To be Featured at Two Medical Conferences in Montreal
ATLANTA, May 9 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today announced that its BioDisc(TM) Nucleus Pulposus Replacement will be featured at two separate medical conferences in Montreal, Canada, this week. BioDisc, now undergoing clinical evaluation, is a fast-setting protein hydrogel designed to fill the void created during the removal, or discectomy, of nucleus material after a lumbar spinal disc herniation. At the Sp... 
Printer Friendly Version
05/03/06CryoLife Reports First Quarter 2006 Financial Results
First quarter 2006 revenues increased 10 percent over first quarter 2005 ATLANTA, May 3 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that revenues for the first quarter of 2006 increased 10 percent to $19.4 million compared to $17.7 million in the first quarter of 2005. The net loss in the first quarter of 2006 was $1.8 million, or $0.08 per basic and fully diluted common share, compared to a net loss of $1.4 mi... 
Printer Friendly Version
04/26/06CryoLife Announces Interim Results of European BioDisc(TM) Spinal Disc Repair System Study at Britspine
Plans to Seek CE Mark for European Distribution in 2006 ATLANTA, April 26 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today announced that preliminary results of a BioDisc(TM) clinical study show that patients experienced significantly reduced back pain and improved function after spinal disc repair with the protein hydrogel. These interim results are detailed in a poster entitled "Early clinical results of an in situ... 
Printer Friendly Version
04/20/06CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2006 Financial Results
ATLANTA, April 20, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that first quarter 2006 financial results will be released on Wednesday, May 3, 2006. The Company will hold a teleconference call and live webcast at 11:15 a.m. Eastern Time, May 3, 2006, to discuss the results followed by a question and answer session hosted by Steven G. Anderson, President and CEO of CryoLife, Inc. To list... 
Printer Friendly Version
04/13/06CryoLife Announces Preliminary First Quarter 2006 Revenues
Total revenues increased 10 percent over first quarter 2005 and 8 percent over fourth quarter 2005; Company increases revenue guidance for 2006 ATLANTA, April 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that revenues for the first quarter of 2006 were approximately $19.4 million compared to $17.7 million in the first quarter of 2005, an increase of 10 percent. Revenues for the first quarter of 2006 incr... 
Printer Friendly Version
04/06/06CryoLife to Conduct Annual Cardiac Surgery Fellows Program
ATLANTA, April 6 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that it will conduct its annual Cardiac Surgery Fellows Program on April 7, 2006, at the company's corporate headquarters training facility in Kennesaw, Ga. The program will include discussions and demonstrations of aortic valve replacement techniques using allografts. In addition, there will be demonstrations of complex ascending and thoracic aortic r... 
Printer Friendly Version
03/13/06CryoLife Declares a Dividend of Approximately $0.75 on Its Convertible Preferred Stock
ATLANTA, March 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that the Company declared a dividend of approximately $0.75 per share on its 6% convertible preferred stock payable on April 3, 2006, to shareholders of record at the close of business on March 23, 2006. About CryoLife Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in c... 
Printer Friendly Version
02/22/06CryoLife Reports Fourth Quarter and Full Year 2005 Financial Results
Fourth quarter 2005 revenues increased 13% over fourth quarter 2004 Gross margins for full year 2005 increased to 53% compared to 40% in 2004Feb 22, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that revenues for the fourth quarter of 2005 increased 13% to $18.0 million compared to $15.9 million in the fourth quarter of 2004. The net loss in the fourth quarter of 2005 was $681,000, or $0.04 pe... 
Printer Friendly Version
02/13/06CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter and Year End 2005 Financial Results
Feb 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that fourth quarter and year end 2005 financial results will be released on Wednesday, February 22, 2006. The Company will hold a teleconference call and live webcast at 11:15 a.m. Eastern Time, February 22, 2006, to discuss the results followed by a question and answer session hosted by Steven G. Anderson, President and CEO of CryoLife,... 
Printer Friendly Version
02/09/06CryoLife Receives FDA Approval of New Spreader Tips for BioGlue(R) Syringe Applicators
Fan-like Extensions Provide Surgeons with Improved Application and Ease of UseFeb 09, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials and biosurgical device company, today announced that it has received approval from the Food and Drug Administration (FDA) for two new spreader tips for its BioGlue(R) Syringe applicators. The new 12 mm and 16 mm fan-like extensions deliver a thinner, wider band of BioGlue Surgical Adhesive designed to more q... 
Printer Friendly Version
01/24/06Signed Defense Bill Provides Continued Funding Stream for BioFoam(TM) Development
ATLANTA, Jan. 24 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials and biosurgical device company, today announced that President George W. Bush recently signed into law a Department of Defense (DoD) Appropriations Bill that includes $2.27 million for the continued development of protein hydrogel and bio-foam sealant in this fiscal year. CryoLife's BioFoam(TM), now in preclinical studies, is included in this product category, making CryoLife eligible to apply for fu... 
Printer Friendly Version
01/18/06CryoLife Retains Piper Jaffray & Co. to Assist in the Review of Potential Strategies
ATLANTA, Jan. 18 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today announced that it has engaged Piper Jaffray & Co. to assist the Company's management and Board of Directors in identifying and evaluating potential strategies to enhance shareholder value. Piper Jaffray & Co. has had an investment banking relationship with CryoLife, most recently leading the Company's offering of 6% convertible preferred stock in 2005. Steven... 
Printer Friendly Version
01/12/06CryoLife Receives FDA Approval of New, Larger Delivery System for BioGlue(R) Surgical Adhesive
Disposable Syringe Provides Surgeons with Improved Site Access and Ease of Use ATLANTA, Jan. 12 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials and biosurgical device company, today announced that it has received approval from the Food and Drug Administration (FDA) for a new 10ml disposable syringe for BioGlue Surgical Adhesive. The 10ml BioGlue Syringe provides surgeons with an effective adhesive in an easy-to-use, self-contained, disposable syringe, ideally s... 
Printer Friendly Version
01/10/06CryoLife Announces Preliminary 2005 Revenues
Posts Highest Quarterly Revenue Total Since Third Quarter of 2002 Increases Revenue Guidance for 2006 ATLANTA, Jan. 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that revenues for 2005 were approximately $69.3 million compared to $62.4 million in 2004, an increase of 11%. Revenues for the fourth quarter of 2005 were approximately $18.0 million compared to $15.9 million in the fou... 
Printer Friendly Version
12/28/05CryoLife Amends Its Bylaws
ATLANTA, Dec. 28 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that its Board of Directors has amended the Company's bylaws in order to affirmatively opt out of the Control Share Acquisition Statute contained in the Florida Business Corporation Act. The Board believes that the Company no longer has "substantial assets" in the State of Florida and therefore the Control Share Acquisition Statute does not apply to Cry... 
Printer Friendly Version
12/28/05CryoLife Names Former FDA Official James S. Benson to its Board of Directors
ATLANTA, Dec 28, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today announced the appointment of James S. Benson to its Board of Directors. Mr. Benson retired in 2002 from Advanced Medical Device Association (AdvaMed, formerly known as the Health Industry Manufacturers Association), where he was Executive Vice President for Technical and Regulatory Affairs. Prior to his tenure at AdvaMed, Mr. Benson serv... 
Printer Friendly Version
12/12/05CryoLife Declares a Dividend of Approximately $0.75 on its Convertible Preferred Stock
ATLANTA, Dec 12, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today, that the Company declared a dividend of approximately $0.75 on its 6% convertible preferred stock payable on January 3, 2006, to shareholders of record at the close of business on December 23, 2005. About CryoLife Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissue... 
Printer Friendly Version
11/03/05CryoLife Reports Third Quarter 2005 Financial Results
Company Settles Class Action and Derivative Shareholder Litigation Strong Growth in Orthopaedic Tissue Processing Revenues Amends and Restates Stockholder Rights Agreement ATLANTA, Nov. 3 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that revenues for the third quarter of 2005 increased 2% to $16.5 million compared to $16.1 million in the third quarter of 2004. The net loss in th... 
Printer Friendly Version
11/02/05CryoLife Updates Status of BioDisc(TM) Spinal Disc Repair System at MedTech Insight's In Spine & Orthopedics Conference
ATLANTA, Nov. 2 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today at the MedTech Insight In Spine & Orthopedics Meeting in North Dallas, Texas that BioDisc(TM) Spinal Disc Repair System, a nucleus pulposus repair device, has been successfully implanted in four patients. The implants are part of a 10 patient feasibility study conducted at a hospital located in the United Kingdom. The study, targeted to address spinal d... 
Printer Friendly Version
10/20/05CryoLife to Present at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference in New York
ATLANTA, Oct. 20 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today announced that it is scheduled to participate in the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference at The Palace Hotel in New York City on Tuesday, October 25, 2005. Steven G. Anderson, President and CEO of CryoLife, Inc., will deliver the Company's presentation beginning at approximately 4:20 p.m. EDT. About CryoLife, Inc. Founded ... 
Printer Friendly Version
10/19/05CryoLife Announces Release Date and Teleconference Call Details for the Third Quarter 2005 Financial Results
ATLANTA, Oct. 19 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that third quarter 2005 financial results will be released on Thursday, November 3, 2005. The Company will hold a teleconference call and live webcast at 11:15 a.m. Eastern Time, November 3, 2005, to discuss third quarter 2005 financial results followed by a question and answer session hosted by Steven G. Anderson, President and CEO of CryoLife, Inc. ... 
Printer Friendly Version
10/06/05CryoLife Conducts Cardiac Reconstruction Surgery Symposium
ATLANTA, Oct. 6 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that it is conducting a cardiac reconstruction symposium utilizing human heart valves and tissues at its corporate headquarters training facility in Kennesaw, Georgia, from October 6-8. The program will include the following: Current indications, current clinical outcomes, and surgical techniques associated with aortic valve replacement utilizing allogr... 
Printer Friendly Version
09/28/05Positive Results of BioGlue(R) in Treating Alveolar Air Leaks Presented at International Medical Conference
ATLANTA, Sept 28, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today the positive results of a study on the use of BioGlue(R) Surgical Adhesive to treat alveolar air leaks after surgical procedures were presented this week at the European Association for Cardio-Thoracic Surgery in Barcelona, Spain. Patients in the study who were treated with BioGlue had a shorter median duration of air leaks, che... 
Printer Friendly Version
09/12/05CryoLife Declares a Dividend of Approximately $0.75 on its Convertible Preferred Stock
ATLANTA, Sept. 12 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today, that the Company declared a dividend of approximately $0.75 on its 6% convertible preferred stock payable on October 3, 2005, to shareholders of record at the close of business on September 22, 2005. About CryoLife Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in card... 
Printer Friendly Version
09/06/05CryoLife Announces First Human Implants of BioDisc(TM) Spinal Disc Repair System
ATLANTA, Sept. 6 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that BioDisc(TM) Spinal Disc Repair System, a nucleus pulposus repair device, was successfully implanted in two patients. These patients underwent a discectomy approximately 6 weeks ago, to treat a herniated disc in the lumbar spinal area. The BioDisc implant material was easily delivered into the void space as a simple additional step at the completion of... 
Printer Friendly Version
08/11/05CryoLife to Label High-Dose Irradiated Orthopaedic Tissue Sterile
ATLANTA, Aug. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that its cryopreserved high-dose irradiated human orthopaedic tissues will be labeled sterile. This sterility claim on the label is based on a comprehensive validation that was completed by the Company in the second quarter of 2005. In May 2005, CryoLife began distributing cryopreserved high-dose irradiated patellar, tibialis, achilles, quadriceps, and pero... 
Printer Friendly Version
08/04/05Cryolife's Second Quarter 2005 Revenues Increased 12% Over Second Quarter 2004
Strong Growth in International BioGlue Sales and Orthopaedic Tissue Processing Revenues In Second Quarter of 2005 Compared to Second Quarter of 2004 ATLANTA, Aug. 4 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that second quarter revenues of 2005 increased 12% to $17.2 million compared to $15.3 million in the second quarter of 2004. The net loss in the second quarter of 2005 was $14.4 million or $0.61 per ... 
Printer Friendly Version
07/28/05CryoLife Announces Release Date and Teleconference Call Details for the Second Quarter 2005 Financial Results
ATLANTA, July 28 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that second quarter 2005 financial results will be released on Thursday, August 4, 2005. The Company will hold a teleconference call and live webcast at 11:15 a.m. Eastern Time, August 4, 2005, to discuss second quarter 2005 financial results followed by a question and answer session hosted by Steven G. Anderson, President and Chief Executive Officer. ... 
Printer Friendly Version
07/28/05CryoLife Announces Agreements in Principle to Settle Shareholder Class Action and Shareholder Derivative Action Lawsuits
ATLANTA, July 28 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that it has reached an agreement in principle to settle the securities class action lawsuit pending in the United States District Court for the Northern District of Georgia arising out of allegedly inadequate disclosures prior to the FDA's August 2002 tissue recall. The settlement will resolve all claims asserted against the Company and the individual defen... 
Printer Friendly Version
07/07/05CryoLife Appoints Gerald B. Seery Vice President of International Operations
ATLANTA, July 7, 2005 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that Gerald B. Seery has been appointed to the newly created position of Vice President of International Operations. Mr. Seery has been President of CryoLife Europa, based in the U.K. for the past three years, and has returned to the corporate headquarters in Kennesaw, Georgia. Mr. Seery joined CryoLife in 1993 and has held several position... 
Printer Friendly Version
06/20/05CryoLife and The Magdi Yacoub Institute Sign Research Collaboration to Improve Xenografts for Human Transplantation
ATLANTA, June 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that CryoLife and The Magdi Yacoub Institute, at the Imperial College, London, UK, have entered into a three year research collaboration to develop methods to improve the utilization of unfixed xenografts (animal tissues) for human transplantation. A primary focus of the collaboration will be on the technology that is used to decellulari... 
Printer Friendly Version
06/02/05CryoLife Declares a Dividend of Approximately $0.87 on Its Convertible Preferred Stock
Shareholders Reelect Current Board Members At Annual Meeting ATLANTA, June 2 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today, that the Company declared a dividend of approximately $0.87 on its 6% convertible preferred stock payable on July 1, 2005, to shareholders of record at the close of business on June 20, 2005. At the Company's Annual Meeting, shareholders reelected the eight current members of the Board of Di... 
Printer Friendly Version
05/26/05Positive Results of CryoLife's SynerGraft Model #100 Arteriovenous (AV) Access Device Presented at International Medical Congress
ATLANTA, May 26 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that positive results of its SynerGraft(R) Model #100, a bovine ureter used for arteriovenous (AV) access in dialysis patients, were presented at the Fourth International Congress of the Vascular Access Society in Berlin, Germany. The data showed freedom from infection of 94% and secondary patency of 79% at one year. The objective of the study, conducted at... 
Printer Friendly Version
05/10/05CryoLife Announces Implant of its Cryopreserved Orthopaedic Tissues Treated With the Clearant Process
ATLANTA, May 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today the first human implant of its cryopreserved orthopaedic tissues utilizing the Clearant Process(R). They were implanted in a patient to reconstruct the anterior cruciate ligament (ACL) and the posterior cruciate ligament (PCL) in his knee. In this case, two tibialis tendons were used to replace the patient's damaged ACL and PCL. CryoLife plans to make avail... 
Printer Friendly Version
05/06/05CryoLife Conducts Annual Cardiac Surgery Fellows Program
ATLANTA, May 6 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced that it is conducting its annual Cardiac Surgery Fellows Program today at the Company's corporate headquarters training facility in Kennesaw, Georgia. The program will include discussions and demonstrations of surgical techniques of aortic valve replacement and complex ascending and thoracic aortic repair, as well as provide a practical laboratory to demonstrate an... 
Printer Friendly Version
05/05/05CryoLife First Quarter Revenues Increase 17% Over First Quarter 2004
* Tissue processing revenues increased 21% and BioGlue(R) revenues increased 14% in the first quarter of 2005, compared to the first quarter of 2004 * Financial position strengthened with $20 million convertible preferred offering and $15 million line of credit * First cryopreserved osteoarticular (OA) allografts implanted in patients ATLANTA, May 5 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY) announced today that first quarter... 
Printer Friendly Version
04/26/05CryoLife Announces Release Date and Teleconference Call Details for the First Quarter 2005 Financial Results
ATLANTA, April 26 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that first quarter 2005 financial results will be released on Thursday, May 5, 2005. The Company will hold a teleconference call and live webcast at 11:15 a.m. Eastern Time, May 5, 2005, to discuss first quarter 2005 financial results followed by a question and answer session hosted by Steven G. Anderson, President and Chief Executive Officer. To li... 
Printer Friendly Version
04/14/05CryoLife Appoints David M. Fronk Vice President, Regulatory Affairs and Quality Assurance
ATLANTA, April 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that David M. Fronk has been appointed to the position of Vice President, Regulatory Affairs and Quality Assurance. Mr. Fronk was formerly the Vice President of Clinical Research at CryoLife, a position he assumed in 1998. Since joining the Company in 1992, Mr. Fronk has held several positions in the Clinical Research Department. Mr. Fronk will continue ... 
Printer Friendly Version
03/15/05CryoLife Announces Pricing of 6% Convertible Preferred Stock
Mar 15, 2005 /PRNewswire via COMTEX/ -- ATLANTA, March 15 /PRNewswire-FirstCall/ CryoLife, Inc. (NYSE: CRY), announced today the offering of 400,000 shares of 6% convertible preferred stock at a public offering price of $50 per share. CryoLife has granted the underwriter in the offering a 30-day option to purchase up to an additional 60,000 shares of convertible preferred stock to cover over-allotments, if any. The convertible preferred stock has been listed on the New York Stock Exchange ... 
Printer Friendly Version
02/23/05CryoLife Announces First Implant of Cryopreserved Osteoarticular Allograft
ATLANTA, Feb 23, 2005 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that a patient received the first Cryopreserved osteoarticular (OA) allograft transplant for resurfacing articular cartilage in the knee. The OA allograft is a section of bone with overlying cartilage derived from the end of the femur, in this case from the femoral condyle. Patients suffering from a damaged articular surface of the femor... 
Printer Friendly Version
02/22/05CryoLife Reports Fourth Quarter and Full Year 2004 Financial Results
*BioGlue(R) sales increased 29% to $35.7 million for full year 2004 compared to 2003 *Continued strong growth in orthopaedic tissue processing revenues *Reaffirms revenue growth of at least 17% in 2005 ATLANTA, Feb 22, 2005 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, reported financial results for the fourth quarter and year ended December 31, 2004. Revenues for the fourth quarter of 2004 increased 24% to $15.9 million ... 
Printer Friendly Version
02/15/05CryoLife Announces Release Date and Teleconference Call Details for the 4th Quarter and Year End 2004 Financial Results
ATLANTA, Feb 15, 2005 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that fourth quarter and year end 2004 financial results will be released on Tuesday, February 22, 2005. The Company will hold a teleconference call and live web cast at 11:15 a.m. Eastern Time, February 22, 2005, to discuss fourth quarter and year end 2004 results followed by a question and answer session hosted by Steven G. Anderson, Presid... 
Printer Friendly Version
02/10/05CryoLife Receives American Association of Tissue Banks (AATB) Accreditation
ATLANTA, Feb. 1 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that it received accreditation from the American Association of Tissue Banks (AATB). The AATB is a scientific, not-for-profit peer group organization that facilitates the provision of high quality transplantable human tissues in quantities sufficient to meet national needs. "CryoLife is pleased to join the AATB, which is highly regarded and recognized... 
Printer Friendly Version
02/09/05CryoLife, Inc. Receives Line of Credit for up to $15 Million; Strengthens the Company's Financial Position
ATLANTA, Feb 09, 2005 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced it has entered into a credit agreement with Wells Fargo Foothill, part of Wells Fargo & Company (NYSE: WFC), providing for a revolving credit facility in an aggregate amount equal to the lesser of $15.0 million or a specified borrowing base. The credit agreement expires in February 2008, at which time the outstanding principal balance will be due. ... 
Printer Friendly Version
02/01/05CryoLife Receives American Association of Tissue Banks (AATB) Accreditation
ATLANTA, Feb. 1 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that it received accreditation from the American Association of Tissue Banks (AATB). The AATB is a scientific, not-for-profit peer group organization that facilitates the provision of high quality transplantable human tissues in quantities sufficient to meet national needs. "CryoLife is pleased to join the AATB, which is highly regarded and recognized... 
Printer Friendly Version
01/20/05CryoLife Human Heart Valve Clinical Experience Report Demonstrates Positive Long-Term Outcomes
ATLANTA, Jan 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced updated results from its registry, tracking clinical performance of its cryopreserved human heart valve allografts. Data from this registry is used to project long-term performance by actuarial statistical analysis(1). Results indicate 100 percent of pediatric patients and 98 percent of adult patients receiving human heart valves processed by the... 
Printer Friendly Version
01/10/05CryoLife and Endologix Sign Development Agreement for BioFoam
ATLANTA and IRVINE, Calif., Jan 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY) and Endologix, Inc. (Nasdaq: ELGX) today announced the signing of a development and marketing agreement for the percutaneous or endovascular delivery of CryoLife's BioFoam(TM) as a self-expanding sealant for endovascular aortic aneurysm grafts. Under the agreement, Endologix will be responsible for preclinical, clinical, and regulatory activities and costs, and CryoLife will manufactur... 
Printer Friendly Version
12/17/04CryoLife Files Shelf Registration Statement
ATLANTA, Dec. 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY) today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission ("SEC"). Upon being declared effective by the SEC, the registration statement will allow CryoLife to sell from time to time up to $50 million of its common stock, preferred stock, depositary shares, or any combination of these securities for its own account in one or more offerings from time to time. ... 
Printer Friendly Version
12/14/04Albert E. Heacox, Ph.D. Assumes Senior Vice President of Research and Development Position for CryoLife, Inc.
ATLANTA, Dec. 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY) a biomaterials and biosurgical device company, announced today that Albert E. Heacox, Ph.D. has assumed the position of Senior Vice President of Research and Development of CryoLife, Inc. Reporting to Dr. Heacox will be CryoLife's Research and Development Laboratory, Product and Process Engineering and Aurazyme Pharmaceuticals' Research Department. Dr. Heacox, (54) joined CryoLife in 1985 as Director of Laboratory Oper... 
Printer Friendly Version
11/11/04CryoLife Presents Positive Preclinical Results for Its BioDisc(TM) Spinal Disc Nucleus Repair System
ATLANTA, Nov 11, 2004 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced that positive preclinical results for its BioDisc(TM) spinal disc nucleus repair system were presented today at the IN SPINE Medtech conference in Dallas, Texas. BioDisc, a protein-based hydrogel, demonstrated durability by withstanding 10 million cycles of compression that mimicked physiological stresses. These studies compared the mechanical pr... 
Printer Friendly Version
11/04/04CryoLife Reports Third Quarter 2004 Financial Results
BioGlue(R) Sales Increased 33% Over Third Quarter 2003 Projects Revenue Growth and Margin Improvement in 2005 Strong Growth in Orthopaedic Tissue Revenues Progress with New Protein Hydrogel Products ATLANTA, Nov. 4 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today reported financial results for the third quarter and first nine months of 2004. Revenues fo... 
Printer Friendly Version
11/03/04Updated Information on CryoLife Promotion of D. Ashley Lee to Executive Vice President, Chief Operating Officer and Chief Financial Officer
ATLANTA, Nov. 3 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, reported today that it has promoted D. Ashley Lee from Vice President Finance, Treasurer and Chief Financial Officer to Executive Vice President, Chief Operating Officer and Chief Financial Officer. He will continue to report directly to Steven G. Anderson, CryoLife's President, Chief Executive Officer and founder. Mr. Lee, 40, a University of Mississippi graduate and... 
Printer Friendly Version
11/03/04CryoLife Promotes D. Ashley Lee to Executive Vice President
ATLANTA, Nov. 3 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, reported today that it has promoted D. Ashley Lee, 40, from Vice President Finance, Treasurer and Chief Financial Officer to Executive Vice President, Treasurer and Chief Financial Officer. In this newly created position, he will be responsible for all financial operations, purchasing, human resources, corporate communications, information technology and Wall Street relatio... 
Printer Friendly Version
10/29/04CryoLife Reports Settlement of Cases
ATLANTA, Oct. 29 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today reported that on Monday, October 25, 2004, it agreed to a binding settlement of three general liability lawsuits pending in the Multnomah Circuit Court in Oregon. Additionally, the Company settled one product liability case and two product liability claims since June 30, 2004. As a result of these settlements and the evaluation of all other outstanding litigation an... 
Printer Friendly Version
10/18/04CryoLife Announces Release Date and Teleconference Call Details for the Third Quarter 2004 Financial Results
ATLANTA, Oct 18, 2004 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and bio-surgical device company, announced today that third quarter 2004 financial results will be released on Thursday, November 4, 2004. The Company will hold a teleconference call and live web cast at 11:15 a.m. Eastern Time, November 4, 2004, to discuss third quarter 2004 results followed by a question and answer session hosted by Steven G. Anderson, President and Chief Executive Offic... 
Printer Friendly Version
09/16/04Positive Results of Cryolife's Synergraft(R) Arteriovenous Access Device In Dialysis Patients Presented At A European Medical Congress
83% Secondary Patency at One Year 94% Freedom of Infection at One Year ATLANTA, Sep 16, 2004 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that Mr. Chris Darby, of the Oxford Transplant Center at Churchill Hospital in Oxford, UK, presented positive results of the SynerGraft(R) arteriovenous (AV) access device, which showed secondary patency of 83% and freedom of infection of 94% at one year in patients underg... 
Printer Friendly Version
08/05/04CryoLife Reports Second Quarter 2004 Financial Results
BioGlue(R) Sales Increased 31% Over Second Quarter 2003 BioGlue Syringe Delivery System Launched in the Second Quarter Orthopaedic Tissue Revenues Increasing ATLANTA, Aug. 5 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, today reported financial results for the second quarter and first six months of 2004. Revenues for the second quarter 2004 were $15.3 million compared to $15.7... 
Printer Friendly Version
07/29/04Defense Bill Passed by the U.S. Senate and U.S. House of Representatives Provides Funding for BioFoam(TM) Development
ATLANTA, July 29 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company, announced today that the U.S. Senate and the U.S. House of Representatives have passed the 2005 Defense Appropriations Conference Report which included $1 million for the development of BioFoam(TM). The bill will now go to President Bush for his approval and signature to be enacted. BioFoam is a protein hydrogel adhesive that is in the pre-clinical stage of develo... 
Printer Friendly Version
07/14/04CryoLife Announces Release Date and Teleconference Call Details for the Second Quarter 2004 Financial Results
ATLANTA, July 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company, announced today that second quarter 2004 financial results will be released on Thursday, August 5, 2004. The Company will hold a teleconference call and live web cast at 11:15 a.m. Eastern Time, August 5, 2004, to discuss second quarter 2004 results followed by a question and answer session hosted by Steven G. Anderson, CryoLife President and Chief Executive Of... 
Printer Friendly Version
07/01/04Measure for Funding the Development of BioFoam(TM) was Passed by the U.S. House of Representatives
Innovative Therapy From CryoLife is Designed to Control Bleeding of Severe Wounds ATLANTA, July 1 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a bio-surgical device and human tissue processing company, announced today that a recommendation to provide $1 million to fund the development of BioFoam(TM) was recently passed by the U.S. House of Representatives. U.S. Rep. Phil Gingrey, a member of the House Armed Services Committee, introduced t... 
Printer Friendly Version
05/19/04CryoLife Receives CE Mark Approval for Distribution in the European Union of a New Delivery System for BioGlue(R) Surgical Adhesive
Disposable Syringe Provides Surgeons with Improved Site Access and Ease of Use ATLANTA, May 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc., (NYSE: CRY) a human tissue processing and surgical device company, today announced the CE mark approval for distribution in the European Union of a new disposable delivery system for BioGlue Surgical Adhesive. The new BioGlue Syringe is expected to provide clinicians with improved convenience and ease of use. On Monday, May 17, 2004, the... 
Printer Friendly Version
05/17/04CryoLife Receives FDA Approval of New Delivery System for BioGlue(R) Surgical Adhesive
Disposable Syringe Provides Surgeons with Improved Site Access and Ease of Use ATLANTA, May 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc., (NYSE: CRY) a human tissue processing and surgical device company, today announced the FDA approval of a new disposable delivery system for BioGlue Surgical Adhesive. The new BioGlue Syringe is expected to provide clinicians with improved convenience and ease of use. "Since its introduction in the U.S. in December 2001, BioGlue has se... 
Printer Friendly Version
05/13/04Cryolife Files Form 10-Q For First Quarter 2004
ATLANTA, May 13, 2004 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a bio-surgical device and human tissue processing company, announced today that it has addressed with the Securities and Exchange Commission ("SEC") its accounting for product liability claims and filed its Form 10-Q for the first quarter. Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgerie... 
Printer Friendly Version
05/10/04CryoLife First Quarter 2004 Revenues Up 18% Over Fourth Quarter 2003
Continued Strong Growth of U.S. and International BioGlue(R) Sales Positive Trend in Human Tissue Processing Revenues ATLANTA, May 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a bio-surgical device and human tissue processing company, today reported financial results for the first quarter of 2004. Revenues for the first quarter of 2004 were $15.1 million, an increase of 18% compared to the fourth quarter of 2003. Revenues for the first qu... 
Printer Friendly Version
04/26/04CryoLife Announces Release Date and Teleconference Call Details for the First Quarter 2004 Financial Results
ATLANTA, April 26 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company, announced today that first quarter 2004 financial results will be released on Monday, May 10, 2004. The Company will hold a teleconference call and live web cast at 11:15 a.m. Eastern Time, May 10, 2004, to discuss first quarter 2004 results followed by a question and answer session hosted by Steven G. Anderson, CryoLife President and Chief Executive Officer. ... 
Printer Friendly Version
04/22/04BioGlue(R) Surgical Adhesive is Safe and Effective in Range of Cardiac Surgical Procedures
Data shows BioGlue contributes to improved patient outcomes ATLANTA, Apr 22, 2004 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc., (NYSE: CRY) a bio-surgical device and human tissue processing company, today announced the presentation of clinical data results supporting positive clinical performance of BioGlue(R) Surgical Adhesive as a hemostatic adjunct in aortic valve and proximal aortic surgery. In this single-surgeon consecutive series, use of BioGlue Surgical Adhesive helped faci... 
Printer Friendly Version
02/26/04CryoLife Reports Fourth Quarter and Full Year 2003 Financial Results
Reaffirms tissue processing and product revenue growth estimate of 12 to 18% in 2004 BioGlue sales increased 33% in 2003 compared to 2002 $20 million PIPE Strengthens Financial Position Developing additional protein hydrogel products ATLANTA, Feb. 26 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company reported financial results for the fourth quarter and year ended December 31, 2003. The Company also reaffirmed ... 
Printer Friendly Version
02/10/04CryoLife Announces Release Date and Teleconference Call Details for the Fourth Quarter & Year Ended December 31, 2003 Financial Results
ATLANTA, Feb. 10 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company, announced today that fourth quarter and year ended December 31, 2003 financial results will be released on Thursday, February 26, 2004. The Company will hold a teleconference call and live webcast at 11:15 a.m. Eastern Time, February 26, 2004, to discuss fourth quarter and year ended December 31, 2003 results followed by a question and answer session hosted by ... 
Printer Friendly Version
02/06/04CryoLife Provides Update on 510(K) Premarket Notification for CryoValve SG Decellularized Human Heart Valves
ATLANTA, Feb. 6 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company, announced today that the Food and Drug Administration ("FDA") has requested additional information be provided to support the 510(k) premarket notification for the CryoValve SG decellularized human heart valves. The Company plans to work with the FDA to review and address their requirements. Since February 2003, the Company has been processing tissues wit... 
Printer Friendly Version
01/27/04CryoLife To Present at U.S. Bancorp Piper Jaffray Health Care Conference in New York
ATLANTA, Ga., Jan. 27 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and bio-surgical device company, is scheduled to participate in the 16th Annual U.S. Bancorp Piper Jaffray Health Care Conference at the Pierre Hotel in New York City on Thursday, January 29, 2004. Steven G. Anderson, CryoLife's President and CEO, will deliver the Company's presentation beginning at approximately 12:30 p.m. (Eastern). To listen to a live web cast of the U.S.... 
Printer Friendly Version
01/26/04CryoLife Announces $20 Million Private Placement of Common Stock
Proceeds strengthen the Company's financial position ATLANTA, Jan. 26 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company, announced today that it has sold 3,444,000 shares of common stock at $6.25 per share in a private placement. The net proceeds, estimated to be approximately $20 million after fees and expenses, will be used for general corporate purposes. Piper Jaffray & Co. served as the exclusive placement agent... 
Printer Friendly Version
01/12/04Cryolife Registry Demonstrates Positive Adult and Pediatric Long-Term Outcomes Following Heart Valve Implantation
Comprehensive Allograft Heart Valve Registry Tracks More Than 2,600 Patients for 10 Years Following Implantation ATLANTA, Jan. 12 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company, announced updated results from its registry, tracking clinical performance of its cryopreserved heart valve allografts. Data from this registry is used to project long-term performance by actuarial statistical analysis(1). ... 
Printer Friendly Version
01/07/04CryoLife Announces Revenues for 2003, Expects Increase in 2004
BioGlue(R) sales increased 33% to $27.8 million in 2003 compared to 2002 BioGlue(R) sales increased 39% to $7.8 million in the 4th quarter 2003 compared to 4th quarter 2002 ATLANTA, Jan. 7 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company announced today that revenues for 2003 were approximately $59.6 million and were approximately $12.8 million for the fourth quarter of 2003. Reven... 
Printer Friendly Version
12/15/03CryoLife Licenses Novel Technology for Microorganism Inactivation of Orthopaedic Tissue
Patented Irradiation Process is Designed to Render Pathogenic Organisms Non-Infectious While Preserving Tissue Integrity ATLANTA, Dec. 15 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company, announced today that it has licensed a patented technology from Clearant, Inc. designed to inactivate microorganisms, including pathogens, from tissue obtained from human donors. A pathogen is any agent that causes diseas... 
Printer Friendly Version
12/08/03Thomas Ackerman and Dan Bevevino Join Cryolife, Inc. Board of Directors
ATLANTA, Dec. 8 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that Thomas F. Ackerman and Dan Bevevino have been elected to the company's Board of Directors, effective immediately. These two, newly elected board members increase the number of directors to eight. Thomas F. Ackerman is Senior Vice President and Chief Financial Officer at Charles River Laboratories, a provider of critical research tools and integrated support services that accelerate drug discov... 
Printer Friendly Version
11/04/03CryoLife(R) Reports Third Quarter 2003 Financial Results
BioGlue(R) Revenues on Track to Reach $26-27 Million for 2003 Files Application for AATB Accreditation Submits 510k to the FDA for Decellurized, SynerGraft Processed Heart Valves Restates 2nd Quarter 2003 Results to Reflect Additional $2.4 Million Tax Refund ATLANTA, Nov. 4 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company today reported financial results for t... 
Printer Friendly Version
11/03/03CryoLife(R) Resolves Insurance Coverage Dispute on a $10 Million Policy
ATLANTA, Nov. 3 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that the Company and an insurer have mutually agreed to resolve their coverage dispute on a $10 million policy previously issued to CryoLife, representing the last layer of insurance in place for the 2002-2003 insurance policy year. The full amount of this policy will be placed in escrow for CryoLife to use, together with other funds provided by the Company and another insurer, for the purpose of defendi... 
Printer Friendly Version
10/22/03CryoLife Announces Release Date and Teleconference Call Details for the Third Quarter 2003 Financial Results
ATLANTA, Oct 22, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, announced today that third quarter 2003 financial results will be released on Tuesday, November 4, 2003. The Company will hold a teleconference call and live webcast at 11:15 a.m. Eastern Time, November 4, 2003, to discuss third quarter results followed by a question and answer session hosted by Steven G. Anderson, CryoLife President and Chief Executi... 
Printer Friendly Version
10/20/03CryoLife to Respond to Recent FDA Inspection Observation
ATLANTA, Oct. 20 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today its commitment to promptly respond to an observation made in a recent FDA inspection report (Form 483). The observation requires CryoLife to complete the validation of its processing operations and procedures for decontaminating tissues, written procedures for the prevention of infectious disease contamination during processing, and its anti-microbial solution. "CryoLife is committed to ensuring t... 
Printer Friendly Version
09/09/03CryoLife(R) Announces Results of Aurazyme(R)'S Pre-Clinical Animal Trials of AZ-CINN 310 to Treat Breast Cancer
ATLANTA, Sept. 9 /PRNewswire-FirstCall/ -- CryoLife, Inc.'s (NYSE: CRY), subsidiary, Aurazyme Pharmaceuticals, Inc., announced today that in pre- clinical animal trials AZ-CINN-310 demonstrated accelerated destruction of breast cancer tumor cells at the site of activation with a single low dose of paclitaxel when AZ-CINN 310 was light activated. AZ-CINN 310 links paclitaxel, a drug used in chemotherapy, to Herceptin, an antibody that targets HER-2 antigens that are above normal in certain... 
Printer Friendly Version
08/20/03CryoLife(R) Names Gregory Ray, MD Associate Medical Director
ATLANTA, Aug. 20 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that Gregory Ray, M.D., a board certified pathologist, has been appointed Associate Medical Director. Dr. Ray will report directly to J. Robin de Andrade, M.D., Medical Director. Dr. Ray will be responsible for establishing Cryolife's in-house pathology laboratory, which will work closely with the Quality Assurance department. Dr. Ray will also provide expertise in determining suitability of donors an... 
Printer Friendly Version
08/19/03CryoLife(R) Names Thomas J. Lynch, J.D., Ph.D., Vice President, Regulatory Affairs and Quality Assurance
ATLANTA, Aug. 19 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that Thomas J. Lynch, J.D., Ph.D., has been appointed Vice President, Regulatory Affairs and Quality Assurance. He will report to Steven G. Anderson, President and CEO. Dr. Lynch will oversee the Company's Regulatory Affairs and Quality Assurance operations and will be responsible for compliance with legislative and regulatory requirements. Dr. Lynch joins CryoLife from Clearant, Inc., a leader in p... 
Printer Friendly Version
08/05/03CryoLife(R) Reports Second Quarter 2003 Financial Results
BioGlue(R) Sales Growth Continues Expanding Distribution of Orthopaedic Tissues in August Increased Procurement of Cardiac, Vascular, and Orthopaedic Tissue ATLANTA, Aug 5, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and bio-surgical device company today reported financial results for the second quarter 2003. Revenues for the second quarter 2003 were $15.7 million compared to $23.3 million in the second quarter 2002. Net loss in the s... 
Printer Friendly Version
07/22/03CryoLife Announces Release Date And Teleconference Call Details For The Second Quarter 2003 Financial Results
ATLANTA, July 22 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, announced today that second quarter 2003 financial results will be released on Tuesday, August 5, 2003. The Company will hold a teleconference call and live webcast at 11:15 a.m. Eastern Time, August 5, 2003, to discuss second quarter results followed by a question and answer session hosted by Steven G. Anderson, CryoLife President and Chief Executive Officer. ... 
Printer Friendly Version
07/11/03CryoLife(R) Comments on Product Liability Cases and Related Insurance Coverage
ATLANTA, July 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that it has to date, settled five product liability cases pending against it and three additional cases have been dismissed. Two of the three insurance companies who issued "claims-made" policies to the Company for the 2002-2003 year have confirmed coverage for the first two layers of coverage totaling $15 million. A third insurance company covering the last $10 million of the remaining insurance has i... 
Printer Friendly Version
05/01/03CryoLife Reports First Quarter 2003 Financial Results
Strong Performance of Surgical Adhesive, BioGlue(R) Positive Trend in Heart Valve and Vascular Revenues Procurement of Tissues from Donors Increased in April ATLANTA, May 1, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, today reported financial results for the first quarter of 2003. Revenues for the first quarter of 2003 were $15.9 million, compared to $25.5 million in the first quarter of 2002. Net loss for ... 
Printer Friendly Version
04/22/03CryoLife Announces Release Date and Teleconference Call Details for the First Quarter 2003 Financial Results
ATLANTA, Apr 22, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, announced today that first quarter 2003 financial results will be released on Thursday, May 1, 2003. The Company will hold a teleconference call and live webcast at 11:15 a.m. Eastern Time, May 1, 2003, to discuss first quarter results followed by a question and answer session hosted by Steven G. Anderson, CryoLife President and Chief Executive Offic... 
Printer Friendly Version
04/09/03CryoLife Appoints New Corporate Communications Executive
ATLANTA, April 9 /PRNewswire-FirstCall/ -- CryoLife Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced the appointment of Joseph T. Schepers as Vice President of Corporate Communications. Schepers, who reports directly to CryoLife President and Chief Executive Officer Steven G. Anderson, assumes responsibility for all CryoLife external and internal communications, which include investor, media, employee and interactive efforts. "Joe's reco... 
Printer Friendly Version
03/31/03CryoLife Settles Lawsuit
ATLANTA, Mar 31, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced that a settlement has been reached in the lawsuit brought against the Company by the estate of Brian Lykins. The lawsuit alleged the St. Cloud, Minnesota man received infected tissue during knee surgery. Terms of the settlement will not be disclosed. CryoLife believes that the Company has adequate insurance remaining to cover the oth... 
Printer Friendly Version
03/24/03CryoLife to Present at Banc of America Securities Health Care Conference In Las Vegas
ATLANTA, Mar 24, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced that Steven G. Anderson, President and CEO, will present a Company overview at the Banc of America Securities Health Care Conference at the Four Seasons Hotel in Las Vegas, Thursday, March 27. The CryoLife presentation is scheduled for 11:30 a.m. Pacific Standard Time. A live webcast of the conference will be available at http://ww... 
Printer Friendly Version
03/19/03FDA Renews Interim Agreement With Cryolife
ATLANTA, Mar 19, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading human tissue processing and medical device company, announced that the U.S. Food and Drug Administration (FDA) has again renewed its September 5, 2002 Interim Agreement with the Company. The renewal allows CryoLife to continue distributing non-valved cardiac and vascular tissue processed prior to September 5, 2002 under the terms of the original agreement for an additional 60 working days, endi... 
Printer Friendly Version
03/12/03CryoLife(R), Inc. Pharmaceuticals Subsidiary Awarded Research Grant To Advance Clot-Dissolving Technology
ATLANTA, Mar 12, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading human tissue processing and medical device company, today announced that AuraZyme(TM) Pharmaceuticals, Inc., a wholly owned subsidiary of the Company, has recently been awarded a $100,000 research grant from the National Institutes of Health in Bethesda, Maryland, for "Site Directed Thrombolytic Agent" a feasibility study of its AZ-Plasmin Drug Technology in treating blood clots. Current dr... 
Printer Friendly Version
02/26/03CryoLife, Inc. Management Reviewed 2002 Operating Events In Teleconference Call
ATLANTA, Feb 26, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, held a teleconference yesterday following the release of its financial results for the fourth quarter and year ended December 31, 2002. During the call, company executives commented on operational events, including the following: BioGlue(R) Surgical Adhesive Update For the first time in the Company's history, monthly BioGlue revenues exceeded $... 
Printer Friendly Version
02/25/03CryoLife Reports Fourth Quarter And Full-Year Results; Resumes Processing of Orthopaedic Tissues
ATLANTA, Feb 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, today reported financial results for the fourth quarter and year ended December 31, 2002. Revenues for the fourth quarter of 2002 were $12.2 million, compared to $22.0 million in the fourth quarter of 2001. Net loss for the fourth quarter of 2002 was $5.7 million, compared to net income of $2.0 million in the fourth quarter of 2001. On a fully dil... 
Printer Friendly Version
02/18/03CryoLife Reinspected By U.S. Food And Drug Administration
CryoLife Closes Out Form 483 Notice of Observations That Preceded Warning Letter and Recall ATLANTA, Feb 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced that the Atlanta District Office of the U.S. Food and Drug Administration (FDA) has confirmed that the Company has completed the corrective actions necessary to close out the April 2002 FDA Form 483 Notice of Observations and the subsequent... 
Printer Friendly Version
02/14/03CryoLife Announces Release Date and Teleconference Call Details for The Fourth Quarter and Year Ended December 31, 2002
ATLANTA, Feb. 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, announced today that fourth quarter and year ended December 31, 2002 financial results will be released on Tuesday, February 25, 2003. The Company also announced that following the release of financial results, a teleconference will be held promptly at 11:15 a.m. Eastern Time, February 25, 2003, hosted by Steven G. Anderson, CryoLife President a... 
Printer Friendly Version
02/13/03CryoLife's BioGlue(R) Surgical Adhesive Approved for Soft Tissue Repair in Canada
ATLANTA, Feb 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced that Health Canada, the state ministry that oversees Canadian healthcare, has significantly expanded its approved indications for BioGlue surgical adhesive. BioGlue, a surgical adhesive developed by CryoLife, was initially approved in Canada in January 2000 for use in cardiac and pulmonary soft tissue repair. The new indications al... 
Printer Friendly Version
02/05/03CryoLife(R) Signs Exclusive Distribution Agreement With curasan AG
Company Will Handle U.S. Distribution of curasan's Ceramic Bone Replacement Products ATLANTA, Feb 5, 2003 /PRNewswire-FirstCall via COMTEX/ --CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced that it has signed an exclusive agreement with curasan AG, located in Kleinostheim, Germany, for U.S. distribution of Cerasorb(R) Ortho, curasan's resorbable bone graft substitute. Curasan is a leader in the development of implantable, regenerative bio... 
Printer Friendly Version
02/04/03CryoLife's BioGlue Shown Effective in Pituitary Tumor Surgery
Surgical Adhesive Eliminates Fluid Leak, Reinforces Bony Structure, Says Study in Journal of Clinical Neuroscience ATLANTA, Feb 4, 2003 /PRNewswire-FirstCall via COMTEX/ -- CryoLife(R), Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced that a paper published in the Journal of Clinical Neuroscience reported that using BioGlue(R) Surgical Adhesive in pituitary tumor removal may eliminate cerebrospinal fluid (CSF) leak following surgery. BioGlue, a b... 
Printer Friendly Version
02/03/03CryoLife's BioGlue(R) Surgical Adhesive Shown To Reduce Bleeding In Ventricular Assist Device Surgery
ATLANTA, Feb 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- Surgical Adhesive Eliminated Need for Additional Surgery To Correct Bleeding in Study Patients CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced that a 21 patient study reported at the Society of Thoracic Surgeons annual meeting on February 1, 2003, indicated that CryoLife's BioGlue surgical adhesive may eliminate the need for additional surgery to correct bleeding in patients impl... 
Printer Friendly Version
01/30/03CryoLife Presents at U.S. Bancorp Piper Jaffray Conference in New York
Annual Revenue Run Rate Approximates $60 Million, Based on January Revenues; Cash and Marketable Securities Exceed $26 Million as of January 27 ATLANTA, Jan. 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, will present today at the U.S. Bancorp Piper Jaffray Conference held in New York City. The following are highlights from the presentation to be given by Steven G. Anderson, CryoLife's President a... 
Printer Friendly Version
01/28/03CryoLife To Present At U.S. Bancorp Piper Jaffray Health Care Conference In New York
ATLANTA, Jan. 28 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced that Steven G. Anderson, president and CEO, will present a Company overview at the 15th Annual U.S. Bancorp Piper Jaffray Health Care Conference at the Pierre Hotel in New York City, Thursday, January 30. The CryoLife presentation is scheduled for 2:00 p.m. EST. A live webcast of the conference will be available at http://www... 
Printer Friendly Version
01/13/03FDA Renews Interim Agreement With CryoLife; Company Continues Tissue Processing and Distribution Under Agreement
ATLANTA, Jan. 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company, announced that the U.S. Food and Drug Administration (FDA) has renewed its September 5, 2002 Interim Agreement with the Company. The renewal allows CryoLife to distribute non- valved cardiac and vascular tissue processed prior to September 5, 2002, under the terms of the original agreement for an additional 45 working days, ending March 20, 2003. Fo... 
Printer Friendly Version
01/06/03CryoLife Announces Clarification of Interim Agreement With FDA
ATLANTA, Jan. 6 /PRNewswire-FirstCall/ -- CryoLife Inc. (NYSE: CRY), a leading tissue processing and medical device company, announced that the U.S. Food and Drug Administration has provided clarifying interpretations of the September 5, 2002 Interim Agreement that will expedite processing and distribution of the Company's life-saving and limb-saving non-valved cardiac and vascular tissues. For non-valved cardiac and vascular tissues processed since September 5, 20... 
Printer Friendly Version
12/23/02CryoLife, Inc. Continues Cooperation with the FDA
ATLANTA, Dec. 23 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), today announced that it continues to operate under its renewed Interim Agreement with the U.S. Food and Drug Administration (FDA). The renewal allows CryoLife, a pioneer in implantable tissues and surgical adhesives, to continue processing and distributing its cardiac and vascular tissue under the terms of the original agreement until January 15, 2003, or until a re- inspection is executed and an outcome ... 
Printer Friendly Version
11/08/02FDA Renews Interim Agreement With CryoLife
Company Continues Tissue Processing and Distribution Under Original Agreement Terms ATLANTA, Nov. 8 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), today announced that the U.S. Food and Drug Administration (FDA) has renewed its September 5, 2002, Interim Agreement with the company. The renewal allows CryoLife, a pioneer in implantable tissues and surgical adhesives, to continue processing and distributing its cardiac an... 
Printer Friendly Version
10/30/02CryoLife, Inc. Management Reviewed Third Quarter Operating Events In Teleconference Call
ATLANTA, Oct 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company, commented on operational events during its teleconference call following the release of its financial results for the third quarter and nine months ended September 30, 2002. The following provides highlights from the call: Regulatory Affairs Update CryoLife is cooperating fully with the FDA to reach a full resolution on all outstanding issues... 
Printer Friendly Version
10/29/02CryoLife Reports Third Quarter and Nine-Month Results
Non-Recurring, Non-Cash Pretax Charges Relating to FDA Order Recorded Initial Guidance for 2003 Established ATLANTA, Oct 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company, today reported financial results for the third quarter and nine-month period ended September 30, 2002. Revenues for the third quarter were $16.9 million, compared to $22.6 million in the third quarter of 2001. Net loss for the third quart... 
Printer Friendly Version
10/25/02CryoLife Announces Release Date and Teleconference Call Details for the Third Quarter and Nine Months Ended September 30, 2002
ATLANTA, Oct 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company, announced today that third quarter and nine months financial results will be released on Tuesday, October 29, 2002. The Company also announced that following the release of financial results, a teleconference will be held promptly at 11:15 a.m. Eastern Time, October 29, 2002, hosted by Steven G. Anderson, CryoLife President and Chief Executive O... 
Printer Friendly Version
10/10/02CryoLife's BioGlue(R) Helps to Seal Vessels and Reduce Bleeding in Vascular Surgery Procedures
SAN FRANCISCO, Oct 10, 2002 /PRNewsire-FirstCall via Comtex/ -- FDA Approves Additional BioGlue Manufacturing Facility CryoLife, Inc. (NYSE: CRY) -- Using CryoLife's BioGlue Surgical Adhesive in conjunction with standard vessel repair methods is safe and more effective in preventing intraoperative bleeding than standard methods alone, researchers said yesterday at the American College of Surgeons 88th Annual Clinical Congress in San Francisco. On October 8, 2002, the U.S. Food and ... 
Printer Friendly Version
10/08/02CryoLife Submits Corrective Action Plan to FDA
ATLANTA, Oct. 8 /PRNewswire-FirstCall/ -- CryoLife Inc. (NYSE: CRY) has submitted its corrective action plan to the U.S. Food and Drug Administration as outlined in the September 6, 2002 Interim Agreement with the FDA. The action plan describes proposed steps to validate CryoLife's tissue processing procedures. "We are processing tissue under the terms of the Interim Agreement and we are on schedule with the FDA," said CryoLife's Chief Financial Officer, D. Ashley L... 
Printer Friendly Version
09/06/02CryoLife Reaches Agreement With FDA to Resume Limited Tissue Processing And Distribution
ATLANTA, Sep 6, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife Inc. (NYSE: CRY), a tissue processing and medical device company, reached an agreement with the U.S. Food and Drug Administration permitting the company to immediately resume processing and limited distribution of its life-saving and limb-saving non-valved cardiac and vascular tissues. The agreement allows CryoLife to distribute existing and newly processed non-valved cardiac conduits and patches, saphenous veins, femora... 
Printer Friendly Version
09/04/02CryoLife Announces Filing and Certification of 10-Q; Revises Previously Announced 2002 Second Quarter Results Due to FDA Order
ATLANTA, Sep 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and manufactured implantable tissues and surgical adhesives, reported that today it filed its 10-Q for the quarter ended June 30, 2002. The document is certified by the Company's CEO and CFO. CryoLife revised its previously announced 2002 second quarter results due to the U.S. Food and Drug Administration Order it... 
Printer Friendly Version
08/19/02CryoLife Comments on Filing of Form 10-Q
ATLANTA, Aug 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and manufactured implantable tissues and surgical adhesives, reported that it will be delayed in filing its Form 10-Q. Company management is in the process of resolving the accounting issues raised by the U.S. Food and Drug Administration Order it received on August 13, 2002 (the "FDA Order"), which ordered certain ... 
Printer Friendly Version
08/19/02CryoLife Provides Further Detail Regarding SEC Investigation
ATLANTA, Aug 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and manufactured implantable tissues and surgical adhesives, reported earlier today that it received a letter on Saturday August 17, 2002 from the United States Securities and Exchange Commission (the "SEC Letter") that stated that CryoLife was subject to an investigation requesting information from CryoLife from th... 
Printer Friendly Version
08/19/02CryoLife Announces SEC Investigation
ATLANTA, Aug 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and manufactured implantable tissues and surgical adhesives, today reported that it received a letter on Saturday August 17, 2002, from the United States Securities and Exchange Commission (the "SEC Letter") that stated that CryoLife was subject to an investigation related to CryoLife's August 14, 2002, announcement... 
Printer Friendly Version
08/16/02Doctors Across the Nation Support CryoLife, Inc.; Physicians Voice Support in Media
ATLANTA, Aug 16, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced that physicians across the nation are showing their support of CryoLife. Yesterday in the New York Times, Dr. Warren King, an orthopaedic surgeon at the Palo Alto Medical Foundation in California, said he did 400 to... 
Printer Friendly Version
08/15/02CryoLife, Inc. Details Responses To The FDA; CryoLife Continues to Submit Validation Data to FDA
FDA's Order Does Not Affect Heart Valves ATLANTA, Aug 15, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced a synopsis of CryoLife's recent regulatory events. December 2001: the FDA inspected CryoLife. This inspection reviewed processes, complaint handling systems, donor sc... 
Printer Friendly Version
08/15/02CryoLife, Inc. Intends To File 10-Q on Monday, August 19, 2002
ATLANTA, Aug 15, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced this morning that it did not file its 10-Q for the quarter ended June 30, 2002, on August 14, 2002, as required by SEC rules, because of the FDA order that CryoLife received in the late afternoon of August 13, 2002. Cr... 
Printer Friendly Version
08/14/02CryoLife Announces Additional Information During Conference Call
ATLANTA, Aug. 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced during a conference call that the Company has appealed the FDA's August 13 order for retention, recall, and/or destruction of certain CryoLife processed tissues and requested a hearing with the FDA. The Company has also... 
Printer Friendly Version
08/14/02CryoLife, Inc. Receives FDA Order
ATLANTA, Aug 14, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, announced that it received an order from the Atlanta District Office of the U.S. Food and Drug Administration respecting the vascular, non-valved cardiac and orthopedic tissue processed by the Company since at lea... 
Printer Friendly Version
08/14/02CryoLife, Inc. Announces Conference Call at 4:00 PM Today
ATLANTA, Aug 14, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, will host a conference call today at 4:00 PM to discuss its recent regulatory events. The conference call will be hosted by Steven G. Anderson, President and CEO, D. Ashley Lee, Vice President and CFO, and Jam... 
Printer Friendly Version
08/13/02CryoLife, Inc. Secures $10 Million Line of Credit; Credit Line Strengthens the Company's Financial Position
ATLANTA, Aug 13, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced it has secured a $10 million line of credit from Bank of America. The credit facility replaces a $2 million line of credit that expired in December 2001. Steven G. Anderson, President and Chief Executive Officer, ... 
Printer Friendly Version
08/07/02CryoLife, Inc. Announces Technology Acquisition And Settlement of Litigation With Colorado State University
ATLANTA, Aug 7, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today announced that it has acquired exclusive ownership of tissue engineering technology from Colorado State University Foundation (CSURF), the technology transfer affiliate of Colorado State University. The ... 
Printer Friendly Version
07/30/02CryoLife Announces That It Believes Class Action Lawsuits Are Meritless; Company Intends to Vigorously Defend Suits and Retains King & Spalding
ATLANTA, Jul 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today announced that it intends to vigorously defend itself against securities class action suits recently filed against the Company. CryoLife has retained the services of King & Spalding to represent the Company... 
Printer Friendly Version
07/24/02CryoLife, Inc. Management Reviews Operating Events In Teleconference Call Following Release of Second Quarter and First Half of 2002 Revenues and Earnings Results
ATLANTA, Jul 24, 2002 /PRNewsire-FirstCall via Comtex/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, commented on operational events during its teleconference call following the release of its revenues and earnings results for the second quarter and first six months ended June 30, 2002 yesterday. Steven G. An... 
Printer Friendly Version
07/23/02CryoLife, Inc. Board of Directors Authorizes Purchase of Its Common Stock
ATLANTA, Jul 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced that its Board of Directors has authorized the purchase of up to $10 million of its Common Stock, beginning no sooner than Thursday July 25, 2002. The purchase of shares will be made from time to time in open market ... 
Printer Friendly Version
07/23/02CryoLife, Inc. Reports Record Revenues And Record Net Income For The First Half Of 2002
ATLANTA, Jul 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, today reported record revenues and record net income for the second quarter and six-month period ended June 30, 2002. Revenues for the second quarter were $25,697,000, an increase of 18 percent over the previo... 
Printer Friendly Version
07/11/02CryoLife Announces Release Date and Teleconference Call Details For the Second Quarter 2002 Revenues and Earnings Results
ATLANTA, Jul 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, announced today that second quarter and first six months revenues and earnings will be released on Tuesday, July 23, 2002. The Company also announced that following the release of financial results, a teleconf... 
Printer Friendly Version
07/05/02CryoLife, Inc. Announces Corrections to Its June 24, 2002 Press Release
ATLANTA, Jul 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today announced corrections to two statements it included in its press release of June 24, 2002. First, the Company confirmed that, as it had earlier noted in the Wall Street Journal, its comment to the effect ... 
Printer Friendly Version
06/24/02CryoLife, Inc. Announces Conference Call at 8:30 AM Tomorrow To Discuss FDA Letter
ATLANTA, Jun 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, will host a conference call tomorrow at 8:30 AM to discuss its recent regulatory events The conference call will be hosted by Steven G. Anderson, President and CEO, D. Ashley Lee, Vice President and CFO, and J... 
Printer Friendly Version
06/24/02CryoLife, Inc. Updates Actions of FDA
Letter Relating to April 2002 Inspection Received; No Actions Expected on Current Inventory ATLANTA, Jun 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced that it has received a warning letter from the Food and Drug Administration related to an inspection of the C... 
Printer Friendly Version
06/12/02CryoLife, Inc., Pharmaceuticals Subsidiary Awarded Research Grant To Advance Cancer Treatment Drug Delivery System
ATLANTA, Jun 12, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, today announced that its wholly owned subsidiary, AuraZyme(TM) Pharmaceuticals, Inc., has been awarded a $360,583 research grant to advance a site specific cancer drug delivery system. The research grant award... 
Printer Friendly Version
05/07/02CryoLife, Inc. Appoints New Accounting Firm
ATLANTA, May 7, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, announced that its Board of Directors has appointed the accounting firm of Deloitte & Touche, LLP as the Company's independent auditors. Founded in 1984, CryoLife, Inc. is the leader in the development and comm... 
Printer Friendly Version
04/23/02CryoLife, Inc. Management Reviewed Operating Events in Teleconference Call Following Release of Record First Quarter Revenues and Earnings Results
ATLANTA, Apr 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, commented on operational events during its teleconference call following the release of its record revenue and earnings results for the first quarter ended March 31, 2002. Steven G. Anderson, President and Chi... 
Printer Friendly Version
04/23/02CryoLife, Inc. Reports Record Revenues and Record Earnings For the First Quarter of 2002
Major Lines of Business Post Increases Over 2001 Levels ATLANTA, Apr 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today reported record revenues and record earnings for the first quarter ended March 31, 2002. Revenues for the first quarter of 2002 were $25.5 millio... 
Printer Friendly Version
04/16/02CryoLife Announces Release Date and Teleconference Call Details for the First Quarter 2002 Revenues and Earnings Results
ATLANTA, Apr 16, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced today that first quarter revenues and earnings will be released on April 23, 2002. The Company also announced that following the release of financial results, a teleconference will be held promptly a... 
Printer Friendly Version
04/09/02CryoLife(R), Inc. Terminates Its Accounting Services With Arthur Andersen, LLP
ATLANTA, Apr 9, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today said that its Board of Directors has dismissed its independent auditors, Arthur Andersen, LLP, effective April 9, 2002. The Atlanta office of Arthur Andersen had been CryoLife's accounting firm since May... 
Printer Friendly Version
03/29/02CryoLife, Inc. Corrects Previously Announced 2001 Earnings to Record Non-Cash Non-Operating Charges Related to Marketable Securities
Earnings Guidance for 2002 Remains Unchanged ATLANTA, Mar 29, 2002 /PRNewswire-FirstCall via COMTEX/ CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and distributor of stentless heart valves, vascular grafts and surgical adhesives, announced today that it is revising its previously announced 2001 results by recording non-operating, non-cash after-tax charges for the quarters ended March 31, 200... 
Printer Friendly Version
03/15/02CryoLife, Inc. Replies to Recent Articles and Announces Conference Call At 12:45 pm Today
ATLANTA, Mar 15, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today replied to an announcement by the CDC regarding certain human tissue allograft transplants. Steven G. Anderson, President and CEO commented, "The report of twenty six infections in tissue transplants released by the CDC t... 
Printer Friendly Version
03/12/02CryoLife(R), Inc. Selected as Recipient of Frost & Sullivan Market Penetration Award for Its BioGlue(R) Surgical Adhesive
ATLANTA, Mar 12, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today said it was one of the companies selected to receive the Frost & Sullivan Marketing Engineering Award for Market Penetration of its BioGlue surgical adhesive. Frost & Sullivan is a global leader in strat... 
Printer Friendly Version
03/11/02CryoLife, Inc. Appoints Gerald B. Seery President, CryoLife Europa, Ltd.
ATLANTA, Mar 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today announced that it has appointed Gerald B. Seery as President and CEO of its European subsidiary, CryoLife Europa, Ltd. Mr. Seery, a native of Long Island, New York, joined CryoLife as Director of Vascular Marketing in 19... 
Printer Friendly Version
02/12/02CryoLife(R), Inc.'S BioGlue Surgical Adhesive Approved for General Surgery Procedures in Europe
BioGlue Surgical Adhesive Receives Third CE Mark ATLANTA, Feb 12, 2002 /PRNewswire-FirstCall via COMTEX/ --CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today announced that it has been awarded a CE product certification mark for its BioGlue surgical adhesive for use in general surgery procedures. The award re... 
Printer Friendly Version
01/29/02CryoLife, Inc. Management Reviewed Operating Events In Teleconference Call Following Release of Fourth Quarter and Year End 2001 Revenues and Earnings Results
ATLANTA, Jan 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, commented on operational events during its teleconference call following the release of its revenues and earnings results for the fourth quarter and year ended December 31, 2001 earlier today (January 29, 2002). ... 
Printer Friendly Version
01/29/02CryoLife(R), Inc., Signs Distribution and Allocation Agreements With AlloSource(R)
Contract Expands Availability of Tissue for Use in Reconstructive Knee Surgeries ATLANTA, Jan 29, 2002 /PRNewswire-FirstCall via COMTEX/ --CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today announced that it has signed a series of agreements with AlloSource, one of the nation's largest non-profit tissue bank cooperatives. The agre... 
Printer Friendly Version
01/29/02CryoLife, Inc. Reports Record Revenues and Record Earnings For Both The Fourth Quarter and The Year 2001
ATLANTA, Jan 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, today reported earnings for both the fourth quarter and year ended December 31, 2001. Revenues for the twelve-month period ended December 31, 2001, were $87.7 million, up 14 percent over the previous record of $77.1 million set ... 
Printer Friendly Version
01/17/02CryoLife Announces Release Date and Teleconference Call Details for the Fiscal Year 2001 Revenues and Earnings Results
ATLANTA, Jan. 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced today that year-end and fourth quarter revenues and earnings will be released on January 29, 2002. The Company also announced that following the release of financial results, a teleconference will be held promptly a... 
Printer Friendly Version
01/03/02CryoLife, Inc. to Post Record Revenues for the Year 2001; FDA Approved BioGlue Shipped in December 2001
ATLANTA, Jan 3, 2002 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, announced today that based upon early analysis of financial results, the Company expects revenues for the year ended December 31, 2001, to set a new record. CryoLife Inc. has achieved record revenues for 17 consecutive years. Steven G. An... 
Printer Friendly Version
12/20/01CryoLife, Inc. Stock to be Listed on the Chicago Board Options Exchange
ATLANTA, Dec 20, 2001 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts and surgical adhesives, today announced that it has been selected for listing on the Chicago Board Options Exchange (CBOE). Trading is scheduled to begin on or about Thursday, December 20, 2001. The CBOE ticker symbol will be CRY. ... 
Printer Friendly Version
12/14/01CryoLife, Inc. Reports CDC Provides Additional Information Relating To Rare Bacterial Infection Case
ATLANTA, Dec 14, 2001 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts, and surgical adhesives, today announced that the U. S. Centers for Disease Control and Prevention (CDC), has completed its testing of CryoLife-processed tissue from the donor of condyle tissue implanted in the Minnesota knee surge... 
Printer Friendly Version
12/07/01Cryolife, Inc. Cooperates With Health Agencies on Rare Bacterial Infection
ATLANTA, Dec 7, 2001 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopedic reconstruction grafts, and surgical adhesives, today said that it is cooperating with the Minnesota Department of Public Health, The Centers for Disease Control and Prevention (CDC), and the U.S. Food and Drug Administration (FDA) in an investigation into ... 
Printer Friendly Version
12/04/01CryoLife, Inc. Reports FDA Approval for BioGlue(R) Surgical Adhesive Use in Vascular Repair for Hemostasis
ATLANTA, Dec 4, 2001 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular, and orthopedic reconstruction grafts and surgical adhesives, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Premarket Approval (PMA) application for use of BioGlue surgical adhesive. This device is indicated for use as an adj... 
Printer Friendly Version
11/29/01CryoLife, Inc. Hosts Industry Analysts at its Newly Expanded Headquarters, Laboratory, and Manufacturing Facilities
New 100,000 Square Foot Wing Designed to Accommodate Roll-Out of BioGlue(R) and SynerGraft(R) Product Lines ATLANTA, Nov 29, 2001 /PRNewswire via COMTEX/ --CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopedic reconstruction grafts, and surgical adhesives, today hosted a meeting of approximately 30 prominent biotechnology and healthcare security analysts... 
Printer Friendly Version
11/19/01CryoLife, Inc. Announces Baylor College of Medicine Animal Study Supports Use of BioGlue(R) in Phrenic Nerve Environment
CryoLife, Inc. Announces Baylor College of Medicine Animal Study Supports Use of BioGlue(R) in Phrenic Nerve Environment   CryoLife, Inc. Announces Baylor College of Medicine Animal Study Supports Use of BioGlue(R) in Phrenic Nerve Environment ... 
Printer Friendly Version
10/31/01Cryolife, Inc. Presents Research Results on Injectable Spinal Disc Device At Industry Forum
ATLANTA, Oct 31, 2001 /PRNewswire via COMTEX/ -- Protein Hydrogel Technology Evaluated to Restore Spinal Disc Function CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today will be presenting the results of animal bench tests on the use of its protein hydrogel technology (PHT) in the repair of denucleated interve... 
Printer Friendly Version
10/17/01CryoLife, Inc. Management Reviews Operating Events in Teleconference Call Following Release of 3rd Quarter and Nine Month Revenues and Earnings Results
ATLANTA, Oct. 17 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts, and surgical adhesives, commented on operational events in its teleconference call following release of its revenues and earnings for the third quarter and nine-month period ended September 30, 2001 on October 16, 2001. S... 
Printer Friendly Version
10/16/01CryoLife, Inc. Reports Record Revenues and Record Net Income For Both Third Quarter and Nine Months Of 2001
ATLANTA, Oct. 16 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today reported record revenues and record net income for the third quarter and nine-month period ended September 30, 2001. Revenues for the third quarter of 2001 were $22,567,000, up 16 percent over the previous ... 
Printer Friendly Version
10/15/01CryoLife, Inc. Selected for the FORBES Magazine 200 Best Small Companies in America
ATLANTA, Oct 15, 2001 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts, and surgical adhesives, today announced that it was selected as one of the FORBES 200 Best Small Companies in America for 2001. The list is published in the October 29, 2001 issue of FORBES. According to the FORBES Magazine cri... 
Printer Friendly Version
10/10/01CryoLife, Inc. Reports Record Revenues for Third Quarter 2001 At Industry Conference
NEW YORK, Oct 10, 2001 /PRNewswire via COMTEX/ -- Participants Briefed on Company's Emerging SynerGraft(R) And BioGlue(R) Technologies CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, will announce revenue results for the third quarter ended September 30, 2001, at the UBS Warburg Global Life Sciences Conference, b... 
Printer Friendly Version
10/02/01CryoLife Announces Release Date and Teleconference Call Details For Third Quarter 2001 Revenues and Earnings Results
ATLANTA, Oct. 2 /PRNewswire/ -- CryoLife, Inc.(NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced today that third quarter revenues and earnings will be released on Tuesday, October 16, 2001. The Company also announced that following the release of financial results, a teleconference will be held prompt... 
Printer Friendly Version
09/25/01CryoLife Inc. Files Trademark Infringement Suit Against Sulzer Carbomedics, Inc.
ATLANTA, Sep 25, 2001 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts, and surgical adhesives, today announced that it has filed a civil action against Sulzer Carbomedics, Inc., for trademark infringement under the Federal Trademark Act and violation of Georgia's Uniform Deceptive Trade Practices Act. The c... 
Printer Friendly Version
09/19/01CryoLife's BioGlue(R) Surgical Adhesive Featured at Military Combat Care Conference
ATLANTA, Sep 19, 2001 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts, and surgical adhesives, today announced that its BioGlue technology was presented at the Advanced Technology Applications for Combat Casualty Care 2001 Conference (ATACCC) at Fort Walton Beach, Florida. The conference was sponsored by the... 
Printer Friendly Version
09/17/01FDA Panel Recommends Approval of CryoLife's BioGlue(R) Surgical Adhesive for Use in Vascular and Cardiac Repair
ATLANTA, Sept. 17 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts, and surgical adhesives, today announced that the U.S. Food and Drug Administration's (FDA) Circulatory System Devices Panel has unanimously recommended to approve the Company's BioGlue Surgical Adhesive as an adjunct to the use of ... 
Printer Friendly Version
09/05/01CryoLife's Pharmaceutical Subsidiary to Present Progress Report on Development of Cancer Treatment Drug Delivery System at International Conference
ATLANTA, Sept. 5 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts, and surgical adhesives, today announced that its wholly owned subsidiary, AuraZyme(TM) Pharmaceuticals, Inc., presented results of animal studies on its A-Z-CINN(TM) Linker for targeted delivery of anti-cancer chemotherapy drugs. Th... 
Printer Friendly Version
08/23/01CryoLife, Inc. Receives CE Mark Approval For Synergraft(R) Tissue-Engineered Vascular Graft For Dialysis Access And Peripheral Vascular Reconstruction
ATLANTA, Aug 23, 2001 /PRNewswire/ -- New Graft Has the Potential to Repopulate Itself With the Recipient's Own Cells CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopedic reconstruction grafts, and surgical adhesives, today announced that it has received a CE (product certification) Mark allowing the commercial distribution of its SynerGraft Model 10... 
Printer Friendly Version
08/16/01CryoLife, Inc. Files Premarket Approval Application (PMA) With FDA for CryoLife-O'Brien(R) Aortic Heart Valve
ATLANTA, Aug. 16 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic reconstruction grafts, and surgical adhesives, today announced that it had filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for the CryoLife-O'Brien stentless porcine heart valve. The CryoLife-O'Brien heart ... 
Printer Friendly Version
07/17/01CryoLife, Inc. Management Reviews Operating Events in Teleconference Call Following Release of 2nd Quarter and First Half Of 2001 Revenues and Earnings Results
ATLANTA, July 17 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, commented on operational events in its teleconference call following release of its revenues and earnings for the 2nd quarter and first six months ended June 30, 2001 earlier today (July 17, 2001). Steven G. Anders... 
Printer Friendly Version
07/17/01CryoLife, Inc. Reports Record Revenues and Record Net Income for Both Second Quarter and First Half of 2001
ATLANTA, July 17 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today reported record revenues and record net income for the second quarter and six month period ended June 30, 2001. Revenues for the second quarter of 2001 were $21,697,000, an increase of 12% over the previous re... 
Printer Friendly Version
07/09/01CryoLife Announces Release Date and Teleconference Call Details for 2nd Quarter 2001 Revenues and Earnings Results
ATLANTA, Jul 9, 2001 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced today that 2nd quarter revenues and earnings will be released on Tuesday, July 17, 2001. The Company also announced that following the release of financial results, a teleconference will be held promptly at 11:15 a.m. Eastern Time July 17,... 
Printer Friendly Version
06/21/01Results of Thirteen Year Follow-Up Study on Aortic Heart Valve Replacement Therapy Reported at Thoracic Surgery Conference
SAN DIEGO, June 21 /PRNewswire/ -- Results of aortic valve replacement surgery covering a 13 year follow-up review, January 1986 through December 1998, conducted at the University of Oklahoma, Health Science Center, and the Prince Charles Hospital, Brisbane, Australia, were presented at the Western Thoracic Surgical Association, 27th Annual Meeting, held at Rancho Bernardo Inn, San Diego, California, June 20-23, 2001. The study reviewed the survival and morbidity rate... 
Printer Friendly Version
06/18/01CryoLife, Inc. Tissue-Engineered Replacement Heart Valve Featured at International Conference
ATLANTA, June 18 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, presented results of studies on CryoLife's tissue-engineered porcine replacement heart valves processed with the Company's SynerGraft(R) technology at the First Biennial Meeting of the Society for Heart Valve Disease, held in... 
Printer Friendly Version
06/15/01CryoLife, Inc.'s SynerGraft Heart Valve Technology Presented at International Heart Valve Symposium
ATLANTA, June 15 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, presented a comprehensive review of its patented SynerGraft(R) technology in the development of a series of heart valve replacement devices. The SynerGraft technology centers around the removal of antigens from human and anim... 
Printer Friendly Version
06/12/01CryoLife, Inc. Advances Its SynerGraft Tissue-Engineering Technology For Transpecies Applications
ATLANTA, Jun 12, 2001 /PRNewswire/ -- Animal Study Centered on Use of Bovine Tissue in Development of A-V Access Grafts for Hemodialysis Patients CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryo-preserved and tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, presented the results of an animal study, on the use of animal tissues to create A-V (arteriovenous) access grafts in hem... 
Printer Friendly Version
05/30/01CryoLife, Inc. Advances Development Of An Injectable Spinal Disc Replacement Device
ATLANTA, May 30 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, presented the results of a biomechanical study on the use of CryoLife's protein hydrogel device (PHD) technology in the repair of denucleated intervertebral discs at the 14th Annual Meeting for the International Intradiscal Ther... 
Printer Friendly Version
05/29/01CryoLife, Inc. Confirms Dispute
ATLANTA, May 29 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today confirmed that Colorado State University Research Foundation (CSURF) has filed suit against the Company asserting claims with regard to patent and intellectual property matters related to technology CryoLife uses in its SynerGraft(R) proce... 
Printer Friendly Version
05/08/01CryoLife, Inc. BioGlue Surgical Adhesive Study Results Presented At American Association for Thoracic Surgery Meeting
ATLANTA, May 8 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced the results of a clinical study on the use of BioGlue(R) surgical adhesive in acute thoracic aortic dissection. The paper was presented at the Annual Meeting of the American Association for Thoracic Surgery, held in San Diego, Californ... 
Printer Friendly Version
05/07/01CryoLife, Inc. Tissue-Engineering Heart Valve Technology Featured At Cardiovascular Surgical Conference
ATLANTA, May 7 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced the results of two separate medical studies featuring CryoLife's patented SynerGraft(R) technology. The study results were presented by Ronald C. Elkins, M.D. Chief, Section of Thoracic and Cardiovascular Surgery, University of Oklahom... 
Printer Friendly Version
04/18/01CryoLife, Inc. Receives 'CE Mark' Approval for Distribution of Model 700 Synergraft Tissue-Engineered Pulmonary Heart Valves in Europe
ATLANTA, April 18 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of tissue- engineered implantable heart valves, vascular and orthopaedic grafts and surgical adhesives, today announced that it has received a "CE" (product certification) Mark allowing for the commercial distribution of its Model 700 SynerGraft tissue-engineered pulmonary heart valves within the European Community. CryoLife's Model... 
Printer Friendly Version
04/17/01CryoLife, Inc. Reports 54% Increase in Net Income During the First Quarter Of 2001 as Compared to the First Quarter of 2000
ATLANTA, April 17 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life- science company involved in the development and commercialization of tissue- engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today reported record first quarter revenues and earnings during the quarter ended March 31, 2001. Revenues for the quarter ended March 31, 2001 were $21.4 million, a 9% increase over the previous record of $19.6 million set in the... 
Printer Friendly Version
04/10/01CryoLife Announces Release Date for First Quarter Revenues and Earnings And Shareholder Access to Teleconference Call Following Release of First Quarter Results
ATLANTA, April 10 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of tissue-engineered implantable heart valves, vascular grafts and protein-based adhesives, announced today that first quarter revenues and earnings figures would be released on April 17, 2001. The Company also announced that immediately following the release of financial results, an analysts' teleconference would be held promptly at 11:15 a.m. Eastern Ti... 
Printer Friendly Version
03/13/01CryoLife, Inc. Announces Formation of a New Wholly Owned Pharmaceutical Subsidiary and Corporate Marketing Management Changes
ATLANTA, March 13 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of tissue-engineered implantable heart valves, vascular grafts and protein-based surgical adhesives, today announced the formation of AuraZyme Pharmaceuticals(TM), Inc., a new wholly owned operating subsidiary to foster commercial development of light-activated drug delivery systems that have potential applications in cancer treatment, heart attack, stroke and b... 
Printer Friendly Version
03/06/01CryoLife, Inc. Reports Results Of Eight Year Follow-Up Study On Cryopreserved Meniscus Use In Knee Reconstructive Surgery
ATLANTA, March 6 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of tissue-engineered implantable heart valves, vascular grafts and protein-based surgical adhesives, today reported results of an eight-year follow-up study of patients who have undergone total or partial meniscus replacement knee reconstructive surgery. The results of the follow-up study (1991-2000) involving 13 implanting surgeons and 136 patients were pr... 
Printer Friendly Version
02/22/01CryoLife, Inc. Announces First Implant Of Its Tissue-Engineered Synergraft Heart Valve in Norway
ATLANTA, Ga., Feb. 22 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of tissue-engineered implantable heart valves, vascular grafts and protein-based surgical adhesives, today announced that its revolutionary SynerGraft(R) heart valve was successfully implanted in a 3 year old male child at a hospital in Norway. CryoLife's SynerGraft technology represents a major development in tissue- engineered replacement biologic de... 
Printer Friendly Version
02/07/01CryoLife, Inc Receives Approval to Market BioGlue Surgical Adhesive in Australia
ATLANTA, Feb. 7 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of tissue-engineered implantable heart valves, vascular grafts and protein based surgical adhesives announced today that the Australian Therapeutic Good Administration (TGA) has issued a Certificate of Registration for BioGlue Surgical Adhesive. This approval allows the commercial distribution of BioGlue Surgical Adhesive in Australia. The TGA is comparable to the Fo... 
Printer Friendly Version
02/06/01CryoLife, Inc. Enters A Long-Term Agreement With Mid-South Tissue Bank
ATLANTA, Feb. 6 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of tissue-engineered implantable heart valves, vascular grafts and protein based surgical adhesives, today announced that it entered into a five year preferred provider agreement with Mid-South Tissue Bank of Memphis, Tennessee. Under the terms of the agreement, Mid- South will send to CryoLife for processing all cardiac and vascular tissues and selected orthopaedic ... 
Printer Friendly Version
02/01/01CryoLife, Inc. Files Premarket Approval Application With FDA for Bioglue Surgical Adhesive for Vascular and Cardiac Repair
ATLANTA, Feb. 1 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has filed a Premarket Approval (PMA) application with the U. S. Food and Drug Administration (FDA) for the use of its BioGlue surgical adhesive in vascular and cardiac repair. The application is based upon results ... 
Printer Friendly Version
01/31/01CryoLife, Inc. Reports Record Revenues and Record Earnings for the Year 2000
ATLANTA, Jan. 31 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of tissue-engineered implantable heart valves, vascular grafts and protein based surgical adhesives, today reported record revenues and record earnings for the year ended December 31, 2000. Revenues for the year ended December 31, 2000 were $77.1 million, a 16% increase over the previous record of $66.7 million set in 1999. Net income for the year 2000 was... 
Printer Friendly Version
01/24/01CryoLife Announces Fiscal Year 2000 Revenues and Earnings, Release Date and Teleconference Call Details
ATLANTA, Jan. 24 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of tissue-engineered heart valves, vascular grafts and surgical adhesives, announced today that year end and fourth quarter revenues and earnings will be released on January 31, 2001. The year end financial results are being released ahead of the scheduled release date of February 13, 2001, in conjunction with CryoLife management's presentation at the U.S. ... 
Printer Friendly Version
01/17/01CryoLife, Inc. Announces New Tissue-Engineered Vascular Graft for Dialysis Patients
ATLANTA, Jan. 17 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it had expanded its human vascular graft program to include a new method of preserving vascular tissue used as an A-V (arteriovenous) access graft for application with dialysis patients. The new vascular graft, calle... 
Printer Friendly Version
11/28/00CryoLife, Inc. Files Investigational Device Exemption With FDA for BioGlue Surgical Adhesive for Use in Pulmonary Repair
ATLANTA, Nov. 28 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced that it has filed an Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) for use of its BioGlue Surgical Adhesive in all pulmonary surgical repairs. The BioGlue clinical study is expe... 
Printer Friendly Version
11/27/00CryoLife, Inc. Declares A 3-For-2 Stock Split
ATLANTA, Nov. 27 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer of stentless heart valves and surgical adhesives, announced that its Board of Directors has authorized a 3-for-2 stock split, to be effected as a stock dividend, to shareholders of record on December 8, 2000. New share certificates will be mailed to shareholders on December 27, 2000. Fractional shares wi... 
Printer Friendly Version
11/15/00CryoLife, Inc. Awarded Grant From The National Institutes Of Health (NIH) for Its SynerGraft Tissue Technology
ATLANTA, Nov. 15 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced today that it has been awarded a $750,000 grant from the National Institutes of Health (NIH) to advance CryoLife's SynerGraft tissue-engineering technology in the development of biologic implantable vascular devices for application... 
Printer Friendly Version
11/07/00CryoLife, Inc. Added to Standard & Poor's SmallCap 600 Health Care Specialized Services Index
ATLANTA, Nov. 7 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced that effective after the close of trading on Thursday, November 9, 2000, it will be added to Standard & Poor's S&P SmallCap 600 Health Care Specialized Services industry group index. Standard & Poor's, a division of The McGraw Hill... 
Printer Friendly Version
11/06/00CryoLife's SynerGraft Tissue-Engineering Technology Featured At Cardiac Bioprostheses Symposium
ATLANTA, Nov. 6 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced today that two studies on its patented SynerGraft Technology on heart valves and vascular grafts were presented at the VIII International Symposium -- Cardiac Bioprostheses held in Cancun, Mexico, November 3-5, 2000. The presentati... 
Printer Friendly Version
10/17/00CryoLife, Inc. Reports Record Revenues and Improved Earnings For the Third Quarter and Nine Months Ended September 30, 2000
ATLANTA, Oct. 17 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a diversified biological implantable device company, today reported record revenues and improved earnings for the third quarter and nine months ended September 30, 2000. Revenues for the third quarter ended September 30, 2000 were $19,524,000, an increase of 18% over the $16,529,000 recorded in the third quarter of 1999. Net income for the third quarter of 2000 was $2,308,000, an increase of 35% over the net i... 
Printer Friendly Version
10/16/00CryoLife, Inc. Receives 'Ce Mark' Approval for Distribution of Synergraft(R) Tissue-Engineered Pulmonary Heart Valves in Europe
ATLANTA, Oct. 16 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced today that it has received the "CE" (product certification) mark for the commercial distribution in the European Union of its recently introduced SynerGraft tissue-engineered pulmonary heart valves. SynerGraft technology ... 
Printer Friendly Version
10/11/00CryoLife, Inc. Completes Sale of Ideas for Medicine Assets To Horizon Medical Products, Inc
ATLANTA, Oct. 11 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced today that Horizon Medical Products, Inc. (Amex: HMP) has acquired substantially all of the remaining assets of Ideas For Medicine, Inc. (IFM), a wholly owned subsidiary of CryoLife, located in St. Petersburg, Florida. The assets ... 
Printer Friendly Version
09/06/00CryoLife, Inc. Reports Record Revenues For The First Two Months of the Third Quarter
ATLANTA, Sept. 6 /PRNewswire/ -- Steven G. Anderson, President and Chief Executive Officer of CryoLife, Inc. (NYSE: CRY), in remarks to securities analysts touring corporate headquarters today, reported record revenues through the first two months, ended August 31, 2000, of the third quarter. Third quarter financial results for the three-month period ending September 30, 2000 are scheduled to be released on October 17, 2000. Distribution of the information provided to... 
Printer Friendly Version
08/11/00CryoLife, Inc. Advances Application of Its Tissue-Engineered Human Heart Valves
NEW YORK, Aug. 11 /PRNewswire/ -- Steven G. Anderson, President and Chief Executive Officer of CryoLife, Inc. (NYSE: CRY), in remarks today on overall Company operations also discussed clinical results of human allograft valves processed with the Company's unique proprietary SynerGraft(R) technology. This preserved allograft valve, called CryoValve(R)-SG, has been implanted in 33 patients and has been undergoing human clinical trials and evaluations since February of this year. ... 
Printer Friendly Version
08/01/00CryoLife, Inc. Files Application With FDA for SynerGraft: World's First Tissue-Engineered Heart Valve
ATLANTA, Aug. 1 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a diversified biological implantable device company, announced today that it has submitted an application to the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to conduct human clinical trials for its SynerGraft tissue-engineered replacement heart valves. If successful, SynerGraft technology will represent a major advancement in heart valve replacement. It incorporates the us... 
Printer Friendly Version
07/18/00CryoLife, Inc., Reports Record Revenues and Improved Earnings During the Second Quarter and First Half of 2000
ATLANTA, July 18 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a diversified biological implantable device company, today reported record revenues and improved earnings for the second quarter and first half of 2000. Revenues for the second quarter ended June 30, 2000 were $19,454,000, an increase of 12% over the $17,395,000 recorded in the second quarter of 1999. Net income for the second quarter of 2000 was $1,979,000, an increase of 15% over the net income of $1,727,000 rep... 
Printer Friendly Version
07/12/00CryoLife-O'Brien Stentless Porcine Heart Valve Approved for Distribution in Canada
ATLANTA, July 12 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a diversified biological implantable device company, announced today that its CryoLife- O'Brien(R) stentless aortic heart valve has been approved by the Canadian Government's Therapeutic Products Programme (TPP) for general distribution in the Canadian tissue heart valve replacement market. The TPP is similar to the Food and Drug Administration (FDA) in the United States. The CryoLife-O'Brien porcine valve, with ... 
Printer Friendly Version
07/11/00CryoLife, Inc. Announces Inclusion in the Russell 2000 Index
ATLANTA, July 11 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a diversified biological implantable device company, today announced that it has been added to the Russell 2000 Equity Index, a leading composite of small-cap stocks compiled by the Frank Russell Company. The addition of CryoLife, Inc. stock, effective June 30, 2000, is part of the annual reconstitution of the Russell indexes. The Russell 2000 is comprised of the 2000 largest U.S. stocks ranked by market capitali... 
Printer Friendly Version
06/29/00CryoLife, Inc. Purchases Acreage Designated For Future Growth and Expansion of Company Operations
ATLANTA, June 29 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it had acquired a six-acre parcel of land adjacent to its headquarters and main laboratory facilities in Kennesaw, Georgia. The purchase brings CryoLife, Inc.'s total corporate headquarters campus to 21 acres. Stev... 
Printer Friendly Version
06/26/00CryoLife's BioGlue Surgical Adhesive Presented At Thoracic Surgical Association Meeting
ATLANTA, June 26 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that a presentation on a preliminary animal study on the use of its BioGlue(R) surgical adhesive as an alternative to the standard lung volume reduction (LVR) surgical procedure was made at the Annual Meeting of The Western Thoraci... 
Printer Friendly Version
06/07/00CryoLife, Inc. Interview to be Broadcast on the Web
ATLANTA, June 7 /PRNewswire/ -- Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc. (NYSE: CRY), will be interviewed live on www.informedinvestors.com on Wednesday, June 7, 2000, at approximately 11:32 AM Eastern Time, during the BioTalk broadcast, beginning at 11:00 AM. The live-format interview will feature discussions of innovative developments in biotech medical care and can be accessed at http://www.informedinvestors.com/radio. The program, devel... 
Printer Friendly Version
05/01/00CryoLife's BioGlue Surgical Adhesive Presented at Aortic Surgery Symposium
ATLANTA, May 1 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that a presentation on the results of a clinical study in Canada made on the use of BioGlue(R) surgical adhesive as an adjunct in the repair of thoracic aortic dissections was made at the Aortic Surgery Symposium, held in New York Ci... 
Printer Friendly Version
04/19/00CryoLife, Inc. Appoints David Ashley Lee Chief Financial Officer
ATLANTA, April 19 /PRNewswire/ -- Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc. (NYSE: CRY), today announced the appointment of David Ashley Lee, 35, as Vice President of Finance and Chief Financial Officer of CryoLife, Inc. Mr. Lee has served as CryoLife's Controller since 1994. Prior to joining CryoLife, Inc., Mr. Lee was Director of Finance at Compass Retail, a wholly-owned subsidiary of Equitable Real Estate. Mr. Lee was also an audit mana... 
Printer Friendly Version
04/18/00CryoLife, Inc. Reports Record Revenues And Record Earnings for First Quarter
ATLANTA, April 18 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced record first quarter revenues and earnings for the first quarter ended March 31, 2000. Revenues for the first quarter ended March 31, 2000 were $19.6 million, up 20 percent over the previous first quarter record of $16.3 milli... 
Printer Friendly Version
04/13/00CryoLife, Inc. Expects Record Revenues And Improved Earnings for the First Quarter
ATLANTA, April 13 /PRNewswire/ -- Steven G. Anderson, President and Chief Executive Officer of CryoLife, Inc. (NYSE: CRY), today told a group of biotechnology and medical device analysts, who were attending CryoLife's "Medical Analyst's Day," that the Company would set a new first quarter revenues record in 2000 and would exceed First Call corporate monitor analysts consensus earnings estimates of $0.11 per common share diluted. Complete financial results for CryoLife's first quarte... 
Printer Friendly Version
03/30/00CryoLife, Inc. Receives Approval to Expand IDE Indications for BioGlue Under Conditions Specified by FDA
ATLANTA, March 30 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced today that it has received notification from the Food and Drug Administration (FDA) that it may expand its Investigational Device Exemption (IDE) application on the Company's BioGlue(R) surgical adhesive human clinical study to include ... 
Printer Friendly Version
03/22/00CryoLife, Inc. Says Product Diversification Strategy Paying Off
LAS VEGAS, March 22 /PRNewswire/ -- Steven G. Anderson, President and Chief Executive Officer of CryoLife, Inc. (NYSE: CRY), told a group of investors today that the Company's growth strategy centered on product diversification continues to be successful. In remarks prepared for delivery at 3 p.m. (PST) during the Banc of America Securities Annual Healthcare Conference being held here, Anderson said, "Our core business revenues for January and February 2000 are on a r... 
Printer Friendly Version
03/01/00CryoLife, Inc. and Viragen Sign Collaborative Agreement for A Cancer Therapy Research Project
ATLANTA, March 1 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), announced today that it had signed an agreement with Viragen, Inc. (OTC Bulletin Board : VRGN), to develop a project to research the feasibility of site-specific delivery and activation of Viragen's anti-cancer proteins using CryoLife's proprietary light activation technology. Under the research protocol, the Viragen anti-cancer proteins will be delivered to the targeted tumor using monoclonal antibodies and the anti-cance... 
Printer Friendly Version
02/23/00CryoLife, Inc. Announces Implant of World's First Decellularized CryoValve-SG Human Heart Valve
ATLANTA--(BW HealthWire)--Feb. 23, 2000--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that the first decellularized human allograft pulmonary heart valve, using CryoLife's patented process, was successfully implanted in a 28 year old female patient. The surgery was performed by Ronald C. Elkins, M.D.,... 
Printer Friendly Version
02/22/00CryoLife, Inc. Receives Approval by 83 Hospitals for Use of BioGlue In Acute Thoracic Aortic Dissections
ATLANTA--(BW HealthWire)--Feb. 22, 2000--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has received approval from the Institutional Review Boards (IRB) at 83 hospitals in the United States for the use of BioGlue surgical adhesive in acute thoracic aortic dissections. The approval by the IRB fo... 
Printer Friendly Version
02/15/00CryoLife Announces Opening of European Headquarters
ATLANTA--(BW HealthWire)--Feb. 15, 2000--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it had selected the site for its previously announced European headquarters. In August 1999, CryoLife announced that it would be establishing a European headquarters operation near London, England, to provide distribution an... 
Printer Friendly Version
02/10/00CryoLife Breaks Ground On New High-tech Facility; CryoLife Doubles Its Corporate Campus Due to Demand For Company's Services And Products
ATLANTA--(BW HealthWire)--Feb. 10, 2000--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it had broken ground on a major addition to the Company's 15-acre corporate campus located in Kennesaw, Georgia, just outside Atlanta. The new addition will consist of a two-story 100,000-square foot medical device manufactu... 
Printer Friendly Version
02/08/00CryoLife, Inc. Reports Fourth Quarter and Full Year Results
ATLANTA--(BW HealthWire)--Feb. 8, 2000--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced record revenues for the fourth quarter and year ended December 31, 1999. Earnings growth was restricted by a one-time, non-recurring charge related to a manufacturing agreement with Horizon Medical Products, Inc. (AMEX:HMP), in which HM... 
Printer Friendly Version
02/02/00Cryolife's BioGlue Surgical Adhesive Featured At 36th Annual Meeting of the Society of Thoracic Surgeons
ATLANTA--(BW HealthWire)--Feb. 2, 2000-- Animal Study Suggests That The Use Of BioGlue Surgical Adhesive During Open-Heart Surgery Can Significantly Reduce Post-Operative Blood Loss CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that a presentation was g... 
Printer Friendly Version
02/01/00Clinical Results of Synergraft Technology Presented at 36th Annual Meeting of Thoracic Surgeons
Clinical Results Of Tissue-Engineered SynerGraft(R) Replacement Heart Valves In Animals Confirms Repopulation Benefits ATLANTA--(BW HealthWire)--Feb. 1, 2000--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that the clinical results from the implantation of CryoLife's tissue-engineered... 
Printer Friendly Version
01/26/00CryoLife, Inc. Announces New CryoValve-SG for Transplant
ATLANTA--(BW HealthWire)--Jan. 26, 2000--CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has expanded its human heart valve program to include a new human allograft heart valve processing method. Valves processed by this new method will be designated as CryoValve(R)-SG to differentiate them from valves proce... 
Printer Friendly Version
01/24/00Clinical Results of Cryolife's Synergraft Technology Presented at 31st Cardiovascular Conference at Snowmass
Clinical Studies Of Tissue-Engineered Synergraft(R) Replacement Heart Valves In The Aortic Position Of Two Human Patients Continue to be Encouraging ATLANTA--(BW HealthWire)--Jan. 24, 2000-- CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that the clinical re... 
Printer Friendly Version
01/19/00CryoLife Receives Approval to Market BioGlue Surgical Adhesive in Canada
ATLANTA--(BW HealthWire)--Jan. 19, 2000--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that its Medical Device License Application has been approved by the Canadian Government's Therapeutic Products Programme (TPP) for the use of BioGlue(R) surgical adhesive in vascular and pulmonary repair. The TPP is comparable t... 
Printer Friendly Version
01/06/00CryoLife Submits IDE Supplement to Expand Indications Of BioGlue in U.S.
ATLANTA--(BW HealthWire)--Jan. 6, 2000--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of Stentless heart valves and surgical adhesives, today announced that it had submitted an Investigational Device Exemption (IDE) supplement with the Food & Drug Administration (FDA) for an expanded clinical study of the Company's BioGlue(R) surgical adhesive. The supplement requests that the ap... 
Printer Friendly Version
01/04/00CryoLife Ships BioGlue Surgical Adhesive to U.S. Hospitals; HDE Approval Opens Door for Hospitals in the U.S. to Use BioGlue in Aortic Dissections
ATLANTA--(BW HealthWire)--Jan. 4, 2000--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it had received Institutional Review Board (IRB) approval from four United States hospitals and shipped its first commercial shipments of BioGlue(R) surgical adhesive for use in aortic dissections. BioGlue was recently approv... 
Printer Friendly Version
12/13/99FDA Grants CryoLife's BioGlue a Humanitarian Device Exemption for Limited Use in Aortic Dissections
ATLANTA--(BW HealthWire)--Dec. 13, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has received notification from the Food and Drug Administration (FDA) of the approval of the Company's BioGlue(R) surgical adhesive for use in aortic dissections under Humanitarian Device Exemption (HDE) regulations. The ... 
Printer Friendly Version
10/19/99CryoLife, Inc. Continues to Report Record Quarterly Revenues
ATLANTA--(BW HealthWire)--Oct. 19, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced record revenues for the third quarter and nine months ended September 30, 1999, as compared with comparable prior periods. Excluding revenues from Ideas for Medicine, Inc. (IFM), revenues for the third quarter of 1999 incr... 
Printer Friendly Version
10/05/99CryoLife Continues to Make Advances With BioGlue; First Clinical Use of BioGlue in Japan; BG3000 Approved in France
BW1167 OCT 05,1999 5:40 PACIFIC 8:40 EASTERN ( BW)(GA-CRYOLIFE)(CRY) CryoLife Continues to Make Advances With BioGlue; First Clinical Use of BioGlue in Japan; BG3000 Approved in France Business Editors/Health & Medical Writers ATLANTA--(BW HealthWire)--Oct. 5, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless hear... 
Printer Friendly Version
10/04/99CryoLife Continues to See Positive Results in Patients Receiving SynerGraft Tissue-Engineered Heart Valves; Third and Fourth SynerGraft Heart Valve Implants Planned for this Week
BW1236 OCT 04,1999 5:31 PACIFIC 8:31 EASTERN ( BW)(GA-CRYOLIFE)(CRY) CryoLife Continues to See Positive Results in Patients Receiving SynerGraft Tissue-Engineered Heart Valves; Third and Fourth SynerGraft Heart Valve Implants Planned for this Week Business Editors/Health and Medical Writers ATLANTA--(BW HealthWire)--Oct. 4, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implant... 
Printer Friendly Version
09/16/99CryoLife Continues to Add Expertise to Company's Board of Directors
ATLANTA--(BW HealthWire)--Sept. 16, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has added Alexander C. ("Sandy") Schwartz, Jr., age 67, to the Company's Board of Directors, increasing the number of members serving on the Board of Directors to eight. Mr. Schwartz retired from Prudential Securities ... 
Printer Friendly Version
09/08/99CryoLife's BioGlue Surgical Adhesive Featured At European Association for Cardiothoracic Surgery
ATLANTA--(BW HealthWire)--Sept. 8, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that a presentation was given on September 8th to the 13th annual European Association for Cardiothoracic Surgery (EACTS) in Glasgow, Scotland, highlighting an animal study funded by CryoLife and using CryoLife's BioGlue(R) surgi... 
Printer Friendly Version
08/31/99CryoLife Announces First SynerGraft -R- Biologic Heart Valve Implants in Human Patients; Trans-species Transplant Performed Without Use of Immunosuppression
ATLANTA--(BW HealthWire)--Aug. 31, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that two human females had each received a tissue-engineered SynerGraft(R) porcine heart valve in the aortic position. Dr. Mark O'Brien, a paid consultant to CryoLife, Inc. and a member of the CryoLife Cardiovascular Medical Advi... 
Printer Friendly Version
08/30/99CryoLife Expands Board; Adds Two New Board Members and A Wealth of Experience
ATLANTA--(BW HealthWire)--Aug. 30, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced the expansion of the Company's Board of Directors with the addition of two new Board members. The appointment of John M. Cook, age 57, and Bruce J. Van Dyne, M.D., age 58, increases to seven the number of members serving on the B... 
Printer Friendly Version
08/16/99Cryolife, Inc. to Open European Headquarters
ATLANTA--(BW HealthWire)--Aug. 16, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced plans to set up a European headquarters operation near London, England. The new facility will provide distribution and technical services to CryoLife's network of European representatives, institutional customers and surgeons. Steve... 
Printer Friendly Version
07/28/99CryoLife Seeks Canadian Marketing Approval for BioGlue Surgical Adhesive; BioGlue Now in Use in 33 Countries
ATLANTA--(BW HealthWire)--July 28, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has submitted a Medical Device License Application to the Canadian Government's Therapeutic Products Programme (TPP) for the use of BioGlue(R) surgical adhesive in vascular and pulmonary repair. The TPP is comparable to t... 
Printer Friendly Version
07/26/99CryoLife Seeks Australian Marketing Approval for BioGlue Surgical Adhesive
    Business Editors/Health & Medical Writers     ATLANTA--(BW HealthWire)--July 26, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has submitted a Therapeutic Device Application to the Australian Therapeutic Good Administration (TGA) for the use of BioGlue(R) ... 
Printer Friendly Version
07/20/99CryoLife, Inc. Reports Record Revenues for Second Quarter; Increasing Interest in New Products
ATLANTA--(BW HealthWire)--July 20, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced record revenues for the second quarter and six months ended June 30, 1999. This represents the seventh consecutive year that the Company has recorded record revenues for the first six months of the year. The Company also noted that the... 
Printer Friendly Version
07/07/99CryoLife Receives Approval for Clinical Testing of BioGlue in Japan
    Business Editors & Health/Medical Writers     ATLANTA--(BW HealthWire)--July 7, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that its Japanese distributor, Century Medical Inc., has received approval for clinical trials of CryoLife's BioGlue(R) surgical adhesive ... 
Printer Friendly Version
06/30/99CryoLife Stock Ranked Among the 100 Best Stocks to Own for Under $20
    Business Editors/Health and Medical Writers     ATLANTA--(BUSINESS WIRE)--June 30, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that its stock has been ranked 38th among The 100 Best Stocks to Own for Under $20 in a book published by Gene Walden, nationally known... 
Printer Friendly Version
06/14/99CryoLife SynerGraft Technology Highlighted At World Symposium On Heart Valve Disease
    Business Editors/Health and Medical Writers     ATLANTA--(BW HealthWire)--June 14, 1999--     Paper Presented on Transpecies Heart Valve Transplants     Indicates Reduced Rejection Rates     CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgi... 
Printer Friendly Version
06/10/99CryoLife Files Application With FDA For Humanitarian Device Exemption for BioGlue
    Business Editors/Health and Medical Writers     ATLANTA--(BW HealthWire)--June 10, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has applied for a Humanitarian Device Exemption (HDE) approval from the Food and Drug Administration (FDA). The HDE approval is... 
Printer Friendly Version
06/09/99CryoLife Product Holds Great Promise for Dialysis Patients
    Business Editors/Health and Medical Writers     ATLANTA--(BW HealthWire)--June 9 , 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that the Company's cryopreserved femoral veins are reported to significantly reduce infection rates at access sites for dialysis patien... 
Printer Friendly Version
05/17/99CryoLife's SynerGraft, First Effective ''Tissue Engineered'' Heart Valve Implant, Highlighted At International Symposium
    Health/Medical Writers     ATLANTA--(BW HealthWire)--May 17, 1999--     Paper Presented by Dr. Mark O'Brien, Renowned Heart Surgeon     CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has transplanted an unfixed pig valv... 
Printer Friendly Version
05/06/99CryoLife Files for FDA Clearance to Distribute BioGlue Surgical Patch in U.S.
ATLANTA--(BW HealthWire)--May 6, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has filed a 510(k) premarket notification submission with the U. S. Food and Drug Administration (FDA) requesting clearance to market its BioGlue(R) Surgical Patch in the United States. There is a statutory 90-day review pe... 
Printer Friendly Version
04/22/99CryoLife, Inc. Reports Record Revenues for 1999 First Quarter; Product and Service Diversification on Track
ATLANTA, Ga.--(BW HealthWire)--April 22, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced revenues and earnings for the quarter ended March 31, 1999. In addition, the Company also confirmed that its diversification strategy was on track, strengthening product and service mix and helping to reduce the Company's depende... 
Printer Friendly Version
04/21/99CryoLife's BioGlue Surgical Adhesive Eliminates Need for Sutures in Experimental Coronary Bypass Surgery On Animals
ATLANTA--(BW HealthWire)--April 21, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that its BioGlue(R) surgical adhesive has been used in experimental cardiac bypass surgery to reconnect saphenous vein grafts and internal mammary arteries to goat hearts. Subsequent to this experimental surgery, the connected v... 
Printer Friendly Version
04/19/99CryoLife, Inc. Introduces Heart Valve Warranty
ATLANTA--(BUSINESS WIRE)--April 19, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has implemented an allograft valve warranty program. The program, which applies to heart valves implanted after April 15, 1999, includes a ten-year limited warranty against problems due to structural deterioration and a ... 
Printer Friendly Version
04/05/99CryoLife, Inc. Announces First Shipment of BG3000 Pre-filled BioGlue Surgical Adhesive Delivery System
ATLANTA--(BUSINESS WIRE)--April 5, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of implantable living human tissues and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced today that the first shipment into the European Union of the Company's new pre-filled BioGlue(R) surgical adhesive delivery system, BG3000, was made in late March. In mid-February, the Company received "CE" (product certification) mark approv... 
Printer Friendly Version
03/16/99CryoLife, Inc. Receives ''CE'' Mark for Distribution of BioGlue for Pulmonary Applications in the European Union
ATLANTA--(BUSINESS WIRE)--March 16, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of implantable living human tissues and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced today that it has received "CE" (product certification) mark approval for the distribution in the European Union of its BioGlue(R) Surgical Adhesive for pulmonary applications. Pulmonary applications include the sealing of trachea, esophagea... 
Printer Friendly Version
02/17/99CryoLife, Inc. Receives ''CE'' Mark For International Distribution Of New BioGlue Delivery System
ATLANTA--(BUSINESS WIRE)--Feb. 17, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of implantable living human tissues and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced today that it had received ``CE'' (product certification) mark approval for the distribution of the new 3000 Series of BioGlue® Surgical Adhesive (BG 3000) in European markets. The BG 3000 provides surgeons with a pre-filled, ready-to-use deliver... 
Printer Friendly Version
02/09/99CryoLife, Inc. Will Add On-Line Tissue Availability Service To Its Worldwide Web Site
ATLANTA--(BUSINESS WIRE)--Feb. 9, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced that it will significantly update its web site (http://www.cryolife.com.) The updated web site will include a daily report on the availability of certain cryopreserved human tissues for transplant. This database of CryoLife Available Ti... 
Printer Friendly Version
02/02/99CryoLife, Inc. Reports Revenues and Earnings for 1998
ATLANTA--(BUSINESS WIRE)--Feb. 2, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced revenues and earnings for the year ended December 31, 1998.     Revenues for the year were $60.7 million, an increase of 20% as compared with $50.6 million in 1997. Net income for the year 1998 was $6.5 million, an ... 
Printer Friendly Version
01/21/99CryoLife(R), Inc. Expands Its Line of Orthopaedic Tissues
ATLANTA, Jan. 21 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced that it has expanded its line of processed and preserved human knee tissue to include osteoarticular (OA) allografts cartilage for application in repair of damaged knees. CryoLife currently supplies orthopaedic surgeons with cryopreserved hum... 
Printer Friendly Version
10/14/98CryoLife(R), Inc. Reports Record Revenues And Earnings For Third Quarter And First Nine Months Of 1998
ATLANTA, Oct. 14 -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced record revenues and earnings for the third quarter and for the first nine months of 1998 ended September 30, 1998, as compared to comparable periods of prior years. Operating revenues for the third quarter ended September 30, 1998 were $16,014,000, ... 
Printer Friendly Version
10/14/98CryoLife(R), Inc. Board Of Directors Authorize Purchase Of Its Common Stock
ATLANTA, Oct. 14 -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and a distributor of stentless heart valves and surgical adhesives, announced that its Board of Directors has authorized the purchase of up to 1 million shares of its Common Stock, beginning no sooner than October 15, 1998. The purchase of shares will be made from time to time in open market or privately-negotiated transaction... 
Printer Friendly Version
10/07/98CryoLife, Inc. Receives $2 Million Grant For Creation Of Bioengineered Heart Valves
ATLANTA, Oct. 7 -- CryoLife, Inc. (NYSE: CRY), a leader in human tissue and cell preservation and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced that the Company has been awarded a $1,996,545 grant from the U.S. Department of Commerce, National Institute of Standards and Technology (NIST) for the technological advancement of its SynerGraft(R) heart valve replacement program. Since its inception in 1991, and including this recent grant, the Syn... 
Printer Friendly Version
10/01/98CryoLife(R), Inc. Announces Sale Of Its Ideas For Medicine(R), Inc. Product Line
ATLANTA, Oct., 1 -- CryoLife, Inc. (NYSE: CRY), a leader in human tissue and cell preservation and a manufacturer and distributor of stentless heart valves and surgical adhesives, announced that it has closed the sale of the product line of its wholly owned subsidiary, Ideas for Medicine, Inc. (IFM) to Horizon Medical Products, Inc. (Nasdaq: HMPS), of Atlanta, Georgia. Horizon Medical paid CryoLife the sum of $15 million for IFM's finished goods inventory and the intellectual pr... 
Printer Friendly Version
09/30/98Horizon Medical Products, Inc. Announces Acquisition Of CryoLife, Inc. Subsidiary
ATLANTA, Sept. 30 -- Horizon Medical Products, Inc. (Nasdaq: HMPS), announced today the completion of its previously signed intent to acquire Ideas for Medicine, Inc. (``IFM''), a wholly-owned subsidiary of CryoLife(R), Inc. (NYSE: CRY), to acquire the IFM product lines, inventory and intellectual property. The purchase price, paid in cash, was $15 million. The IFM product line consists of proprietary single use medical devices such as the Pruit-Inahara carotid shunts, whic... 
Printer Friendly Version
09/30/98CryoLife, Inc. Begins Shipments Of Porcine Pulmonary Heart Valves To Europe
ATLANTA, Sept. 30 -- CryoLife, Inc. (NYSE: CRY), a leader in human tissue and cell preservation and a manufacturer and distributor of specialty cardiovascular and vascular medical devices and surgical adhesives, announced today that it has made its first shipment of the CryoLife-Ross(TM) porcine pulmonary heart valves to Europe from its laboratories in suburban Atlanta. On July 1, 1998, CryoLife announced that the CryoLife-Ross heart valve was awarded the European CE (product certifi... 
Printer Friendly Version
09/23/98CryoLife, Inc. Signs Agreement For Japanese Distribution Of BioGlue
ATLANTA, Sept. 23 -- CryoLife(R), Inc. (NYSE: CRY), a leader in human tissue and cell preservation, announced that it has signed a five- year exclusive agreement with Century Medical, Inc. (CMI), for the introduction and distribution of CryoLife's BioGlue(R), an animal protein- based surgical adhesive, within the Japanese medical community. Under the terms of the agreement, Century Medical, Inc. will make application to the Japanese Ministry of Health and Welfare to begin human clini... 
Printer Friendly Version
09/18/98Horizon Medical Products, Inc. Signs Letter Of Intent To Acquire Cryolife, Inc. Subsidiary
ATLANTA, Sept. 18 -- Horizon Medical Products, Inc. (Nasdaq: HMPS) has signed a letter of intent with Ideas for Medicine, Inc. (``IFM''), a wholly-owned subsidiary of Cryolife(R), Inc. (NYSE: CRY), to acquire the IFM product lines, inventory and intellectual property. The purchase price is $15 million to be paid in cash at closing. The IFM product line consists of single use medical devices such as carotid shunts, which divert blood through arteries while surgeons remove plaque in t... 
Printer Friendly Version
09/18/98CryoLife, Inc. Signs Letter Of Intent For Ideas For Medicine, Inc. Product Line
ATLANTA, Sept. 18 -- CryoLife(R), Inc. (NYSE: CRY), a leader in human tissue and cell preservation, announced that it has signed a letter of intent to sell the product line of its wholly-owned subsidiary, Ideas for Medicine(R), Inc. (IFM) to Horizon Medical Products, Inc. (Nasdaq: HMPS), of Atlanta, Georgia, and to enter into an exclusive four year agreement to manufacture IFM products for Horizon. The transaction calls for Horizon to pay CryoLife the sum of $15 Million for IFM's fin... 
Printer Friendly Version
07/29/98CryoLife, Inc. Announces Expansion Of Production Capacity For BioGlue And Porcine Heart Valves
ATLANTA, July 29 -- CryoLife, Inc. (NYSE: CRY), a leader in human tissue and cell preservation, and a manufacturer and distributor of specialty cardiovascular and vascular medical instruments and devices, announced expansion of production capacity for BioGlue(R), an animal protein-based surgical adhesive. On January 6, 1998, BioGlue was awarded the European CE (product certification) mark, allowing unrestricted commercial distribution of BioGlue for vascular sealing and reconstructio... 
Printer Friendly Version
07/21/98CryoLife, Inc. Reports Record Revenues And Earnings For Second Quarter And First Half Of 1998, Revenues For First Half Increase 35%
ATLANTA, July 21 -- CryoLife, Inc. (NYSE: CRY), a leader in human tissue and cell preservation, and a manufacturer and distributor of specialty cardiovascular and vascular devices and surgical adhesives announced record revenues and earnings for the second quarter and for the first half of 1998 as compared to comparable periods of prior years. Revenues for the six month period ended June 30, 1998 were $31,286,000, a 35 percent increase over the previous record of $23,136,000 set in th... 
Printer Friendly Version
04/21/98CryoLife, Inc. Reports Record Revenues And Earnings For The First Quarter Of 1998
ATLANTA, April 21 -- CryoLife, Inc. (NYSE:CRY), a leader in human tissue and cell preservation, and a manufacturer and distributor of specialty cardiovascular and vascular medical instruments and devices, announced record revenues and earnings for the first quarter ended March 31, 1998. Revenues for the first quarter of 1998 were $14,625,000, a 40 percent increase over the previous first quarter record of $10,413,000, set in 1997. Net income for the first quarter of 1998 was $... 
Printer Friendly Version
Receive E-mail Alerts
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!